

chain nodes :

13 15 16 17

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12

chain bonds :

5-15 6-13 9-13 15-16

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12

exact/norm bonds :

6-13 9-13

exact bonds :

5-15 15-16

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12

isolated ring systems :

containing 1 : 7 :

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom
12:Atom 13:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS

=>Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end

=> screen 2016 OR 2026 OR 1840 OR 2039 OR 2040 OR 2045 OR 2047

L1 SCREEN CREATED

=>

Uploading C:\STNEXP4\QUERIES\10010651.str

L2 STRUCTURE UPLOADED

=> que L2 NOT L1


L3 QUE L2 NOT L1

=> d 13

L3 HAS NO ANSWERS

L1 SCR 2016 OR 2026 OR 1840 OR 2039 OR 2040 OR 2045 OR 2047

L2 STR



Structure attributes must be viewed using STN Express query preparation.

L3 QUE L2 NOT L1

=> s 13 sss sam

SAMPLE SEARCH INITIATED 17:36:29 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 4094 TO ITERATE

24.4% PROCESSED 1000 ITERATIONS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

19 ANSWERS

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

10/010,651

BATCH **COMPLETE**
PROJECTED ITERATIONS: 78044 TO 85716
PROJECTED ANSWERS: 1026 TO 2084

L4 19 SEA SSS SAM L2 NOT L1

=>Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end

=> screen 2016 OR 2026 OR 1840 OR 2039 OR 2040 OR 2045 OR 2047

L5 SCREEN CREATED

=>

Uploading C:\STNEXP4\QUERIES\10010651.str

L6 STRUCTURE UPLOADED

=> que L6 NOT L5


L7 QUE L6 NOT L5

=> d 17

L7 HAS NO ANSWERS

L5 SCR 2016 OR 2026 OR 1840 OR 2039 OR 2040 OR 2045 OR 2047

L6 STR



Structure attributes must be viewed using STN Express query preparation.

L7 QUE L6 NOT L5

=> s 17 sss sam

SAMPLE SEARCH INITIATED 17:38:05 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 122 TO ITERATE

100.0% PROCESSED 122 ITERATIONS
SEARCH TIME: 00.00.01

19 ANSWERS

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 1778 TO 3102
PROJECTED ANSWERS: 118 TO 640

L8 19 SEA SSS SAM L6 NOT L5

=> s 17 sss ful
FULL SEARCH INITIATED 17:38:15 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 2587 TO ITERATE

100.0% PROCESSED 2587 ITERATIONS
SEARCH TIME: 00.00.01

399 ANSWERS

L9 399 SEA SSS FUL L6 NOT L5

=> s 19
L10 21 L9

=> d 110 1-21 bib,ab,hitstr

L10 ANSWER 1 OF 21 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 2003:696859 CAPLUS
 TI Preparation of substituted amines prodrugs useful in treating Alzheimer's disease
 IN Varghese, John; Jagodzinska, Barbara; Maillard, Michel; Beck, James P.; Tenbrink, Ruth E.; Getman, Daniel
 PA Elan Pharmaceuticals, Inc., USA; Pharmacia & Upjohn
 SO PCT Int. Appl., 483 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003072535	A2	20030904	WO 2003-US7287	20030227
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRAI US 2002-359953P P 20020227

AB Amines [I; R1 = (un)substituted alkyl, alkenyl, alkynyl, etc.; R2 = H, (un)substituted alkyl, alkenyl, etc.; R3 = H, (un)substituted alkyl, alkenyl, etc.; R4 = XR; X = CO, SO2, a bond, etc.; R = Ph, naphthyl, indanyl, etc.; R5 = (un)substituted alkyl, (CH2)0-3cycloalkyl, etc.; e.g. N1-[(1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-[(3-methoxybenzyl)amino]propyl]-5-methyl-N3,N3-dipropylisophthalamide], useful in treating Alzheimer's disease and other similar diseases, were prepd. Although the methods of prepn. are not claimed, hundreds of example prepn. are included. Thus, reacting (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-methoxybenzyl)amino]-2-butanol trifluoroacetate with 5-methyl-N,N-dipropylisophthalamide in the presence of Et3N, 1-hydroxybenzotriazole and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride in DMF afforded (1S,2R)-II (N1-[(1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-[(3-methoxybenzyl)amino]propyl]-5-methyl-N3,N3-dipropylisophthalamide). The compds. I exhibit an IC50 of < 50 .mu.M against .beta.-secretase.


IT INDEXING IN PROGRESS

IT 175136-89-7

RL: RCT (Reactant); RACT (Reactant or reagent)
 (prepn. of substituted amine prodrugs useful in treating Alzheimer's disease)

RN 175136-89-7 CAPLUS

CN Benzenemethanamine, 2-chloro-6-phenoxy- (9CI) (CA INDEX NAME)



L10 ANSWER 2 OF 21 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 2003:678291 CAPLUS
 DN 139:202503
 TI Osmotic delivery system containing a polyethylene oxide and an osmagent
 IN Waterman, Kenneth C.
 PA USA
 SO U.S. Pat. Appl. Publ., 12 pp.
 CODEN: USXXCO
 DT Patent
 LA English
 FAN.CNT 1

not print

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003161882	A1	20030828	US 2003-352258	20030127
PRAI	US 2002-353502P	P	20020201		


AB An osmotic pharmaceutical tablet is described which comprises a single-layer compressed core surrounded by a water permeable layer having a passageway. The single-layer core contains (i) a non-ripening drug having a soly. per dose less than about 1 mL -1, (ii) about 2.0% to about 30% by wt. of a polyethylene oxide having a wt.-av., mol. wt. from about 200,000 to about 7,000,000, (iii) an osmagent, and (iv) an optional disintegrant. Many osmotic tablets were prep'd. and their dissoln. rate were studied.

IT **289716-93-4**

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (osmotic delivery system contg. polyethylene oxide and osmagent)

RN 289716-93-4 CAPLUS


CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N-methyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl


L10 ANSWER 3 OF 21 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 2002:925264 CAPLUS
 DN 138:11431
 TI 5-HT1a antagonist or an .alpha.2-adrenergic antagonist in combination with
 an serotonin reuptake inhibitor for treatment of sleep disorders,
 including sleep apnea
 IN Howard, Harry Ralph, Jr.
 PA Pfizer Products Inc., USA
 SO Eur. Pat. Appl., 22 pp.
 CODEN: EPXXDW
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 1262197	A2	20021204	EP 2002-253589	20020522
	EP 1262197	A3	20021218		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	US 2002183306	A1	20021205	US 2002-75849	20020213 ←
	BR 2002001974	A	20030422	BR 2002-1974	20020528
	JP 2003026602	A2	20030129	JP 2002-155222	20020529
PRAI	US 2001-294322P	P	20010530		
OS	MARPAT 138:11431				
AB	The invention provides a method of treating sleep disorders, including sleep apnea, in a mammal, including a human, by administering to the mammal a 5-HT1a antagonist or an .alpha.2-adrenergic antagonist in combination with an serotonin reuptake inhibitor (SRI) antidepressant agent with improvement in efficacy. Also provided are pharmaceutical compns. contg. a pharmaceutically acceptable carrier, a 5-HT1a antagonist or an .alpha.2-adrenergic antagonist, and an SRI antidepressant agent.				
IT	289716-79-6 289716-94-5 289717-01-7 289717-16-4 289717-18-6 289717-48-2 289717-52-8 289717-56-2 289717-57-3 289717-59-5 289717-60-8 289717-61-9 289717-62-0 289717-63-1 289717-64-2 289717-65-3 289717-66-4 289717-69-7 289717-70-0 289717-71-1 289717-72-2 444888-23-7 444888-24-8 444888-25-9 444888-27-1 444888-29-3 444888-31-7 444888-34-0 444888-35-1 444888-36-2 444888-37-3 444888-38-4 444888-39-5 444888-49-7 477337-55-6				
	RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)				
	(5-HT1a antagonist or .alpha.2-adrenergic antagonist in combination with serotonin reuptake inhibitor for treatment of sleep disorders, including sleep apnea)				
RN	289716-79-6 CAPLUS				
CN	Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N,N-dimethyl-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)				



RN 289716-94-5 CAPLUS


CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N-methyl- (9CI) (CA INDEX NAME)



*Electro
Species.*


RN 289717-01-7 CAPLUS

CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N,N-dimethyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 289717-16-4 CAPLUS


CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N-methyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)





RN 289717-18-6 CAPLUS

CN Benzenemethanamine, 4-chloro-2-(3,4-dichlorophenoxy)-N-methyl- (9CI) (CA INDEX NAME)


INDEX NAME)



RN 289717-48-2 CAPLUS


CN Acetamide, N-[4-(3,4-dichlorophenoxy)-3-[(dimethylamino)methyl]phenyl]-
(9CI) (CA INDEX NAME)

RN 289717-52-8 CAPLUS

CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N,N-dimethyl- (9CI)
(CA INDEX NAME)


RN 289717-56-2 CAPLUS

CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-methoxy-N-methyl- (9CI) (CA
INDEX NAME)




RN 289717-57-3 CAPLUS

CN Benzenemethanamine, 2-(4-chlorophenoxy)-5-fluoro-N-methyl- (9CI) (CA INDEX NAME)




RN 289717-59-5 CAPLUS

CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N,N,5-trimethyl- (9CI) (CA INDEX NAME)




RN 289717-60-8 CAPLUS

CN Benzenemethanamine, 4-bromo-2-(3,4-dichlorophenoxy)-N-methyl- (9CI) (CA INDEX NAME)




RN 289717-61-9 CAPLUS

CN Benzenemethanamine, 5-bromo-2-(3,4-dichlorophenoxy)-N-methyl- (9CI) (CA INDEX NAME)




RN 289717-62-0 CAPLUS

CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-4,5-dimethoxy-N-methyl- (9CI)
(CA INDEX NAME)




RN 289717-63-1 CAPLUS

CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-4-methoxy-N,N-dimethyl- (9CI)
(CA INDEX NAME)



RN 289717-64-2 CAPLUS


CN Benzonitrile, 4-(3,4-dichlorophenoxy)-3-[(methylamino)methyl]- (9CI) (CA
INDEX NAME)



RN 289717-65-3 CAPLUS


CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N,4,5-trimethyl- (9CI) (CA

INDEX NAME)




RN 289717-66-4 CAPLUS

CN Benzonitrile, 3-(3,4-dichlorophenoxy)-4-[(methylamino)methyl]- (9CI) (CA INDEX NAME)




RN 289717-69-7 CAPLUS

CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N-methyl-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 289717-70-0 CAPLUS


CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-4-methoxy-N-methyl- (9CI) (CA INDEX NAME)




RN 289717-71-1 CAPLUS

CN Benzenemethanamine, 2-(4-chloro-3-fluorophenoxy)-5-fluoro-N-methyl- (9CI)
(CA INDEX NAME)

RN 289717-72-2 CAPLUS


CN Benzenemethanamine, 2-(3-chloro-4-fluorophenoxy)-5-fluoro-N-methyl- (9CI)
(CA INDEX NAME)

RN 444888-23-7 CAPLUS

CN Benzenemethanamine, 4-chloro-2-(4-chlorophenoxy)-5-fluoro-N-methyl- (9CI)
(CA INDEX NAME)


RN 444888-24-8 CAPLUS

CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-4-methoxy-N-methyl- (9CI) (CA INDEX NAME)




RN 444888-25-9 CAPLUS

CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-(dimethylamino)-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 444888-27-1 CAPLUS

CN Benzenemethanamine, 2-(4-chlorophenoxy)-N-methyl-5-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 444888-29-3 CAPLUS

CN Benzenemethanamine, 2-(4-chlorophenoxy)-N,4,5-trimethyl- (9CI) (CA INDEX NAME)




RN 444888-31-7 CAPLUS

CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N-methyl-5-(methylthio)- (9CI) (CA INDEX NAME)




RN 444888-34-0 CAPLUS

CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N,N-dimethyl-5-(methylthio)-
(9CI) (CA INDEX NAME)




RN 444888-35-1 CAPLUS

CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N,N-dimethyl-5-
(methylsulfinyl)- (9CI) (CA INDEX NAME)



RN 444888-36-2 CAPLUS


CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N-methyl-5-(methylsulfonyl)-
(9CI) (CA INDEX NAME)



RN 444888-37-3 CAPLUS


CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N-methyl-5-(methylsulfonyl)-

(9CI) (CA INDEX NAME)




RN 444888-38-4 CAPLUS

CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N,N-dimethyl-5-(methylsulfonyl)- (9CI) (CA INDEX NAME)





RN 444888-39-5 CAPLUS

CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N-methyl-5-[(1-methylethyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 444888-49-7 CAPLUS

CN Benzenemethanamine, 4-chloro-2-(3,4-dichlorophenoxy)-N-methyl-5-(methylsulfonyl)- (9CI) (CA INDEX NAME)




RN 477337-55-6 CAPLUS

CN Benzenemethanamine, 5-fluoro-2-(4-fluoro-3-methoxyphenoxy)-N-methyl- (9CI)
(CA INDEX NAME)




L10 ANSWER 4 OF 21 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 2002:925263 CAPLUS
 DN 138:336
 TI Combination of a monoamine reuptake inhibitor and an opioid antagonist for use in alcoholism and alcohol dependence
 IN Howard, Harry Ralph, Jr.
 PA Pfizer Products Inc., USA
 SO Eur. Pat. Appl., 37 pp.
 CODEN: EPXXDW
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 1262196	A2	20021204	EP 2002-253105	20020502
	EP 1262196	A3	20021218		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2002370975	A2	20021224	JP 2002-132804	20020508
	AU 2002040686	A5	20021205	AU 2002-40686	20020516
	US 2003130322	A1	20030710	US 2002-153379	20020522 ←
	CN 1386503	A	20021225	CN 2002-120350	20020523
PRAI	US 2001-293088P	P	20010523		
OS	MARPAT 138:336				
AB	The present invention relates to a method of treating alcoholism or alc. dependence in a mammal, including a human, by administering to the mammal a monoamine reuptake inhibitor in combination with an opioid antagonist. It also relates to pharmaceutical compns. contg. a pharmaceutically acceptable carrier, a monoamine reuptake inhibitor and an opioid antagonist. An example monoamine reuptake inhibitor is I.				
IT	289716-79-6 289716-94-5 289717-01-7 289717-16-4 289717-18-6 289717-48-2 289717-52-8 289717-56-2 289717-57-3 289717-59-5 289717-60-8 289717-61-9 289717-62-0 289717-63-1 289717-64-2 289717-65-3 289717-66-4 289717-69-7 289717-70-0 289717-71-1 289717-72-2 476310-75-5 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (combination of a monoamine reuptake inhibitor and an opioid antagonist for use in alcoholism and alc. dependence)				
RN	289716-79-6 CAPLUS				
CN	Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N,N-dimethyl-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)				




RN 289716-94-5 CAPLUS
 CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N-methyl- (9CI) (CA

INDEX NAME)

Elected Species -


RN 289717-01-7 CAPLUS

CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N,N-dimethyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 289717-16-4 CAPLUS

CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N-methyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)





RN 289717-18-6 CAPLUS


CN Benzenemethanamine, 4-chloro-2-(3,4-dichlorophenoxy)-N-methyl- (9CI) (CA INDEX NAME)




RN 289717-48-2 CAPLUS

CN Acetamide, N-[4-(3,4-dichlorophenoxy)-3-[(dimethylamino)methyl]phenyl]-
(9CI) (CA INDEX NAME)

RN 289717-52-8 CAPLUS


CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N,N-dimethyl- (9CI)
(CA INDEX NAME)

RN 289717-56-2 CAPLUS

CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-methoxy-N-methyl- (9CI) (CA
INDEX NAME)


RN 289717-57-3 CAPLUS

CN Benzenemethanamine, 2-(4-chlorophenoxy)-5-fluoro-N-methyl- (9CI) (CA
INDEX NAME)




RN 289717-59-5 CAPLUS

CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N,N,5-trimethyl- (9CI) (CA INDEX NAME)




RN 289717-60-8 CAPLUS

CN Benzenemethanamine, 4-bromo-2-(3,4-dichlorophenoxy)-N-methyl- (9CI) (CA INDEX NAME)




RN 289717-61-9 CAPLUS

CN Benzenemethanamine, 5-bromo-2-(3,4-dichlorophenoxy)-N-methyl- (9CI) (CA INDEX NAME)




RN 289717-62-0 CAPLUS

CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-4,5-dimethoxy-N-methyl- (9CI) (CA INDEX NAME)




RN 289717-63-1 CAPLUS

CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-4-methoxy-N,N-dimethyl- (9CI)
(CA INDEX NAME)




RN 289717-64-2 CAPLUS

CN Benzonitrile, 4-(3,4-dichlorophenoxy)-3-[(methylamino)methyl]- (9CI) (CA
INDEX NAME)



RN 289717-65-3 CAPLUS


CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N,4,5-trimethyl- (9CI) (CA
INDEX NAME)




RN 289717-66-4 CAPLUS

CN Benzonitrile, 3-(3,4-dichlorophenoxy)-4-[(methylamino)methyl]- (9CI) (CA


INDEX NAME)




RN 289717-69-7 CAPLUS

CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N-methyl-5-(trifluoromethyl)-
(9CI) (CA INDEX NAME)


RN 289717-70-0 CAPLUS

CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-4-methoxy-N-methyl- (9CI) (CA
INDEX NAME)

RN 289717-71-1 CAPLUS


CN Benzenemethanamine, 2-(4-chloro-3-fluorophenoxy)-5-fluoro-N-methyl- (9CI)
(CA INDEX NAME)

RN 289717-72-2 CAPLUS.

CN Benzenemethanamine, 2-(3-chloro-4-fluorophenoxy)-5-fluoro-N-methyl- (9CI)
(CA INDEX NAME)

RN 476310-75-5 CAPLUS

CN Benzenemethanamine, 5-fluoro-N-methyl-2-phenoxy- (9CI) (CA INDEX NAME)




L10 ANSWER 5 OF 21 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 2002:904325 CAPLUS
 DN 137:380038
 TI Combination treatment with monoamine reuptake inhibitor and dopamine D3 receptor agonist for depression and anxiety
 IN Howard, Harry Ralph, Jr.
 PA Pfizer Products Inc., USA
 SO Eur. Pat. Appl., 31 pp.
 CODEN: EPXXDW

DT Patent
 LA English


FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 1260221	A2	20021127	EP 2002-253135	20020503
	EP 1260221	A3	20021218		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	AU 2002040681	A5	20021205	AU 2002-40681	20020516
	JP 2002370976	A2	20021224	JP 2002-141515	20020516
	CN 1386504	A	20021225	CN 2002-120351	20020523
PRAI	US 2001-293063P	P	20010523	← no cont. US appl.	
OS	MARPAT 137:380038				
AB	The present invention relates to a method of treating depression or anxiety in a mammal, including a human, by administering to the mammal a monoamine reuptake inhibitor in combination with a dopamine D3 receptor agonist. It also relates to pharmaceutical compns. contg. a pharmaceutically acceptable carrier, a monoamine reuptake inhibitor and a dopamine D3 receptor agonist.				
IT	289716-79-6 289716-94-5 289717-01-7 289717-16-4 289717-18-6 289717-48-2 289717-52-8 289717-56-2 289717-57-3 289717-59-5 289717-60-8 289717-61-9 289717-62-0 289717-63-1 289717-64-2 289717-65-3 289717-66-4 289717-69-7 289717-70-0 289717-71-1 289717-72-2 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (monoamine reuptake inhibitor; combination treatment with monoamine reuptake inhibitor and dopamine D3 receptor agonist for depression and anxiety)				
RN	289716-79-6 CAPLUS				
CN	Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N,N-dimethyl-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)				




RN 289716-94-5 CAPLUS
 CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N-methyl- (9CI) (CA

INDEX NAME)

Electro species


RN 289717-01-7 CAPLUS

CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N,N-dimethyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 289717-16-4 CAPLUS

CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N-methyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)





RN 289717-18-6 CAPLUS


CN Benzenemethanamine, 4-chloro-2-(3,4-dichlorophenoxy)-N-methyl- (9CI) (CA INDEX NAME)




RN 289717-48-2 CAPLUS

CN Acetamide, N-[4-(3,4-dichlorophenoxy)-3-[(dimethylamino)methyl]phenyl]-
(9CI) (CA INDEX NAME)

RN 289717-52-8 CAPLUS


CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N,N-dimethyl- (9CI)
(CA INDEX NAME)

RN 289717-56-2 CAPLUS

CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-methoxy-N-methyl- (9CI) (CA
INDEX NAME)


RN 289717-57-3 CAPLUS

CN Benzenemethanamine, 2-(4-chlorophenoxy)-5-fluoro-N-methyl- (9CI) (CA
INDEX NAME)




RN 289717-59-5 CAPLUS

CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N,N,5-trimethyl- (9CI) (CA INDEX NAME)




RN 289717-60-8 CAPLUS

CN Benzenemethanamine, 4-bromo-2-(3,4-dichlorophenoxy)-N-methyl- (9CI) (CA INDEX NAME)




RN 289717-61-9 CAPLUS

CN Benzenemethanamine, 5-bromo-2-(3,4-dichlorophenoxy)-N-methyl- (9CI) (CA INDEX NAME)




RN 289717-62-0 CAPLUS

CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-4,5-dimethoxy-N-methyl- (9CI) (CA INDEX NAME)




RN 289717-63-1 CAPLUS

CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-4-methoxy-N,N-dimethyl- (9CI)
(CA INDEX NAME)




RN 289717-64-2 CAPLUS

CN Benzonitrile, 4-(3,4-dichlorophenoxy)-3-[(methylamino)methyl]- (9CI) (CA
INDEX NAME)



RN 289717-65-3 CAPLUS


CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N,4,5-trimethyl- (9CI) (CA
INDEX NAME)



RN 289717-66-4 CAPLUS


CN Benzonitrile, 3-(3,4-dichlorophenoxy)-4-[(methylamino)methyl]- (9CI) (CA

INDEX NAME)




RN 289717-69-7 CAPLUS

CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N-methyl-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 289717-70-0 CAPLUS

CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-4-methoxy-N-methyl- (9CI) (CA INDEX NAME)



RN 289717-71-1 CAPLUS


CN Benzenemethanamine, 2-(4-chloro-3-fluorophenoxy)-5-fluoro-N-methyl- (9CI) (CA INDEX NAME)



10/010,651

RN 289717-72-2 CAPLUS

CN Benzenemethanamine, 2-(3-chloro-4-fluorophenoxy)-5-fluoro-N-methyl- (9CI)
(CA INDEX NAME)



L10 ANSWER 6 OF 21 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 2002:755211 CAPLUS
 DN 137:262839
 TI Preparation of phenoxybenzylamines as monoamine reuptake inhibitors for treatment of CNS disorders.
 IN Howard, Harry R.; Schmidt, Christopher J.; Seeger, Thomas F.; Elliott, Mark L.
 PA USA
 SO U.S. Pat. Appl. Publ., 24 pp., Cont.-in-part of U.S. Ser. No. 529,207. CODEN: USXXCO
 DT Patent
 LA English
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2002143003	A1	20021003	US 2001-845992	20010430
	WO 2000050380	A1	20000831	WO 2000-IB108	20000202
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
PRAI	US 1999-121313P	P	19990223		
	US 2000-529207	A2	20000202		
	WO 2000-IB108	W	20000202		
OS	MARPAT 137:262839				
AB	ROZCR3R4NR1R2 [R = (un)substituted Ph; R1,R2 = H, alk(en)yl, alkynyl; NR1R2 = heterocyclyl; R3,R4 = H or (fluoro)alkyl; R3R4 = (un)substituted alkylene; R2R3 = atoms to complete a heterocyclic ring; Z = (un)substituted phenylene] were prepd. as monoamine reuptake inhibitors (no data). Such compds. are useful exhibit activity as serotonin, norepinephrine and dopamine reuptake inhibitors, and their pharmaceutically acceptable salts, and their use in the treatment of central nervous system and other disorders.				
IT	289716-74-1P , Benzenemethanamine, 2-fluoro-6-(4-methylphenoxy)- 289716-75-2P , Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro- 289716-79-6P , Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N,N-dimethyl-5-(trifluoromethyl)- 289716-80-9P , Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N,N-dimethyl-5-(trifluoromethyl)-, (2Z)-2-butenedioate (1:1) 289716-89-8P , Benzenemethanamine, 2-(4-chlorophenoxy)-5-fluoro-N-methyl-, hydrochloride 289716-92-3P , Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N,N-dimethyl-, hydrochloride 289716-93-4P , Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N-methyl-, hydrochloride 289716-94-5P , Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N-methyl- 289716-95-6P , Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N-methyl-, (2Z)-2-butenedioate (2:1) 289716-96-7P , Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N,N-dimethyl-5-nitro- 289716-97-8P , Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N,N-dimethyl-3-(trifluoromethyl)-, hydrochloride 289717-01-7P , Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N,N-dimethyl-4-(trifluoromethyl)- 289717-02-8P , Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N,N-dimethyl-4-(trifluoromethyl)-, (2Z)-2-butenedioate (1:1) 289717-09-5P , Benzenemethanamine,				


2-(3,4-dichlorophenoxy)-N,N-dimethyl-6-(trifluoromethyl)-, hydrochloride
289717-11-9P, Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N-methyl-
 6-(trifluoromethyl)-, (2Z)-2-butenedioate (1:1) **289717-13-1P**,
 Benzenemethanamine, 2-(3,4-dimethylphenoxy)-5-fluoro-N-methyl-,
 (2Z)-2-butenedioate (1:1) **289717-16-4P**, Benzenemethanamine,
 2-(3,4-dichlorophenoxy)-N-methyl-4-(trifluoromethyl)- **289717-17-5P**
 , Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N-methyl-4-(trifluoromethyl)-
 , (2Z)-2-butenedioate (1:1) **289717-18-6P**, Benzenemethanamine,
 4-chloro-2-(3,4-dichlorophenoxy)-N-methyl- **289717-19-7P**,
 Benzenemethanamine, 4-chloro-2-(3,4-dichlorophenoxy)-N-methyl-,
 (2Z)-2-butenedioate (1:1) **289717-23-3P**, Benzenemethanamine,
 2-(3,4-dichlorophenoxy)-3-fluoro-N-methyl-, (2Z)-2-butenedioate (1:1)
289717-28-8P, Benzenemethanamine, 2-(3,4-dichlorophenoxy)-4-fluoro-
 N-methyl-, (2Z)-2-butenedioate (1:1) **289717-29-9P**,
 Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-methoxy-N-methyl-,
 hydrochloride **289717-32-4P**, Benzenemethanamine,
 2-(4-chlorophenoxy)-5-fluoro-N,N-dimethyl-, (2Z)-2-butenedioate (1:1)
289717-33-5P, Benzenemethanamine, 2-(3,4-dichlorophenoxy)-4,5-
 dimethoxy-N-methyl-, hydrochloride **289717-34-6P**,
 Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N,4,5-trimethyl-,
 hydrochloride **289717-35-7P**, Benzenemethanamine,
 5-bromo-2-(3,4-dichlorophenoxy)-N-methyl-, hydrochloride
289717-36-8P, Benzenemethanamine, 4-bromo-2-(3,4-dichlorophenoxy)-
 N-methyl-, hydrochloride **289717-39-1P**, Benzonitrile,
 3-(3,4-dichlorophenoxy)-4-[(methylamino)methyl]-, monohydrochloride
289717-40-4P, Benzenesulfonamide, 4-(3,4-dichlorophenoxy)-N-methyl-
 3-[(methylamino)methyl]-, monohydrochloride **289717-41-5P**,
 Benzenemethanamine, 2-(3,4-dichlorophenoxy)-4-methoxy-N,N-dimethyl-,
 hydrochloride **289717-42-6P**, Benzenemethanamine,
 2-(3,4-dichlorophenoxy)-N,N,5-trimethyl-, hydrochloride
289717-43-7P, Benzenemethanamine, 2-fluoro-N,N-dimethyl-6-(4-
 methylphenoxy)- **289717-44-8P**, Benzenemethanamine,
 2-fluoro-N,N-dimethyl-6-(4-methylphenoxy)-, (2Z)-2-butenedioate (1:1)
289717-45-9P, Benzenemethanamine, 5-amino-2-(3,4-dichlorophenoxy)-
 N,N-dimethyl-, monohydrochloride **289717-46-0P**,
 Benzenemethanamine, 5-amino-2-(3,4-dichlorophenoxy)-N,N-dimethyl-
289717-47-1P, Acetamide, N-[4-(3,4-dichlorophenoxy)-3-
 [(dimethylamino)methyl]phenyl]-, monohydrochloride **289717-48-2P**,
 Acetamide, N-[4-(3,4-dichlorophenoxy)-3-[(dimethylamino)methyl]phenyl]-
289717-51-7P, Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-
 , hydrochloride **289717-52-8P**, Benzenemethanamine,
 2-(3,4-dichlorophenoxy)-5-fluoro-N,N-dimethyl- **289717-56-2P**,
 Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-methoxy-N-methyl-
289717-57-3P, Benzenemethanamine, 2-(4-chlorophenoxy)-5-fluoro-N-
 methyl- **289717-59-5P**, Benzenemethanamine, 2-(3,4-
 dichlorophenoxy)-N,N,5-trimethyl- **289717-60-8P**,
 Benzenemethanamine, 4-bromo-2-(3,4-dichlorophenoxy)-N-methyl-
289717-61-9P, Benzenemethanamine, 5-bromo-2-(3,4-dichlorophenoxy)-
 N-methyl- **289717-62-0P**, Benzenemethanamine, 2-(3,4-
 dichlorophenoxy)-4,5-dimethoxy-N-methyl- **289717-63-1P**,
 Benzenemethanamine, 2-(3,4-dichlorophenoxy)-4-methoxy-N,N-dimethyl-
289717-64-2P, Benzonitrile, 4-(3,4-dichlorophenoxy)-3-
 [(methylamino)methyl]- **289717-65-3P**, Benzenemethanamine,
 2-(3,4-dichlorophenoxy)-N,4,5-trimethyl- **289717-66-4P**,
 Benzonitrile, 3-(3,4-dichlorophenoxy)-4-[(methylamino)methyl]-
289717-69-7P, Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N-methyl-
 5-(trifluoromethyl)- **289717-70-0P**, Benzenemethanamine,
 2-(3,4-dichlorophenoxy)-4-methoxy-N-methyl- **289717-71-1P**,

Benzenemethanamine, 2-(4-chloro-3-fluorophenoxy)-5-fluoro-N-methyl-
289717-72-2P, Benzenemethanamine, 2-(3-chloro-4-fluorophenoxy)-5-
 fluoro-N-methyl- **289719-21-7P**, Benzenemethanamine,
 2-(3,4-dichlorophenoxy)-5-methyl-, hydrochloride **289719-22-8P**,
 Benzenemethanamine, 2-(3,4-dichlorophenoxy)-4-methoxy-, hydrochloride
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(prepn. of phenoxybenzylamines as monoamine reuptake inhibitors)


RN 289716-74-1 CAPLUS

CN Benzenemethanamine, 2-fluoro-6-(4-methylphenoxy)- (9CI) (CA INDEX NAME)




RN 289716-75-2 CAPLUS

CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro- (9CI) (CA INDEX NAME)



RN 289716-79-6 CAPLUS

CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N,N-dimethyl-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 289716-80-9 CAPLUS

CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N,N-dimethyl-5-(trifluoromethyl)-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 289716-79-6

CMF C16 H14 Cl2 F3 N O




CM 2


CRN 110-16-7

CMF C4 H4 O4

Double bond geometry as shown.




RN 289716-89-8 CAPLUS

CN Benzenemethanamine, 2-(4-chlorophenoxy)-5-fluoro-N-methyl-, hydrochloride
(9CI) (CA INDEX NAME)

● HCl


RN 289716-92-3 CAPLUS

CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N,N-dimethyl-,
hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 289716-93-4 CAPLUS
 CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N-methyl-,
 hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 289716-94-5 CAPLUS
 CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N-methyl- (9CI) (CA
 INDEX NAME)




*Elected
species.*

RN 289716-95-6 CAPLUS
 CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N-methyl-,
 (2Z)-2-butenedioate (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 289716-94-5
 CMF C14 H12 Cl2 F N O




CM 2


CRN 110-16-7

CMF C4 H4 O4

Double bond geometry as shown.




RN 289716-96-7 CAPLUS

CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N,N-dimethyl-5-nitro- (9CI)
(CA INDEX NAME)


RN 289716-97-8 CAPLUS

CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N,N-dimethyl-3-(trifluoromethyl)-, hydrochloride (9CI) (CA INDEX NAME)



HCl


RN 289717-01-7 CAPLUS
 CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N,N-dimethyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 289717-02-8 CAPLUS
 CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N,N-dimethyl-4-(trifluoromethyl)-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 289717-01-7
 CMF C16 H14 Cl2 F3 N O





CM 2

CRN 110-16-7
 CMF C4 H4 O4

Double bond geometry as shown.



RN 289717-09-5 CAPLUS
 CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N,N-dimethyl-6-(trifluoromethyl)-, hydrochloride (9CI) (CA INDEX NAME)



● HCl



RN 289717-11-9 CAPLUS

CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N-methyl-6-(trifluoromethyl)-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 289717-10-8

CMF C15 H12 Cl2 F3 N O




CM 2

CRN 110-16-7

CMF C4 H4 O4

Double bond geometry as shown.




RN 289717-13-1 CAPLUS

CN Benzenemethanamine, 2-(3,4-dimethylphenoxy)-5-fluoro-N-methyl-,
(2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 289717-12-0

CMF C16 H18 F N O




CM 2

CRN 110-16-7


CMF C4 H4 O4

Double bond geometry as shown.



RN 289717-16-4 CAPLUS

CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N-methyl-4-(trifluoromethyl)-
(9CI) (CA INDEX NAME)



RN 289717-17-5 CAPLUS


CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N-methyl-4-(trifluoromethyl)-,

(2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 289717-16-4

CMF C15 H12 Cl2 F3 N O




CM 2

CRN 110-16-7


CMF C4 H4 O4

Double bond geometry as shown.



RN 289717-18-6 CAPLUS

CN Benzenemethanamine, 4-chloro-2-(3,4-dichlorophenoxy)-N-methyl- (9CI) (CA INDEX NAME)




RN 289717-19-7 CAPLUS

CN Benzenemethanamine, 4-chloro-2-(3,4-dichlorophenoxy)-N-methyl-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 289717-18-6

CMF C14 H12 Cl3 N O




CM 2

CRN 110-16-7

CMF C4 H4 O4

Double bond geometry as shown.




RN 289717-23-3 CAPLUS

CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-3-fluoro-N-methyl-,
(2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 289717-22-2

CMF C14 H12 Cl2 F N O




CM 2

CRN 110-16-7

CMF C4 H4 O4


Double bond geometry as shown.



RN 289717-28-8 CAPLUS
 CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-4-fluoro-N-methyl-,
 (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 289717-27-7
 CMF C14 H12 Cl2 F N O




CM 2

CRN 110-16-7
 CMF C4 H4 O4

Double bond geometry as shown.



RN 289717-29-9 CAPLUS
 CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-methoxy-N-methyl-,
 hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 289717-32-4 CAPLUS
 CN Benzenemethanamine, 2-(4-chlorophenoxy)-5-fluoro-N,N-dimethyl-,
 (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 289717-31-3
 CMF C15 H15 Cl F N O




CM 2

CRN 110-16-7
 CMF C4 H4 O4

Double bond geometry as shown.




RN 289717-33-5 CAPLUS
 CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-4,5-dimethoxy-N-methyl-,
 hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 289717-34-6 CAPLUS
 CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N,4,5-trimethyl-,
 hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 289717-35-7 CAPLUS
 CN Benzenemethanamine, 5-bromo-2-(3,4-dichlorophenoxy)-N-methyl-,
 hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 289717-36-8 CAPLUS
 CN Benzenemethanamine, 4-bromo-2-(3,4-dichlorophenoxy)-N-methyl-,
 hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 289717-39-1 CAPLUS
 CN Benzonitrile, 3-(3,4-dichlorophenoxy)-4-[(methylamino)methyl]-,
 monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 289717-40-4 CAPLUS
 CN Benzenesulfonamide, 4-(3,4-dichlorophenoxy)-N-methyl-3-[(methylamino)methyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 289717-41-5 CAPLUS
 CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-4-methoxy-N,N-dimethyl-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 289717-42-6 CAPLUS
 CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N,N,5-trimethyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 289717-43-7 CAPLUS
 CN Benzenemethanamine, 2-fluoro-N,N-dimethyl-6-(4-methylphenoxy)- (9CI) (CA INDEX NAME)



RN 289717-44-8 CAPLUS
 CN Benzenemethanamine, 2-fluoro-N,N-dimethyl-6-(4-methylphenoxy)-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 289717-43-7
 CMF C16 H18 F N O



CM 2


CRN 110-16-7
 CMF C4 H4 O4

Double bond geometry as shown.



RN 289717-45-9 CAPLUS


CN Benzenemethanamine, 5-amino-2-(3,4-dichlorophenoxy)-N,N-dimethyl-,
monohydrochloride (9CI) (CA INDEX NAME)



● HCl



RN 289717-46-0 CAPLUS

CN Benzenemethanamine, 5-amino-2-(3,4-dichlorophenoxy)-N,N-dimethyl- (9CI)
(CA INDEX NAME)





RN 289717-47-1 CAPLUS

CN Acetamide, N-[4-(3,4-dichlorophenoxy)-3-[(dimethylamino)methyl]phenyl]-,
monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 289717-48-2 CAPLUS
 CN Acetamide, N-[4-(3,4-dichlorophenoxy)-3-[(dimethylamino)methyl]phenyl]-
 (9CI) (CA INDEX NAME)




RN 289717-51-7 CAPLUS
 CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-, hydrochloride (9CI)
 (CA INDEX NAME)



● HCl


RN 289717-52-8 CAPLUS

CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N,N-dimethyl- (9CI)
(CA INDEX NAME)




RN 289717-56-2 CAPLUS

CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-methoxy-N-methyl- (9CI) (CA
INDEX NAME)




RN 289717-57-3 CAPLUS

CN Benzenemethanamine, 2-(4-chlorophenoxy)-5-fluoro-N-methyl- (9CI) (CA
INDEX NAME)




RN 289717-59-5 CAPLUS

CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N,N,5-trimethyl- (9CI) (CA
INDEX NAME)




RN 289717-60-8 CAPLUS

CN Benzenemethanamine, 4-bromo-2-(3,4-dichlorophenoxy)-N-methyl- (9CI) (CA INDEX NAME)




RN 289717-61-9 CAPLUS

CN Benzenemethanamine, 5-bromo-2-(3,4-dichlorophenoxy)-N-methyl- (9CI) (CA INDEX NAME)




RN 289717-62-0 CAPLUS

CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-4,5-dimethoxy-N-methyl- (9CI) (CA INDEX NAME)




RN 289717-63-1 CAPLUS


CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-4-methoxy-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 289717-64-2 CAPLUS
 CN Benzonitrile, 4-(3,4-dichlorophenoxy)-3-[(methylamino)methyl]- (9CI) (CA INDEX NAME)




RN 289717-65-3 CAPLUS
 CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N,4,5-trimethyl- (9CI) (CA INDEX NAME)



RN 289717-66-4 CAPLUS
 CN Benzonitrile, 3-(3,4-dichlorophenoxy)-4-[(methylamino)methyl]- (9CI) (CA INDEX NAME)




RN 289717-69-7 CAPLUS
 CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N-methyl-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 289717-70-0 CAPLUS

CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-4-methoxy-N-methyl- (9CI) (CA INDEX NAME)




RN 289717-71-1 CAPLUS

CN Benzenemethanamine, 2-(4-chloro-3-fluorophenoxy)-5-fluoro-N-methyl- (9CI) (CA INDEX NAME)



RN 289717-72-2 CAPLUS


CN Benzenemethanamine, 2-(3-chloro-4-fluorophenoxy)-5-fluoro-N-methyl- (9CI) (CA INDEX NAME)



RN 289719-21-7 CAPLUS


CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-methyl-, hydrochloride (9CI)

(CA INDEX NAME)



● HCl

RN 289719-22-8 CAPLUS

CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-4-methoxy-, hydrochloride
(9CI) (CA INDEX NAME)

● HCl

L10 ANSWER 7 OF 21 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 2002:674788 CAPLUS
 DN 137:195595
 TI Atypical antipsychotic-antidepressant combination for treatment of
 depression, obsessive compulsive disorder, and psychosis
 IN Howard, Harry R., Jr.
 PA Pfizer Inc., USA
 SO U.S. Pat. Appl. Publ., 20 pp.
 CODEN: USXXCO
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2002123490	A1	20020905	US 2001-10651	20011206 ←
	EP 1238676	A1	20020911	EP 2002-251153	20020220
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2002308801	A2	20021023	JP 2002-50579	20020227
PRAI	US 2001-272619P	P	20010301		
OS	MARPAT 137:195595				

AB The invention provides a method for treating depression, obsessive compulsive disorder, and psychosis in a mammal, including a human, by administering to the mammal an atypical antipsychotic in combination with an antidepressant agent with improvement in efficiency. It also provides pharmaceutical compns. contg. a pharmaceutically acceptable carrier, an atypical antipsychotic, and a serotonin reuptake inhibitor.


IT 289716-79-6 289716-94-5 289717-01-7
 289717-16-4 289717-18-6 289717-48-2
 289717-52-8 289717-56-2 289717-57-3
 289717-59-5 289717-60-8 289717-61-9
 289717-62-0 289717-63-1 289717-64-2
 289717-65-3 289717-66-4 289717-69-7
 289717-70-0 289717-71-1 289717-72-2
 444888-23-7 444888-24-8 444888-25-9
 444888-27-1 444888-29-3 444888-31-7
 444888-34-0 444888-35-1 444888-36-2
 444888-37-3 444888-38-4 444888-39-5
 444888-49-7 454456-43-0 454456-75-8

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(atypical antipsychotic-antidepressant combination for treatment of depression, obsessive compulsive disorder, and psychosis)


RN 289716-79-6 CAPLUS

CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N,N-dimethyl-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 289716-94-5 CAPLUS

CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N-methyl- (9CI) (CA INDEX NAME)




RN 289717-01-7 CAPLUS

CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N,N-dimethyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 289717-16-4 CAPLUS

CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N-methyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)





RN 289717-18-6 CAPLUS

CN Benzenemethanamine, 4-chloro-2-(3,4-dichlorophenoxy)-N-methyl- (9CI) (CA INDEX NAME)




RN 289717-48-2 CAPLUS

CN Acetamide, N-[4-(3,4-dichlorophenoxy)-3-[(dimethylamino)methyl]phenyl]-
(9CI) (CA INDEX NAME)




RN 289717-52-8 CAPLUS

CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N,N-dimethyl- (9CI)
(CA INDEX NAME)




RN 289717-56-2 CAPLUS

CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-methoxy-N-methyl- (9CI) (CA
INDEX NAME)




RN 289717-57-3 CAPLUS

CN Benzenemethanamine, 2-(4-chlorophenoxy)-5-fluoro-N-methyl- (9CI) (CA INDEX NAME)




RN 289717-59-5 CAPLUS

CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N,N,5-trimethyl- (9CI) (CA INDEX NAME)




RN 289717-60-8 CAPLUS

CN Benzenemethanamine, 4-bromo-2-(3,4-dichlorophenoxy)-N-methyl- (9CI) (CA INDEX NAME)




RN 289717-61-9 CAPLUS

CN Benzenemethanamine, 5-bromo-2-(3,4-dichlorophenoxy)-N-methyl- (9CI) (CA INDEX NAME)




RN 289717-62-0 CAPLUS

CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-4,5-dimethoxy-N-methyl- (9CI)
(CA INDEX NAME)




RN 289717-63-1 CAPLUS

CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-4-methoxy-N,N-dimethyl- (9CI)
(CA INDEX NAME)



RN 289717-64-2 CAPLUS


CN Benzonitrile, 4-(3,4-dichlorophenoxy)-3-[(methylamino)methyl]- (9CI) (CA
INDEX NAME)



RN 289717-65-3 CAPLUS


CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N,4,5-trimethyl- (9CI) (CA

INDEX NAME)




RN 289717-66-4 CAPLUS

CN Benzonitrile, 3-(3,4-dichlorophenoxy)-4-[(methylamino)methyl]- (9CI) (CA INDEX NAME)




RN 289717-69-7 CAPLUS

CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N-methyl-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 289717-70-0 CAPLUS


CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-4-methoxy-N-methyl- (9CI) (CA INDEX NAME)




RN 289717-71-1 CAPLUS

CN Benzenemethanamine, 2-(4-chloro-3-fluorophenoxy)-5-fluoro-N-methyl- (9CI)
(CA INDEX NAME)

RN 289717-72-2 CAPLUS


CN Benzenemethanamine, 2-(3-chloro-4-fluorophenoxy)-5-fluoro-N-methyl- (9CI)
(CA INDEX NAME)

RN 444888-23-7 CAPLUS

CN Benzenemethanamine, 4-chloro-2-(4-chlorophenoxy)-5-fluoro-N-methyl- (9CI)
(CA INDEX NAME)


RN 444888-24-8 CAPLUS

CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-4-methoxy-N-methyl- (9CI) (CA INDEX NAME)




RN 444888-25-9 CAPLUS

CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-(dimethylamino)-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 444888-27-1 CAPLUS

CN Benzenemethanamine, 2-(4-chlorophenoxy)-N-methyl-5-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 444888-29-3 CAPLUS

CN Benzenemethanamine, 2-(4-chlorophenoxy)-N,4,5-trimethyl- (9CI) (CA INDEX NAME)




RN 444888-31-7 CAPLUS

CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N-methyl-5-(methylthio)- (9CI) (CA INDEX NAME)




RN 444888-34-0 CAPLUS

CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N,N-dimethyl-5-(methylthio)-
(9CI) (CA INDEX NAME)




RN 444888-35-1 CAPLUS

CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N,N-dimethyl-5-
(methylsulfinyl)- (9CI) (CA INDEX NAME)



RN 444888-36-2 CAPLUS


CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N-methyl-5-(methylsulfonyl)-
(9CI) (CA INDEX NAME)



RN 444888-37-3 CAPLUS


CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N-methyl-5-(methylsulfonyl)-

(9CI) (CA INDEX NAME)




RN 444888-38-4 CAPLUS

CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N,N-dimethyl-5-(methylsulfonyl)- (9CI) (CA INDEX NAME)





RN 444888-39-5 CAPLUS

CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N-methyl-5-[(1-methylethyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 444888-49-7 CAPLUS

CN Benzenemethanamine, 4-chloro-2-(3,4-dichlorophenoxy)-N-methyl-5-(methylsulfonyl)- (9CI) (CA INDEX NAME)




RN 454456-43-0 CAPLUS

CN Benzenemethanamine, 5-fluoro-2-(4-fluoro-3-methoxyphenoxy)-N,N-dimethyl-
(9CI) (CA INDEX NAME)




RN 454456-75-8 CAPLUS

CN Acetamide, N-[4-(3,4-dichlorophenoxy)-3-[(methylamino)methyl]phenyl]-
(9CI) (CA INDEX NAME)




L10 ANSWER 8 OF 21 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 2002:595509 CAPLUS
 DN 137:135106
 TI Combination of a 5-HT3 receptor antagonist with a serotonin reuptake inhibitor for the treatment of depression
 IN Howard, Harry R.
 PA USA
 SO U.S. Pat. Appl. Publ., 20 pp.
 CODEN: USXXCO
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2002107244	A1	20020808	US 2001-2303	20011102
	EP 1230921	A1	20020814	EP 2002-250541	20020128
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2002275097	A2	20020925	JP 2002-20186	20020129
	BR 2002000246	A	20021029	BR 2002-246	20020131
PRAI	US 2001-266340P	P	20010202		
OS	MARPAT 137:135106				
AB	The present invention relates to a method of treating depression or anxiety in a mammal, including a human, by administering to the mammal a 5-HT3 receptor antagonist in combination with a serotonin reuptake inhibitor (SRI) antidepressant agent with improvement in sexual function and/or redn. in gastro-intestinal side effects. It also relates to pharmaceutical compns. contg. a pharmaceutically acceptable carrier, a 5-HT3 receptor antagonist and an SRI antidepressant. The ratio of the 5-HT3 receptor antagonist and the SRI antidepressant agent is between 0.001 to 1 and 1000 to 1, and esp. between 0.01 to 1 and 100 to 1 (no data).				
IT	289716-79-6 289716-94-5 289717-01-7 289717-16-4 289717-18-6 289717-48-2 289717-52-8 289717-56-2 289717-57-3 289717-59-5 289717-60-8 289717-61-9 289717-62-0 289717-63-1 289717-64-2 289717-65-3 289717-66-4 289717-69-7 289717-70-0 289717-71-1 289717-72-2 444888-23-7 444888-24-8 444888-25-9 444888-26-0 444888-27-1 444888-29-3 444888-31-7 444888-34-0 444888-35-1 444888-36-2 444888-37-3 444888-38-4 444888-39-5 444888-49-7 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (combination of 5-HT3 receptor antagonist with serotonin reuptake inhibitor for treatment of depression)				
RN	289716-79-6 CAPLUS				
CN	Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N,N-dimethyl-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)				




RN 289716-94-5 CAPLUS

CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N-methyl- (9CI) (CA INDEX NAME)




RN 289717-01-7 CAPLUS

CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N,N-dimethyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 289717-16-4 CAPLUS


CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N-methyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 289717-18-6 CAPLUS

CN Benzenemethanamine, 4-chloro-2-(3,4-dichlorophenoxy)-N-methyl- (9CI) (CA INDEX NAME)


INDEX NAME)



RN 289717-48-2 CAPLUS

CN Acetamide, N-[4-(3,4-dichlorophenoxy)-3-[(dimethylamino)methyl]phenyl]-
(9CI) (CA INDEX NAME)


RN 289717-52-8 CAPLUS

CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N,N-dimethyl- (9CI)
(CA INDEX NAME)

*Selected
species.*


RN 289717-56-2 CAPLUS

CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-methoxy-N-methyl- (9CI) (CA
INDEX NAME)




RN 289717-57-3 CAPLUS

CN Benzenemethanamine, 2-(4-chlorophenoxy)-5-fluoro-N-methyl- (9CI) (CA INDEX NAME)




RN 289717-59-5 CAPLUS

CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N,N,5-trimethyl- (9CI) (CA INDEX NAME)




RN 289717-60-8 CAPLUS

CN Benzenemethanamine, 4-bromo-2-(3,4-dichlorophenoxy)-N-methyl- (9CI) (CA INDEX NAME)




RN 289717-61-9 CAPLUS

CN Benzenemethanamine, 5-bromo-2-(3,4-dichlorophenoxy)-N-methyl- (9CI) (CA INDEX NAME)




RN 289717-62-0 CAPLUS

CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-4,5-dimethoxy-N-methyl- (9CI)
(CA INDEX NAME)




RN 289717-63-1 CAPLUS

CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-4-methoxy-N,N-dimethyl- (9CI)
(CA INDEX NAME)



RN 289717-64-2 CAPLUS


CN Benzonitrile, 4-(3,4-dichlorophenoxy)-3-[(methylamino)methyl]- (9CI) (CA
INDEX NAME)



RN 289717-65-3 CAPLUS


CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N,4,5-trimethyl- (9CI) (CA

INDEX NAME)




RN 289717-66-4 CAPLUS

CN Benzonitrile, 3-(3,4-dichlorophenoxy)-4-[(methylamino)methyl]- (9CI) (CA INDEX NAME)




RN 289717-69-7 CAPLUS

CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N-methyl-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 289717-70-0 CAPLUS


CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-4-methoxy-N-methyl- (9CI) (CA INDEX NAME)




RN 289717-71-1 CAPLUS

CN Benzenemethanamine, 2-(4-chloro-3-fluorophenoxy)-5-fluoro-N-methyl- (9CI)
(CA INDEX NAME)

RN 289717-72-2 CAPLUS


CN Benzenemethanamine, 2-(3-chloro-4-fluorophenoxy)-5-fluoro-N-methyl- (9CI)
(CA INDEX NAME)

RN 444888-23-7 CAPLUS

CN Benzenemethanamine, 4-chloro-2-(4-chlorophenoxy)-5-fluoro-N-methyl- (9CI)
(CA INDEX NAME)


RN 444888-24-8 CAPLUS

CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-4-methoxy-N-methyl- (9CI) (CA INDEX NAME)




RN 444888-25-9 CAPLUS

CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-(dimethylamino)-N,N-dimethyl- (9CI) (CA INDEX NAME).




RN 444888-26-0 CAPLUS

CN Benzenemethanamine, 5-fluoro-2-(4-fluoro-3-methoxyphenoxy)-4-methoxy-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 444888-27-1 CAPLUS

CN Benzenemethanamine, 2-(4-chlorophenoxy)-N-methyl-5-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 444888-29-3 CAPLUS

CN Benzenemethanamine, 2-(4-chlorophenoxy)-N,4,5-trimethyl- (9CI) (CA INDEX NAME)




RN 444888-31-7 CAPLUS

CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N-methyl-5-(methylthio)- (9CI)
(CA INDEX NAME)




RN 444888-34-0 CAPLUS

CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N,N-dimethyl-5-(methylthio)-
(9CI) (CA INDEX NAME)



RN 444888-35-1 CAPLUS


CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N,N-dimethyl-5-(methylsulfinyl)-
(9CI) (CA INDEX NAME)




RN 444888-36-2 CAPLUS

CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N-methyl-5-(methylsulfinyl)-


(9CI) (CA INDEX NAME)




RN 444888-37-3 CAPLUS

CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N-methyl-5-(methylsulfonyl)-
(9CI) (CA INDEX NAME)

RN 444888-38-4 CAPLUS



CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N,N-dimethyl-5-(methylsulfonyl)-
(9CI) (CA INDEX NAME)

RN 444888-39-5 CAPLUS

CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N-methyl-5-[(1-methylethyl)sulfonyl]-
(9CI) (CA INDEX NAME)

RN 444888-49-7 CAPLUS

CN Benzenemethanamine, 4-chloro-2-(3,4-dichlorophenoxy)-N-methyl-5-(methylsulfonyl)- (9CI) (CA INDEX NAME)



L10 ANSWER 9 OF 21 CAPLUS COPYRIGHT 2003 ACS on STN

AN 2002:293652 CAPLUS

DN 136:325531

TI Preparation of (poly)azanaphthalenyl carboxamides as HIV integrase inhibitors

IN Anthony, Neville J.; Gomez, Robert P.; Young, Steven D.; Egbertson, Melissa; Wai, John S.; Zhuang, Linghang; Embrey, Mark; Tran, Lekhanh; Melamed, Jeffrey Y.; Langford, H. Marie; Guare, James P.; Fisher, Thorsten E.; Jolly, Samson M.; Kuo, Michelle S.; Perlow, Debra S.; Bennett, Jennifer J.; Funk, Timothy W.

PA Merck & Co., Inc., USA

SO PCT Int. Appl., 434 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002030930	A2	20020418	WO 2001-US31456	20011009
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002011527	A5	20020422	AU 2002-11527	20011009
EP 1326865	A2	20030716	EP 2001-979582	20011009
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 2003055071	A1	20030320	US 2001-973853	20011010
PRAI US 2000-239707P	P	20001012		
US 2001-281656P	P	20010405		
WO 2001-US31456	W	20011009		

OS MARPAT 136:325531

AB Title compds., including certain quinoline carboxamide and naphthyridine carboxamide derivs., I [wherein A = (un)substituted Ph or Ph fused to a carbocycle; L = a single bond, or (un)substituted alkyl, alkenyl, alkylcycloalkylalkyl, or alkyl-M-alkyl; M = NRa, OCO, or CO₂; X = N or CQ₁; Y = N or CQ₂, provided that X and Y are not both N; Z₁ = N or CQ₃; Z₂ = N or CQ₄; Z₃ = N or CH; Q₁-Q₄ = independently H, halo, CN, NR₁CR₁₀, or (un)substituted alkyl, alkoxy, alkenyl, alkynyl, carbamoyl, carboximidamido, amino, etc.; or C₂Q₂Q₃ = (un)substituted 5- or 6-membered carbocycle or heterocycle; R₁ and R₂ = independently H, OH, halo, NO₂, CN, or (un)substituted alkyl, alkenyl, alkoxy, amino, sulfonylamino, etc.; R₃ and R₄ = independently H, halo, CN, NO₂, OH, alkenyl, or (un)substituted alkyl, amino, sulfonylamino, etc.; R₅ = H, CN, CN, or (un)substituted alkyl or aryl; Ra = independently H or (halo)alkyl; or pharmaceutically acceptable salts thereof] were prep'd. I are inhibitors of HIV integrase and inhibitors of HIV replication, and are useful in the prevention or treatment of infection by HIV and the treatment of AIDS, as compds. or pharmaceutically acceptable salts, or as ingredients in pharmaceutical compns., optionally in combination with other antivirals, immunomodulators, antibiotics, or vaccines. For example, Mitsunobu reaction of iso-Pr 3-(hydroxymethyl)pyridine-2-carboxylate with Me N-[(4-methylphenyl)sulfonyl]glycinate, followed by cyclization in the

presence on NaOMe, afforded Me 8-hydroxy-1,6-naphthyridine-7-carboxylate. Coupling with 3,5-dichlorobenzylamine in toluene gave II. Representative compds. were assayed for the inhibition of acute HIV infection of T-lymphoid cells and demonstrated IC95 values of < 20 .mu.M.


IT 175136-89-7, 2-Aminomethyl 3-chlorodiphenyl ether

RL: RCT (Reactant); RACT (Reactant or reagent)

(reactant; prepn. of (poly)azanaphthalenyl carboxamides as HIV integrase inhibitors for treatment of AIDS)

RN 175136-89-7 CAPLUS

CN Benzenemethanamine, 2-chloro-6-phenoxy- (9CI) (CA INDEX NAME)



L10 ANSWER 10 OF 21 CAPLUS COPYRIGHT 2003 ACS on STN

AN 2002:171851 CAPLUS

DN 136:232110

TI Preparation of phenoxybenzylamines as selective serotonin re-uptake inhibitors

IN Adam, Mavis Diane; Andrews, Mark David; Elliott, Mark Leonard; Gymer, Geoffrey Edward; Hepworth, David; Howard, Harry Ralph, Jr.; Middleton, Donald Stuart; Stobie, Alan

PA Pfizer Limited, UK; Pfizer Inc.

SO PCT Int. Appl., 110 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

D. J. D. Ent.

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002018333	A1	20020307	WO 2001-IB1521	20010822
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW:				
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2001078650	A5	20020313	AU 2001-78650	20010822
	EP 1313701	A1	20030528	EP 2001-956734	20010822
	R:				
	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	BR 2001013610	A	20030624	BR 2001-13610	20010822
	US 2003060456	A1	20030327	US 2001-941177	20010827
	US 6610747	B2	20030826		
	NO 2003000842	A	20030428	NO 2003-842	20030224
	HR 2003000141	A1	20030430	HR 2003-141	20030226
PRAI	GB 2000-21593	A	20000831		
	GB 2001-7116	A	20010321		
	US 2000-240271P	P	20001013		
	US 2001-292400P	P	20010521		
	WO 2001-IB1521	W	20010822		
OS	MARPAT 136:232110				
AB	Title compds. I [R1 and R2 independently = H, alkyl or (CH ₂) _n (C ₃ -C ₆ cycloalkyl) wherein n = 0, 1, 2 or 3; or R1 and R2 together with the nitrogen to which they are attached from an azetidine ring; Z or Y is -SR ₃ and the other Z or Y is halogen or -R ₃ ; wherein R ₃ = C1-4 alkyl optionally substituted with fluorine; except that R ₃ is not CF ₃ ; or Z and Y are linked so that, together with the interconnecting atoms, Z and Y form a fused 5 to 7-membered carbocyclic or heterocyclic ring, and wherein when Z and Y form a heterocyclic ring, in addn. to carbon atoms, the linkage contains one or two heteroatoms independently selected from O, S and N; R ₄ and R ₅ independently = A-X, wherein A = -CH=CH- or -(CH ₂) _p - where p is 0, 1 or 2; X = H, halo, CONR ₆ R ₇ , SO ₂ NR ₆ R ₇ , SO ₂ NHC(=O)R ₆ , OH, C1-4alkoxy, etc; or A-X = (un)substituted 5- or 6-membered heterocyclic ring contg. 1, 2 or 3 heteroatoms selected from N, S and O; R ₆ and R ₇ independently = H, (un)substituted alkyl; or R ₆ and R ₇ together with the N to which they are attached form a (un)substituted 4-6 membered heterocyclic ring] and there pharmaceutically acceptable salts are prepd. Thus, II was prepd. via substitution of 5-(aminosulfonyl)-2-fluoro-N-				

methylbenzamide by 2,3-dihydrobenzo[b]thiophen-5-ol with successive BF₃.cntdot.THF catalyzed amide redn., formylation of secondary amine, and redn. II demonstrated a serotonin re-uptake inhibition IC₅₀ of 4.7nM. I inhibit monoamine re-uptake and in particular exhibit activity as selective serotonin reuptake inhibitors.


IT 402911-90-4P 402911-91-5P 402911-92-6P
402911-93-7P 402911-96-0P 402911-97-1P
402911-98-2P 402912-01-0P 402912-02-1P
402912-06-5P 402912-07-6P 402912-08-7P
402912-09-8P 402912-10-1P 402912-13-4P
402912-14-5P 402912-15-6P 402912-16-7P
402912-17-8P 402912-19-0P 402912-23-6P
402912-25-8P 402912-29-2P 402912-30-5P
402912-33-8P 402912-34-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; prepn. of serotonin re-uptake inhibitors phenoxybenzylamines)


RN 402911-90-4 CAPLUS

CN Carbamic acid, [[5-bromo-2-[3-chloro-4-(methylthio)phenoxy]phenyl]methyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 402911-91-5 CAPLUS

CN Carbamic acid, [[5-bromo-2-[3-fluoro-4-(methylthio)phenoxy]phenyl]methyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 402911-92-6 CAPLUS

CN Carbamic acid, [[5-bromo-2-[3-methyl-4-(methylthio)phenoxy]phenyl]methyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 402911-93-7 CAPLUS

CN Carbamic acid, [[5-cyano-2-[3-fluoro-4-(methylthio)phenoxy]phenyl]methyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 402911-96-0 CAPLUS

CN Benzoic acid, 4-[3-chloro-4-(methylthio)phenoxy]-3-[[[(1,1-dimethylethoxy)carbonyl]methylamino]methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 402911-97-1 CAPLUS

CN Benzoic acid, 3-[[[(1,1-dimethylethoxy)carbonyl]methylamino]methyl]-4-[3-fluoro-4-(methylthio)phenoxy]-, methyl ester (9CI) (CA INDEX NAME)




RN 402911-98-2 CAPLUS

CN Benzoic acid, 3-[[[(1,1-dimethylethoxy)carbonyl]methylamino]methyl]-4-[3-methyl-4-(methylthio)phenoxy]-, methyl ester (9CI) (CA INDEX NAME)




RN 402912-01-0 CAPLUS

CN Benzoic acid, 4-[3-chloro-4-(methylthio)phenoxy]-3-[[[(1,1-dimethylethoxy)carbonyl]methylamino]methyl]- (9CI) (CA INDEX NAME)




RN 402912-02-1 CAPLUS

CN Benzoic acid, 3-[[[(1,1-dimethylethoxy)carbonyl]methylamino]methyl]-4-[3-fluoro-4-(methylthio)phenoxy]- (9CI) (CA INDEX NAME)




RN 402912-06-5 CAPLUS

CN Carbamic acid, [[5-(aminocarbonyl)-2-[3-fluoro-4-(methylthio)phenoxy]phenyl]methyl]methyl-, 1,1-dimethylethyl ester (9CI)
(CA INDEX NAME)




RN 402912-07-6 CAPLUS

CN Carbamic acid, [[2-[3-fluoro-4-(methylthio)phenoxy]-5-[(methylamino)carbonyl]phenyl]methyl]methyl-, 1,1-dimethylethyl ester
(9CI) (CA INDEX NAME)




RN 402912-08-7 CAPLUS


CN Carbamic acid, [[2-[3-fluoro-4-(methylthio)phenoxy]-5-[[2-methoxyethyl)amino]carbonyl]phenyl]methyl]methyl-, 1,1-dimethylethyl ester
(9CI) (CA INDEX NAME)




RN 402912-09-8 CAPLUS
 CN Carbamic acid, [[5-(aminocarbonyl)-2-[3-chloro-4-(methylthio)phenoxy]phenyl]methyl]methyl-, 1,1-dimethylethyl ester (9CI)
 (CA INDEX NAME)



RN 402912-10-1 CAPLUS
 CN Carbamic acid, [[2-[3-chloro-4-(methylthio)phenoxy]-5-[(methylamino)carbonyl]phenyl]methyl]methyl-, 1,1-dimethylethyl ester
 (9CI) (CA INDEX NAME)




RN 402912-13-4 CAPLUS
 CN Carbamic acid, [[2-[3-chloro-4-(methylthio)phenoxy]-5-(hydroxymethyl)phenyl]methyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 402912-14-5 CAPLUS

CN Carbamic acid, [[2-[3-fluoro-4-(methylthio)phenoxy]-5-(hydroxymethyl)phenyl]methyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 402912-15-6 CAPLUS

CN Carbamic acid, [[5-(hydroxymethyl)-2-[3-methyl-4-(methylthio)phenoxy]phenyl]methyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 402912-16-7 CAPLUS

CN Carbamic acid, [[3-[[[(1,1-dimethylethoxy)carbonyl]methylamino]methyl]-4-[3-methyl-4-(methylthio)phenoxy]phenyl]methyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 402912-17-8 CAPLUS

CN Carbamic acid, [[3-[[[(1,1-dimethylethoxy)carbonyl]methylamino]methyl]-4-[3-fluoro-4-(methylthio)phenoxy]phenyl]methyl] (methylsulfonyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 402912-19-0 CAPLUS

CN Carbamic acid, methyl[[2-[3-methyl-4-(methylthio)phenoxy]-5-[[[(trifluoromethyl)sulfonyl]amino]methyl]phenyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 402912-23-6 CAPLUS

CN Benzenemethanamine, N-methyl-2-[3-methyl-4-(methylthio)phenoxy]-5-nitro- (9CI) (CA INDEX NAME)




RN 402912-25-8 CAPLUS

CN Carbamic acid, methyl[[2-[3-methyl-4-(methylthio)phenoxy]-5-nitrophenyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 402912-29-2 CAPLUS

CN Carbamic acid, [[5-amino-2-[3-methyl-4-(methylthio)phenoxy]phenyl]methyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 402912-30-5 CAPLUS

CN Carbamic acid, methyl[[2-[3-methyl-4-(methylthio)phenoxy]-5-[(methylsulfonyl)amino]phenyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 402912-33-8 CAPLUS

CN Carbamic acid, methyl[[5-[methyl(methylsulfonyl)amino]-2-[3-methyl-4-(methylthio)phenoxy]phenyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 402912-34-9 CAPLUS


CN Carbamic acid, [[5-[(2-hydroxyethyl)(methylsulfonyl)amino]-2-[3-methyl-4-(methylthio)phenoxy]phenyl]methyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



IT 402912-60-1P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of serotonin re-uptake inhibitors phenoxybenzylamines)
 RN 402912-60-1 CAPLUS
 CN Methanesulfonamide, N-[[4-[(dimethylamino)methyl]-3-[3-methyl-4-(methylthio)phenoxy]phenyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

IT **402912-62-3P**
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (prepn. of serotonin re-uptake inhibitors phenoxybenzylamines)
 RN 402912-62-3 CAPLUS
 CN Carbamic acid, [[4-[(dimethylamino)methyl]-3-[3-methyl-4-(methylthio)phenoxy]phenyl]methyl](methylsulfonyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




IT 402910-16-1P 402910-18-3P 402910-19-4P
 402910-27-4P 402910-43-4P 402910-50-3P
 402910-61-6P 402910-71-8P 402910-73-0P
 402910-81-0P 402910-82-1P 402910-83-2P
 402910-84-3P 402910-85-4P 402910-88-7P
 402910-89-8P 402910-90-1P 402910-91-2P
 402910-92-3P 402910-93-4P 402910-94-5P
 402910-96-7P 402911-10-8P 402911-20-0P
 402911-23-3P 402911-24-4P 402911-25-5P
 402911-26-6P 402911-28-8P 402911-34-6P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP

(Preparation); RACT (Reactant or reagent); USES (Uses)
 (target compd.; prepn. of serotonin re-uptake inhibitors
 phenoxybenzylamines)


RN 402910-16-1 CAPLUS

CN Benzenesulfonamide, 3-[(methylamino)methyl]-4-[3-methyl-4-(methylthio)phenoxy]- (9CI) (CA INDEX NAME)



RN 402910-18-3 CAPLUS


CN Benzenesulfonamide, 4-[3-chloro-4-(methylthio)phenoxy]-3-[(methylamino)methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 402910-19-4 CAPLUS

CN Benzenesulfonamide, 4-[3-fluoro-4-(methylthio)phenoxy]-3-[(methylamino)methyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 402910-27-4 CAPLUS


CN Benzenesulfonamide, 3-[(dimethylamino)methyl]-4-[3-methyl-4-

(methylthio)phenoxy]- (9CI) (CA INDEX NAME)




RN 402910-43-4 CAPLUS

CN Benzenemethanamine, N,N-dimethyl-2-[3-methyl-4-(methylthio)phenoxy]-5-nitro- (9CI) (CA INDEX NAME)




RN 402910-50-3 CAPLUS

CN Benzenemethanamine, 4-bromo-N,N-dimethyl-2-[3-methyl-4-(methylthio)phenoxy]- (9CI) (CA INDEX NAME)




RN 402910-61-6 CAPLUS

CN Benzenemethanamine, 5-bromo-N-methyl-2-[3-methyl-4-(methylthio)phenoxy]- (9CI) (CA INDEX NAME)




RN 402910-71-8 CAPLUS

CN Benzoic acid, 4-[(dimethylamino)methyl]-3-[3-methyl-4-(methylthio)phenoxy]-, methyl ester (9CI) (CA INDEX NAME)




RN 402910-73-0 CAPLUS

CN Benzoic acid, 4-[(dimethylamino)methyl]-3-[3-methyl-4-(methylthio)phenoxy]- (9CI) (CA INDEX NAME)



RN 402910-81-0 CAPLUS


CN Benzamide, 4-[3-fluoro-4-(methylthio)phenoxy]-3-[(methylamino)methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 402910-82-1 CAPLUS

CN Benzamide, 4-[3-fluoro-4-(methylthio)phenoxy]-N-methyl-3-[(methylamino)methyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 402910-83-2 CAPLUS
 CN Benzamide, 4-[3-fluoro-4-(methylthio)phenoxy]-N-(2-methoxyethyl)-3-[(methylamino)methyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 402910-84-3 CAPLUS
 CN Benzamide, 4-[3-chloro-4-(methylthio)phenoxy]-3-[(methylamino)methyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 402910-85-4 CAPLUS
 CN Benzamide, 4-[3-chloro-4-(methylthio)phenoxy]-N-methyl-3-[(methylamino)methyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 402910-88-7 CAPLUS
 CN Benzenemethanol, 4-[3-fluoro-4-(methylthio)phenoxy]-3-[(methylamino)methyl]-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 402910-89-8 CAPLUS
 CN Benzenemethanol, 4-[3-chloro-4-(methylthio)phenoxy]-3-[(methylamino)methyl]-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 402910-90-1 CAPLUS
 CN Benzonitrile, 4-[3-fluoro-4-(methylthio)phenoxy]-3-[(methylamino)methyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 402910-91-2 CAPLUS
 CN Methanesulfonamide, N-[[4-[3-fluoro-4-(methylthio)phenoxy]-3-[(methylamino)methyl]phenyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 402910-92-3 CAPLUS
 CN Benzenemethanol, 3-[(methylamino)methyl]-4-[3-methyl-4-(methylthio)phenoxy]-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 402910-93-4 CAPLUS
 CN Methanesulfonamide, N-[[3-[(methylamino)methyl]-4-[3-methyl-4-(methylthio)phenoxy]phenyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 402910-94-5 CAPLUS
 CN Methanesulfonamide, 1,1,1-trifluoro-N-[[3-[(methylamino)methyl]-4-[3-methyl-4-(methylthio)phenoxy]phenyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 402910-96-7 CAPLUS
 CN Benzonitrile, 3-[(methylamino)methyl]-4-[3-methyl-4-(methylthio)phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 402911-10-8 CAPLUS
 CN Benzonitrile, 3-[(dimethylamino)methyl]-4-[3-methyl-4-(methylthio)phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 402911-20-0 CAPLUS

CN Benzenemethanamine, 5-amino-N,N-dimethyl-2-[3-methyl-4-(methylthio)phenoxy]- (9CI) (CA INDEX NAME)




RN 402911-23-3 CAPLUS

CN Methanesulfonamide, N-[3-(aminomethyl)-4-[3-chloro-4-(methylthio)phenoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 402911-24-4 CAPLUS

CN Methanesulfonamide, N-[3-(aminomethyl)-4-[3-fluoro-4-(methylthio)phenoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 402911-25-5 CAPLUS

CN Methanesulfonamide, N-[3-(aminomethyl)-4-[3-methyl-4-(methylthio)phenoxy]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 402911-26-6 CAPLUS

CN Methanesulfonamide, N-[3-(aminomethyl)-4-[4-methyl-3-(methylthio)phenoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 402911-28-8 CAPLUS

CN Methanesulfonamide, N-[4-[3-fluoro-4-(methylthio)phenoxy]-3-[(methylamino)methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 402911-34-6 CAPLUS
 CN Methanesulfonamide, N-(2-hydroxyethyl)-N-[3-[(methylamino)methyl]-4-[3-methyl-4-(methylthio)phenoxy]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

IT 402910-24-1P 402910-28-5P 402910-32-1P
 402910-33-2P 402910-40-1P 402910-41-2P
 402910-54-7P 402910-56-9P 402910-60-5P
 402910-75-2P 402910-77-4P 402910-95-6P
 402910-97-8P 402911-01-7P 402911-02-8P
 402911-03-9P 402911-04-0P 402911-05-1P
 402911-08-4P 402911-09-5P 402911-11-9P
 402911-14-2P 402911-15-3P 402911-16-4P
 402911-18-6P 402911-29-9P 402911-30-2P
 402911-32-4P 402911-33-5P 402911-37-9P
 402911-39-1P 402911-42-6P 402911-43-7P
 402911-44-8P 402911-45-9P 402911-47-1P
 402911-48-2P 402911-49-3P 402912-53-2P
 402912-54-3P 402912-57-6P 402912-59-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(target compd.; prepn. of serotonin re-uptake inhibitors phenoxybenzylamines)

RN 402910-24-1 CAPLUS
 CN Benzenesulfonamide, 3-[(methylamino)methyl]-4-[4-methyl-3-(methylthio)phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 402910-28-5 CAPLUS
 CN Benzenesulfonamide, 3-[(dimethylamino)methyl]-N-methyl-4-[3-methyl-4-(methylthio)phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 402910-32-1 CAPLUS
 CN Benzenesulfonamide, 4-[3-chloro-4-(methylthio)phenoxy]-3-[(dimethylamino)methyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 402910-33-2 CAPLUS
 CN Benzenesulfonamide, 3-[(dimethylamino)methyl]-4-[3-fluoro-4-(methylthio)phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 402910-40-1 CAPLUS
 CN Benzenesulfonamide, 3-[(dimethylamino)methyl]-4-[4-methyl-3-(methylthio)phenoxy]- (9CI) (CA INDEX NAME)




RN 402910-41-2 CAPLUS
 CN Benzenemethanamine, 5-methoxy-N,N-dimethyl-2-[3-methyl-4-(methylthio)phenoxy]-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 402910-54-7 CAPLUS
 CN Benzenemethanamine, 5-bromo-2-[3-fluoro-4-(methylthio)phenoxy]-N-methyl-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 402910-56-9 CAPLUS
 CN Benzenemethanamine, 5-bromo-2-[3-chloro-4-(methylthio)phenoxy]-N-methyl-
 (9CI) (CA INDEX NAME)




RN 402910-60-5 CAPLUS
 CN Benzenemethanamine, 5-methoxy-N-methyl-2-[3-methyl-4-(methylthio)phenoxy]-
 , hydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 402910-75-2 CAPLUS
 CN Benzamide, 4-[(dimethylamino)methyl]-3-[3-methyl-4-(methylthio)phenoxy]-,
 monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 402910-77-4 CAPLUS


CN Benzenemethanol, 4-[(dimethylamino)methyl]-3-[3-methyl-4-(methylthio)phenoxy]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 402910-95-6 CAPLUS

CN Methanesulfonamide, N-[[3-[(dimethylamino)methyl]-4-[3-methyl-4-(methylthio)phenoxy]phenyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl


RN 402910-97-8 CAPLUS

CN Benzamide, 3-[(methylamino)methyl]-4-[3-methyl-4-(methylthio)phenoxy]-

(9CI) (CA INDEX NAME)




RN 402911-01-7 CAPLUS

CN Benzamide, 3-[(dimethylamino)methyl]-4-[3-fluoro-4-(methylthio)phenoxy]-
(9CI) (CA INDEX NAME)


RN 402911-02-8 CAPLUS

CN Benzamide, 3-[(dimethylamino)methyl]-4-[3-fluoro-4-(methylthio)phenoxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 402911-03-9 CAPLUS

CN Benzamide, 3-[(dimethylamino)methyl]-4-[3-fluoro-4-(methylthio)phenoxy]-N-(2-methoxyethyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 402911-04-0 CAPLUS


CN Benzamide, 4-[3-chloro-4-(methylthio)phenoxy]-3-[(dimethylamino)methyl]-
(9CI) (CA INDEX NAME)

RN 402911-05-1 CAPLUS

CN Benzamide, 4-[3-chloro-4-(methylthio)phenoxy]-3-[(dimethylamino)methyl]-N-
methyl- (9CI) (CA INDEX NAME)


RN 402911-08-4 CAPLUS

CN Benzenemethanol, 3-[(dimethylamino)methyl]-4-[3-fluoro-4-
(methylthio)phenoxy]-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 402911-09-5 CAPLUS
 CN Benzenemethanol, 4-[3-chloro-4-(methylthio)phenoxy]-3-[(dimethylamino)methyl]-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 402911-11-9 CAPLUS
 CN Benzonitrile, 3-[(dimethylamino)methyl]-4-[3-fluoro-4-(methylthio)phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 402911-14-2 CAPLUS
 CN Methanesulfonamide, N-[[3-[(dimethylamino)methyl]-4-[3-fluoro-4-(methylthio)phenoxy]phenyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 402911-15-3 CAPLUS
 CN Benzenemethanol, 3-[(dimethylamino)methyl]-4-[3-methyl-4-(methylthio)phenoxy]-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 402911-16-4 CAPLUS
 CN Methanesulfonamide, N-[[3-[(dimethylamino)methyl]-4-[3-methyl-4-(methylthio)phenoxy]phenyl]methyl]-1,1,1-trifluoro-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 402911-18-6 CAPLUS
 CN Benzamide, 3-[(dimethylamino)methyl]-4-[3-methyl-4-(methylthio)phenoxy]- (9CI) (CA INDEX NAME)



RN 402911-29-9 CAPLUS


CN Methanesulfonamide, N-[4-[3-chloro-4-(methylthio)phenoxy]-3-[(methylamino)methyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 402911-30-2 CAPLUS


CN Methanesulfonamide, N-[3-[(methylamino)methyl]-4-[4-methyl-3-(methylthio)phenoxy]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 402911-32-4 CAPLUS

CN Methanesulfonamide, N-[3-[(methylamino)methyl]-4-[3-methyl-4-(methylthio)phenoxy]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 402911-33-5 CAPLUS
 CN Methanesulfonamide, N-methyl-N-[3-[(methylamino)methyl]-4-[3-methyl-4-(methylthio)phenoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 402911-37-9 CAPLUS
 CN Methanesulfonamide, N-[3-[(dimethylamino)methyl]-4-[3-fluoro-4-(methylthio)phenoxy]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 402911-39-1 CAPLUS
 CN Methanesulfonamide, N-[4-[3-chloro-4-(methylthio)phenoxy]-3-[(dimethylamino)methyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 402911-42-6 CAPLUS



CN Methanesulfonamide, N-[3-[(dimethylamino)methyl]-4-[3-methyl-4-(methylthio)phenoxy]phenyl]-N-(2-hydroxyethyl)-, monohydrochloride (9CI)
(CA INDEX NAME)



● HCl



RN 402911-43-7 CAPLUS

CN Methanesulfonamide, N-[3-[(dimethylamino)methyl]-4-[3-methyl-4-(methylthio)phenoxy]phenyl]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 402911-44-8 CAPLUS
 CN Methanesulfonamide, N-[3-[(dimethylamino)methyl]-4-[4-methyl-3-(methylthio)phenoxy]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 402911-45-9 CAPLUS
 CN Methanesulfonamide, N-[3-[(dimethylamino)methyl]-4-[3-methyl-4-(methylthio)phenoxy]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 402911-47-1 CAPLUS


CN Methanesulfonamide, N-ethyl-N-[3-[(methylamino)methyl]-4-[3-methyl-4-(methylthio)phenoxy]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 402911-48-2 CAPLUS


CN Benzenesulfonamide, 3-[(dimethylamino)methyl]-4-[3-methyl-4-(methylthio)phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 402911-49-3 CAPLUS

CN Benzonitrile, 3-[(methylamino)methyl]-4-[3-methyl-4-(methylthio)phenoxy]- (9CI) (CA INDEX NAME)




RN 402912-53-2 CAPLUS

CN Benzenesulfonamide, 4-[3-chloro-4-(methylthio)phenoxy]-3-[(dimethylamino)methyl]- (9CI) (CA INDEX NAME)




RN 402912-54-3 CAPLUS

CN Benzenesulfonamide, 3-[(dimethylamino)methyl]-4-[3-fluoro-4-(methylthio)phenoxy]- (9CI) (CA INDEX NAME)



RN 402912-57-6 CAPLUS


CN Methanesulfonamide, N-[[3-[(methylamino)methyl]-4-[3-methyl-4-(methylthio)phenoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 402912-59-8 CAPLUS

10/010,651

CN Benzenemethanol, 3-[(dimethylamino)methyl]-4-[3-fluoro-4-(methylthio)phenoxy]- (9CI) (CA INDEX NAME)



RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 11 OF 21 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 2001:730683 CAPLUS
 DN 135:288572
 TI Preparation of diphenyl ether compounds as serotonin re-uptake inhibitors
 IN Andrews, Mark David; Hepworth, David; Middleton, Donald Stuart; Stobie, Alan
 PA Pfizer Limited, UK; Pfizer Inc.
 SO PCT Int. Appl., 158 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001072687	A1	20011004	WO 2001-IB428	20010319
	W:				
					AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
	RW:				GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
	US 2002052395	A1	20020502	US 2001-810378	20010316
	US 6448293	B2	20020910		
	EP 1268396	A1	20030102	EP 2001-917347	20010319
	R:				AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
	BR 2001009547	A	20030610	BR 2001-9547	20010319
	NZ 519972	A	20030725	NZ 2001-519972	20010319
	BG 106912	A	20030131	BG 2002-106912	20020709
	NO 2002004663	A	20020927	NO 2002-4663	20020927
PRAI	GB 2000-7884	A	20000331		
	US 2000-197127P	P	20000414		
	WO 2001-IB428	W	20010319		

OS MARPAT 135:288572

AB Title compds. I [wherein R1 and R2 = independently H or (cycloalkyl)alkyl; or R1 and R2 together with the N to which they are attached form an azetidine ring; R3 = independently CF3, OCF3, alkylthio, or alkoxy; n = 1-3; R4 and R5 = independently AX; A = CH:CH or (CH2)p; p = 0-2; X = H, halo, OH, alkoxy, NO2, CN, CHO, alkylthio, alkylsulfinyl, alkylsulfonyl, or (un)substituted carbamoyl, sulfamoyl, amino, carboxy, etc.; or pharmaceutically acceptable salts, solvates, or polymorphs thereof] were prepd. as monoamine re-uptake inhibitors, particularly as selective serotonin re-uptake inhibitors. For example, 4-(methylmercapto)phenol was coupled with 2-fluorobenzaldehyde using K2CO3 in DMF to give 2-[4-(methylsulfanyl)phenoxy]benzaldehyde (100%). The aldehyde was dissolved in THF, DCM, Me2NH.bul.HCl, and TEA, treated with NaBH(OAc)3, and converted to the salt with 1M HCl in Et2O to afford N,N-dimethyl-N-[2-[4-(methylsulfanyl)phenoxy]benzyl]amine.bul.HCl (84%). Coupling the salt with ClSO3H in CH2Cl2 at 0.degree. to 5.degree.C, followed by stepwise addn. of MeCN with POCl3 and ammonia, produced the desired sulfonamide (II) in 61% yield. The latter showed serotonin re-uptake inhibition (SRI) activity with IC50 .ltoreq. 50 nM and was > 100-fold as potent in the inhibition of serotonin re-uptake than in the inhibition of dopamine and noradrenaline re-uptake. I are useful in the treatment of disorders such as depression, attention deficit

hyperactivity disorder, obsessive-compulsive disorder, post-traumatic stress disorder, substance abuse disorders, and sexual dysfunction, including premature ejaculation (no data).


IT 364323-56-8P 364323-57-9P 364323-58-0P
 364323-59-1P 364323-60-4P 364323-61-5P
 364323-62-6P 364323-99-9P 364324-00-5P
 364324-01-6P 364324-02-7P 364324-03-8P
 364324-04-9P 364324-05-0P 364324-06-1P
 364324-07-2P 364324-08-3P 364324-09-4P
 364324-10-7P 364324-11-8P 364324-12-9P
 364324-13-0P 364324-14-1P 364324-15-2P
 364324-16-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; prepn. of di-Ph ether compds. as serotonin re-uptake inhibitors)


RN 364323-56-8 CAPLUS

CN Benzenesulfonyl chloride, 3-[(dimethylamino)methyl]-4-[4-(methylthio)phenoxy]- (9CI) (CA INDEX NAME)




RN 364323-57-9 CAPLUS

CN Acetamide, N-[[4-bromo-2-[4-(trifluoromethoxy)phenoxy]phenyl]methyl]-2,2,2-trifluoro-N-methyl- (9CI) (CA INDEX NAME)




RN 364323-58-0 CAPLUS

CN Acetamide, N-[[5-(aminosulfonyl)-4-bromo-2-[4-(trifluoromethoxy)phenoxy]phenyl]methyl]-2,2,2-trifluoro-N-methyl- (9CI) (CA INDEX NAME)




RN 364323-59-1 CAPLUS

CN Benzeneacetic acid, .alpha.-cyano-3-[(dimethylamino)methyl]-4-[4-(trifluoromethoxy)phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 364323-60-4 CAPLUS

CN Acetamide, 2,2,2-trifluoro-N-methyl-N-[[5-nitro-2-[4-(trifluoromethyl)phenoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 364323-61-5 CAPLUS

CN Acetamide, N-[[5-amino-2-[4-(trifluoromethyl)phenoxy]phenyl]methyl]-2,2,2-trifluoro-N-methyl- (9CI) (CA INDEX NAME)




RN 364323-62-6 CAPLUS

CN Benzaldehyde, 3-[(dimethylamino)methyl]-4-[4-(trifluoromethoxy)phenoxy]-
(9CI) (CA INDEX NAME)


RN 364323-99-9 CAPLUS

CN Carbamic acid, [[5-bromo-2-[4-(methylthio)-3-(trifluoromethyl)phenoxy]phenyl]methyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 364324-00-5 CAPLUS

CN Carbamic acid, [[5-bromo-2-[3-methoxy-4-(methylthio)phenoxy]phenyl]methyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 364324-01-6 CAPLUS

CN Carbamic acid, [[5-bromo-2-[4-(methylthio)phenoxy]phenyl]methyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 364324-02-7 CAPLUS

CN Benzoic acid, 3-[[[(1,1-dimethylethoxy)carbonyl]methylamino]methyl]-4-[4-(methylthio)-3-(trifluoromethyl)phenoxy]-, methyl ester (9CI) (CA INDEX NAME)




RN 364324-03-8 CAPLUS

CN Benzoic acid, 3-[[[(1,1-dimethylethoxy)carbonyl]methylamino]methyl]-4-[3-methoxy-4-(methylthio)phenoxy]-, methyl ester (9CI) (CA INDEX NAME)




RN 364324-04-9 CAPLUS

CN Benzoic acid, 3-[[[(1,1-dimethylethoxy)carbonyl]methylamino]methyl]-4-[4-(methylthio)phenoxy]-, methyl ester (9CI) (CA INDEX NAME)




RN 364324-05-0 CAPLUS

CN Benzoic acid, 3-[[[(1,1-dimethylethoxy)carbonyl]methylamino]methyl]-4-[4-(methylthio)-3-(trifluoromethyl)phenoxy]- (9CI) (CA INDEX NAME)




RN 364324-06-1 CAPLUS

CN Benzoic acid, 3-[[[(1,1-dimethylethoxy)carbonyl]methylamino]methyl]-4-[4-(methylthio)phenoxy]- (9CI) (CA INDEX NAME)




RN 364324-07-2 CAPLUS

CN Benzoic acid, 3-[[[(1,1-dimethylethoxy)carbonyl]methylamino]methyl]-4-[3-methoxy-4-(methylthio)phenoxy]- (9CI) (CA INDEX NAME)




RN 364324-08-3 CAPLUS

CN Carbamic acid, [[5-(aminocarbonyl)-2-[4-(methylthio)-3-(trifluoromethyl)phenoxy]phenyl]methyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 364324-09-4 CAPLUS

CN Carbamic acid, [[5-[[[(2-methoxyethyl)amino]carbonyl]-2-[4-(methylthio)phenoxy]phenyl]methyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 364324-10-7 CAPLUS

CN Carbamic acid, [[5-[[[(2-hydroxyethyl)amino]carbonyl]-2-[4-(methylthio)phenoxy]phenyl]methyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 364324-11-8 CAPLUS


CN Carbamic acid, [[5-[[[(2-amino-2-oxoethyl)amino]carbonyl]-2-[4-(methylthio)phenoxy]phenyl]methyl]methyl-, 1,1-dimethylethyl ester (9CI)
(CA INDEX NAME)



RN 364324-12-9 CAPLUS

CN Carbamic acid, [[5-[[[(1R)-2-hydroxy-1-methylethyl]amino]carbonyl]-2-[4-(methylthio)phenoxy]phenyl]methyl]methyl-, 1,1-dimethylethyl ester (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 364324-13-0 CAPLUS


CN Carbamic acid, [[5-[[[(1S)-2-hydroxy-1-methylethyl]amino]carbonyl]-2-[4-(methylthio)phenoxy]phenyl]methyl]methyl-, 1,1-dimethylethyl ester (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




RN 364324-14-1 CAPLUS

CN Carbamic acid, methyl[[5-[(methylamino)carbonyl]-2-[4-(methylthio)phenoxy]phenyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 364324-15-2 CAPLUS

CN Carbamic acid, [[5-(aminocarbonyl)-2-[3-methoxy-4-(methylthio)phenoxy]phenyl]methyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 364324-16-3 CAPLUS

CN Carbamic acid, [[2-[3-methoxy-4-(methylthio)phenoxy]-5-[(methylamino)carbonyl]phenyl]methyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




IT 364321-43-7P 364321-47-1P 364321-48-2P
 364321-49-3P 364321-52-8P 364321-53-9P
 364321-54-0P 364321-56-2P 364321-57-3P
 364321-58-4P 364321-59-5P 364321-61-9P
 364321-62-0P 364321-64-2P 364321-65-3P
 364321-66-4P 364321-67-5P 364321-68-6P
 364321-70-0P 364322-18-9P 364322-19-0P
 364322-20-3P 364322-21-4P 364322-28-1P
 364322-29-2P 364322-33-8P 364322-34-9P
 364322-35-0P 364322-36-1P 364322-37-2P
 364322-39-4P 364322-42-9P 364322-43-0P
 364322-59-8P 364322-60-1P 364322-61-2P
 364322-62-3P 364322-64-5P 364322-65-6P
 364322-66-7P 364322-67-8P 364322-77-0P
 364322-79-2P 364322-80-5P 364322-81-6P
 364322-95-2P 364322-96-3P 364322-97-4P
 364322-98-5P 364323-06-8P 364323-07-9P
 364323-08-0P 364323-13-7P 364323-24-0P
 364323-31-9P 364323-32-0P 364323-48-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(prepn. of di-Ph ether compds. as serotonin re-uptake inhibitors)

RN 364321-43-7 CAPLUS


CN Benzenemethanamine, 5-bromo-N,N-dimethyl-2-[4-(trifluoromethyl)phenoxy]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 364321-47-1 CAPLUS

CN Benzenemethanamine, 5-bromo-N,N-dimethyl-2-[4-(trifluoromethoxy)phenoxy]- (9CI) (CA INDEX NAME)




RN 364321-48-2 CAPLUS

CN Benzenemethanamine, 4-bromo-N,N-dimethyl-2-[4-(trifluoromethoxy)phenoxy]-
(9CI) (CA INDEX NAME)



RN 364321-49-3 CAPLUS


CN Benzenemethanamine, 5-bromo-N,N-dimethyl-2-[4-(methylthio)phenoxy]-,
hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 364321-52-8 CAPLUS


CN Benzenemethanamine, 4-bromo-N,N-dimethyl-2-[4-(trifluoromethyl)phenoxy]-
(9CI) (CA INDEX NAME)




RN 364321-53-9 CAPLUS

CN Benzenemethanamine, 4-bromo-N,N-dimethyl-2-[4-(methylthio)phenoxy]- (9CI)


(CA INDEX NAME)




RN 364321-54-0 CAPLUS

CN Benzenemethanamine, 5-methoxy-N,N-dimethyl-2-[4-(methylthio)phenoxy]-
(9CI) (CA INDEX NAME)

RN 364321-56-2 CAPLUS


CN Benzenemethanamine, 5-iodo-N,N-dimethyl-2-[4-(trifluoromethoxy)phenoxy]-
(9CI) (CA INDEX NAME)

RN 364321-57-3 CAPLUS

CN Benzenemethanamine, 5-iodo-N-methyl-2-[4-(trifluoromethoxy)phenoxy]- (9CI)
(CA INDEX NAME)


RN 364321-58-4 CAPLUS

CN Benzenemethanamine, 5-iodo-N,N-dimethyl-2-[4-(trifluoromethyl)phenoxy]-
(9CI) (CA INDEX NAME)




RN 364321-59-5 CAPLUS

CN Benzenemethanamine, N,N-dimethyl-2-[4-(methylthio)phenoxy]-5-nitro- (9CI)
(CA INDEX NAME)




RN 364321-61-9 CAPLUS

CN Benzenemethanamine, N-methyl-5-nitro-2-[4-(trifluoromethyl)phenoxy]- (9CI)
(CA INDEX NAME)





RN 364321-62-0 CAPLUS

CN Benzenemethanamine, N,N-dimethyl-5-nitro-2-[4-(trifluoromethyl)phenoxy]- (9CI) (CA INDEX NAME)




RN 364321-64-2 CAPLUS

CN Benzenemethanamine, N,N-dimethyl-5-nitro-2-[4-(trifluoromethoxy)phenoxy]- (9CI) (CA INDEX NAME)




RN 364321-65-3 CAPLUS

CN Benzenemethanamine, 5-bromo-N-methyl-2-[4-(methylthio)phenoxy]- (9CI) (CA INDEX NAME)



RN 364321-66-4 CAPLUS


CN Benzenemethanamine, 4-bromo-N-methyl-2-[4-(trifluoromethoxy)phenoxy]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 364321-67-5 CAPLUS

CN Benzenemethanamine, 5-methoxy-N-methyl-2-[4-(methylthio)phenoxy]-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 364321-68-6 CAPLUS

CN Benzenemethanamine, 5-bromo-2-[3-methoxy-4-(methylthio)phenoxy]-N-methyl-
(9CI) (CA INDEX NAME)


RN 364321-70-0 CAPLUS

CN Benzenemethanamine, 5-bromo-N-methyl-2-[4-(methylthio)-3-
(trifluoromethyl)phenoxy]- (9CI) (CA INDEX NAME)

RN 364322-18-9 CAPLUS

CN Ethenesulfonamide, 2-[3-[(dimethylamino)methyl]-4-[4-
(methylthio)phenoxy]phenyl]-N,N-dimethyl-, (1E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 364322-19-0 CAPLUS

CN 2-Propenamide, 3-[3-[(dimethylamino)methyl]-4-[4-(methylthio)phenoxy]phenyl]-, (2E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 364322-20-3 CAPLUS

CN 2-Propenamide, 3-[4-[(dimethylamino)methyl]-3-[4-(methylthio)phenoxy]phenyl]-, (2E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 364322-21-4 CAPLUS



CN Ethenesulfonamide, 2-[4-[(dimethylamino)methyl]-3-[4-(methylthio)phenoxy]phenyl]-, (1E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 364322-28-1 CAPLUS

CN Benzenesulfonamide, 2-bromo-5-[(methylamino)methyl]-4-[4-(trifluoromethoxy)phenoxy]- (9CI) (CA INDEX NAME)




RN 364322-29-2 CAPLUS

CN Benzenesulfonamide, 5-[(methylamino)methyl]-2-(methylthio)-4-[4-(trifluoromethoxy)phenoxy]- (9CI) (CA INDEX NAME)




RN 364322-33-8 CAPLUS

CN Benzonitrile, 4-[(dimethylamino)methyl]-3-[4-(trifluoromethyl)phenoxy]- (9CI) (CA INDEX NAME)




RN 364322-34-9 CAPLUS

CN Benzonitrile, 3-[(dimethylamino)methyl]-4-[4-(trifluoromethyl)phenoxy]- (9CI) (CA INDEX NAME)




RN 364322-35-0 CAPLUS

CN Benzonitrile, 3-[(dimethylamino)methyl]-4-[4-(trifluoromethoxy)phenoxy]-
(9CI) (CA INDEX NAME)




RN 364322-36-1 CAPLUS

CN Benzonitrile, 3-[(dimethylamino)methyl]-4-[4-(methylthio)phenoxy]- (9CI)
(CA INDEX NAME)





RN 364322-37-2 CAPLUS

CN Benzonitrile, 4-[(dimethylamino)methyl]-3-[4-(trifluoromethoxy)phenoxy]-
(9CI) (CA INDEX NAME)




RN 364322-39-4 CAPLUS

CN Benzeneacetonitrile, 3-[(dimethylamino)methyl]-4-[4-(methylthio)phenoxy]-
(9CI) (CA INDEX NAME)




RN 364322-42-9 CAPLUS

CN Benzamide, 4-[(dimethylamino)methyl]-3-[4-(trifluoromethyl)phenoxy]- (9CI)
(CA INDEX NAME)




RN 364322-43-0 CAPLUS

CN Benzamide, 3-[(dimethylamino)methyl]-4-[4-(methylthio)phenoxy]- (9CI) (CA INDEX NAME)




RN 364322-59-8 CAPLUS


CN Benzenemethanamine, 5-amino-N,N-dimethyl-2-[4-(trifluoromethyl)phenoxy]- (9CI) (CA INDEX NAME)




RN 364322-60-1 CAPLUS

CN Benzenemethanamine, 5-amino-N,N-dimethyl-2-[4-(trifluoromethoxy)phenoxy]-
(9CI) (CA INDEX NAME)


RN 364322-61-2 CAPLUS

CN Benzenemethanamine, 5-amino-N,N-dimethyl-2-[4-(methylthio)phenoxy]- (9CI)
(CA INDEX NAME)

RN 364322-62-3 CAPLUS


CN 1,3-Benzenedimethanamine, N3,N3-dimethyl-4-[4-(trifluoromethoxy)phenoxy]-
(9CI) (CA INDEX NAME)

RN 364322-64-5 CAPLUS

CN 1,3-Benzenedimethanamine, N3,N3-dimethyl-4-[4-(methylthio)phenoxy]- (9CI)
(CA INDEX NAME)


RN 364322-65-6 CAPLUS

CN 1,3-Benzenedimethanamine, N3,N3-dimethyl-4-[4-(trifluoromethyl)phenoxy]-,
dihydrochloride (9CI) (CA INDEX NAME)





● 2 HCl

RN 364322-66-7 CAPLUS

CN 1,4-Benzenedimethanamine, N1,N1-dimethyl-2-[4-(trifluoromethoxy)phenoxy]-
(9CI) (CA INDEX NAME)


RN 364322-67-8 CAPLUS

CN Methanesulfonamide, N-[3-[(dimethylamino)methyl]-4-[4-(trifluoromethyl)phenoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 364322-77-0 CAPLUS

CN Methanesulfonamide, N-[3-(aminomethyl)-4-[4-(methylthio)phenoxy]phenyl]-N-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)




RN 364322-79-2 CAPLUS

CN Methanesulfonamide, N-[3-(aminomethyl)-4-[4-(methylthio)phenoxy]phenyl]-
(9CI) (CA INDEX NAME)



RN 364322-80-5 CAPLUS


CN Methanesulfonamide, N-[3-(aminomethyl)-4-[4-(methylthio)phenoxy]phenyl]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 364322-81-6 CAPLUS

CN Methanesulfonamide, N-[3-(aminomethyl)-4-[3-methoxy-4-(methylthio)phenoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 364322-95-2 CAPLUS

CN Benzenemethanamine, N,N-dimethyl-5-(methylthio)-2-[4-(trifluoromethoxy)phenoxy]- (9CI) (CA INDEX NAME)




RN 364322-96-3 CAPLUS

CN Benzenemethanamine, N,N-dimethyl-4-(methylthio)-2-[4-(trifluoromethoxy)phenoxy]- (9CI) (CA INDEX NAME)




RN 364322-97-4 CAPLUS

CN Benzenemethanamine, N,N-dimethyl-5-(methylthio)-2-[4-(trifluoromethyl)phenoxy]- (9CI) (CA INDEX NAME)




RN 364322-98-5 CAPLUS

CN Benzenemethanamine, 4-(ethylthio)-N,N-dimethyl-2-[4-(trifluoromethyl)phenoxy]- (9CI) (CA INDEX NAME)




RN 364323-06-8 CAPLUS

CN Benzoic acid, 3-[(dimethylamino)methyl]-4-[4-(trifluoromethyl)phenoxy]-, methyl ester (9CI) (CA INDEX NAME)




RN 364323-07-9 CAPLUS

CN Benzoic acid, 3-[(dimethylamino)methyl]-4-[4-(methylthio)phenoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 364323-08-0 CAPLUS


CN Benzoic acid, 3-[(methylamino)methyl]-4-[4-(methylthio)phenoxy]-, methyl ester (9CI) (CA INDEX NAME)




RN 364323-13-7 CAPLUS

CN Benzoic acid, 3-[(dimethylamino)methyl]-4-[4-(methylthio)phenoxy]- (9CI)


(CA INDEX NAME)



RN 364323-24-0 CAPLUS

CN Benzamide, 4-[3-methoxy-4-(methylthio)phenoxy]-3-[(methylamino)methyl]-
(9CI) (CA INDEX NAME)


RN 364323-31-9 CAPLUS

CN Benzamide, 4-[3-methoxy-4-(methylthio)phenoxy]-N-methyl-3-
[(methylamino)methyl]-, monohydrochloride (9CI) (CA INDEX NAME)

● HCl


RN 364323-32-0 CAPLUS

CN Benzamide, 3-[(methylamino)methyl]-4-[4-(methylthio)-3-(trifluoromethyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 364323-48-8 CAPLUS

CN Benzenemethanamine, 5-chloro-2-[4-(methylthio)phenoxy]- (9CI) (CA INDEX NAME)




IT 364321-41-5P 364321-44-8P 364321-45-9P
 364321-50-6P 364321-51-7P 364321-55-1P
 364321-71-1P 364321-72-2P 364321-73-3P
 364321-74-4P 364321-76-6P 364321-78-8P
 364321-80-2P 364321-81-3P 364321-83-5P
 364321-85-7P 364321-87-9P 364321-89-1P
 364321-90-4P 364321-91-5P 364321-92-6P
 364321-93-7P 364321-94-8P 364321-95-9P
 364321-96-0P 364321-97-1P 364321-98-2P
 364321-99-3P 364322-00-9P 364322-03-2P
 364322-06-5P 364322-07-6P 364322-08-7P
 364322-09-8P 364322-10-1P 364322-11-2P
 364322-12-3P 364322-13-4P 364322-14-5P
 364322-15-6P 364322-16-7P 364322-17-8P
 364322-22-5P 364322-23-6P 364322-24-7P
 364322-25-8P 364322-26-9P 364322-27-0P
 364322-30-5P 364322-31-6P 364322-32-7P
 364322-38-3P 364322-41-8P 364322-44-1P
 364322-45-2P 364322-46-3P 364322-47-4P
 364322-48-5P 364322-49-6P 364322-50-9P
 364322-51-0P 364322-52-1P 364322-53-2P
 364322-54-3P 364322-55-4P 364322-56-5P
 364322-57-6P 364322-58-7P 364322-68-9P
 364322-69-0P 364322-70-3P 364322-71-4P
 364322-72-5P 364322-73-6P 364322-74-7P
 364322-76-9P 364322-78-1P 364322-82-7P
 364322-83-8P 364322-84-9P 364322-85-0P
 364322-86-1P 364322-87-2P 364322-88-3P
 364322-89-4P 364322-90-7P 364322-91-8P
 364322-92-9P 364322-93-0P 364322-94-1P
 364322-99-6P 364323-00-2P 364323-01-3P
 364323-02-4P 364323-04-6P 364323-05-7P
 364323-09-1P 364323-10-4P 364323-11-5P
 364323-12-6P 364323-14-8P 364323-15-9P

364323-16-0P 364323-17-1P 364323-18-2P
 364323-20-6P 364323-22-8P 364323-25-1P
 364323-26-2P 364323-27-3P 364323-28-4P
 364323-29-5P 364323-30-8P 364323-33-1P
 364323-34-2P 364323-35-3P 364323-49-9P
 364323-50-2P 364323-51-3P 364323-52-4P
 364323-53-5P 364323-55-7P 364324-32-3P
 364324-33-4P 364324-34-5P 364324-36-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of di-Ph ether compds. as serotonin re-uptake inhibitors)


RN 364321-41-5 CAPLUS

CN Benzenemethanamine, 5-bromo-N,N-dimethyl-2-[3-(trifluoromethyl)phenoxy]-
 (9CI) (CA INDEX NAME)



RN 364321-44-8 CAPLUS


CN Benzenemethanamine, 5-fluoro-N-methyl-2-[4-(methylthio)phenoxy]-,
 hydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 364321-45-9 CAPLUS

CN Benzenemethanamine, N-ethyl-5-fluoro-2-[4-(methylthio)phenoxy]- (9CI) (CA INDEX NAME)



RN 364321-50-6 CAPLUS


CN Benzenemethanamine, 5-fluoro-N,N-dimethyl-2-[4-(methylthio)phenoxy]-,
 hydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 364321-51-7 CAPLUS

CN Benzenemethanamine, 4-bromo-N-methyl-2-[4-(trifluoromethyl)phenoxy]- (9CI)
(CA INDEX NAME)




RN 364321-55-1 CAPLUS

CN Benzenemethanamine, 4,5-dimethoxy-N,N-dimethyl-2-[4-(methylthio)phenoxy]-
(9CI) (CA INDEX NAME)




RN 364321-71-1 CAPLUS


CN Benzenesulfonamide, 3-[(dimethylamino)methyl]-4-[4-(methylthio)phenoxy]-
(9CI) (CA INDEX NAME)




RN 364321-72-2 CAPLUS
 CN Benzenesulfonamide, N,N-dimethyl-3-[(methylamino)methyl]-4-[4-(trifluoromethyl)phenoxy]- (9CI) (CA INDEX NAME)




RN 364321-73-3 CAPLUS
 CN Benzenesulfonamide, 3-[(dimethylamino)methyl]-N-methyl-4-[4-(trifluoromethyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 364321-74-4 CAPLUS
 CN Benzenesulfonamide, 3-[(dimethylamino)methyl]-N-(2-hydroxyethyl)-4-[4-(trifluoromethyl)phenoxy]- (9CI) (CA INDEX NAME)




RN 364321-76-6 CAPLUS
 CN Benzenesulfonamide, 3-[(dimethylamino)methyl]-N,N-dimethyl-4-[4-(trifluoromethyl)phenoxy]- (9CI) (CA INDEX NAME)




RN 364321-78-8 CAPLUS

CN Benzenesulfonamide, 3-[(dimethylamino)methyl]-4-[4-(trifluoromethyl)phenoxy]- (9CI) (CA INDEX NAME)




RN 364321-80-2 CAPLUS

CN Benzenesulfonamide, N-methyl-3-[(methylamino)methyl]-4-[4-(trifluoromethyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 364321-81-3 CAPLUS


CN Benzenesulfonamide, 3-[(methylamino)methyl]-4-[4-(trifluoromethoxy)phenoxy]- (9CI) (CA INDEX NAME)



RN 364321-83-5 CAPLUS

CN Benzenesulfonamide, 3-[(dimethylamino)methyl]-4-[4-


(trifluoromethoxy)phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 364321-85-7 CAPLUS

CN Benzenesulfonamide, 3-[(dimethylamino)methyl]-N-methyl-4-[4-(trifluoromethoxy)phenoxy]- (9CI) (CA INDEX NAME)



RN 364321-87-9 CAPLUS


CN Benzenesulfonamide, N-(2-hydroxyethyl)-3-[(methylamino)methyl]-4-[4-(methylthio)phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 364321-89-1 CAPLUS

CN Benzenesulfonamide, N-(2-hydroxyethyl)-N-methyl-3-[(methylamino)methyl]-4-[4-(methylthio)phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 364321-90-4 CAPLUS
 CN Benzenesulfonamide, N-(3-hydroxypropyl)-3-[(methylamino)methyl]-4-[4-(methylthio)phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 364321-91-5 CAPLUS
 CN Benzenesulfonamide, N-[(1S)-2-hydroxy-1-methylethyl]-3-[(methylamino)methyl]-4-[4-(methylthio)phenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 364321-92-6 CAPLUS
 CN Benzenesulfonamide, 3-[(methylamino)methyl]-4-[4-(methylthio)phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 364321-93-7 CAPLUS
 CN Benzenesulfonamide, N-methyl-3-[(methylanino)methyl]-4-[4-(methylthio)phenoxy]- (9CI) (CA INDEX NAME)




RN 364321-94-8 CAPLUS
 CN Benzenesulfonamide, N,N-dimethyl-3-[(methylanino)methyl]-4-[4-(methylthio)phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 364321-95-9 CAPLUS
 CN Benzenesulfonamide, 3-[(dimethylanino)methyl]-N-methyl-4-[4-(methylthio)phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 364321-96-0 CAPLUS

CN Benzenesulfonamide, 3-[(dimethylamino)methyl]-N-[(2R)-2-hydroxypropyl]-4-[4-(methylthio)phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 364321-97-1 CAPLUS

CN Benzenesulfonamide, 3-[(dimethylamino)methyl]-N-(2-hydroxyethyl)-N-methyl-4-[4-(methylthio)phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 364321-98-2 CAPLUS

CN Benzenesulfonamide, 3-[(dimethylamino)methyl]-N-(2-methoxyethyl)-4-[4-

(methylthio)phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 364321-99-3 CAPLUS

CN Benzenesulfonamide, 3-[(dimethylamino)methyl]-N-[(1R)-2-hydroxy-1-methylethyl]-4-[4-(methylthio)phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 364322-00-9 CAPLUS

CN Benzenesulfonamide, 3-[(dimethylamino)methyl]-N-ethyl-4-[4-(methylthio)phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)




HCl

RN 364322-03-2 CAPLUS


CN Benzenesulfonamide, 3-[(dimethylamino)methyl]-N-[(1S)-2-hydroxy-1-methylethyl]-4-[4-(methylthio)phenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 364322-06-5 CAPLUS


CN Acetamide, 2-[[[3-[(dimethylamino)methyl]-4-[4-(methylthio)phenoxy]phenyl]sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 364322-07-6 CAPLUS


CN Benzenesulfonamide, 3-[(dimethylamino)methyl]-N-[(2S)-2-hydroxypropyl]-4-[4-(methylthio)phenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 364322-08-7 CAPLUS

CN Benzenesulfonamide, 3-[(dimethylamino)methyl]-N-(3-hydroxypropyl)-4-[4-(methylthio)phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 364322-09-8 CAPLUS
 CN Benzenesulfonamide, 3-[(dimethylamino)methyl]-N-(2-hydroxyethyl)-4-[4-(methylthio)phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 364322-10-1 CAPLUS
 CN Benzenesulfonamide, 3-[(dimethylamino)methyl]-N,N-dimethyl-4-[4-(methylthio)phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 364322-11-2 CAPLUS
 CN Benzenesulfonamide, 3-[(dimethylamino)methyl]-4-[4-(ethylthio)phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 364322-12-3 CAPLUS
 CN Benzenesulfonamide, 4-[4-methoxy-3-(methylthio)phenoxy]-3-[(methylamino)methyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 364322-13-4 CAPLUS
 CN Benzenesulfonamide, 4-[3-methoxy-4-(methylthio)phenoxy]-3-[(methylamino)methyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 364322-14-5 CAPLUS
 CN Benzenesulfonamide, 3-[(methylamino)methyl]-4-[4-(methylthio)-3-(trifluoromethyl)phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 364322-15-6 CAPLUS
 CN Benzenesulfonamide, 3-[(dimethylamino)methyl]-4-[3-methoxy-4-(methylthio)phenoxy]- (9CI) (CA INDEX NAME)




RN 364322-16-7 CAPLUS
 CN Benzenesulfonamide, 3-[(dimethylamino)methyl]-4-[4-methoxy-3-(methylthio)phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 364322-17-8 CAPLUS
 CN Acetamide, N-[[3-[(dimethylamino)methyl]-4-[4-(methylthio)phenoxy]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 364322-22-5 CAPLUS

CN Benzeneethanesulfonamide, 3-[(dimethylamino)methyl]-4-[4-(methylthio)phenoxy]- (9CI) (CA INDEX NAME)




RN 364322-23-6 CAPLUS

CN Benzeneethanesulfonamide, 4-[(dimethylamino)methyl]-3-[4-(methylthio)phenoxy]- (9CI) (CA INDEX NAME)



RN 364322-24-7 CAPLUS


CN Phenol, 3-[(dimethylamino)methyl]-4-[4-(methylthio)phenoxy]- (9CI) (CA INDEX NAME)





RN 364322-25-8 CAPLUS

CN Phenol, 3-[(methylamino)methyl]-4-[4-(methylthio)phenoxy]- (9CI) (CA


INDEX NAME)



RN 364322-26-9 CAPLUS


CN Benzenepropanamide, 3-[(dimethylamino)methyl]-4-[4-(methylthio)phenoxy]-
(9CI) (CA INDEX NAME)

RN 364322-27-0 CAPLUS


CN Benzenepropanamide, 4-[(dimethylamino)methyl]-3-[4-(methylthio)phenoxy]-
(9CI) (CA INDEX NAME)

RN 364322-30-5 CAPLUS

CN Benzenesulfonamide, 2-bromo-5-[(dimethylamino)methyl]-4-[4-(trifluoromethoxy)phenoxy]- (9CI) (CA INDEX NAME)




RN 364322-31-6 CAPLUS
 CN Benzenesulfonamide, 5-[(dimethylamino)methyl]-2-(methylthio)-4-[4-(trifluoromethoxy)phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl



RN 364322-32-7 CAPLUS
 CN Benzonitrile, 3-[(methylamino)methyl]-4-[4-(trifluoromethoxy)phenoxy]- (9CI) (CA INDEX NAME)



RN 364322-38-3 CAPLUS
 CN Benzonitrile, 3-[(methylamino)methyl]-4-[4-(methylthio)phenoxy]- (9CI) (CA INDEX NAME)





RN 364322-41-8 CAPLUS
 CN Benzeneacetonitrile, 3-[(dimethylamino)methyl]-4-[4-(trifluoromethoxy)phenoxy]- (9CI) (CA INDEX NAME)




RN 364322-44-1 CAPLUS

CN Benzeneacetamide, 3-[(dimethylamino)methyl]-4-[4-(methylthio)phenoxy]-
(9CI) (CA INDEX NAME)





RN 364322-45-2 CAPLUS

CN Benzamide, 3-[(methylamino)methyl]-4-[4-(trifluoromethoxy)phenoxy]- (9CI)
(CA INDEX NAME)




RN 364322-46-3 CAPLUS

CN Benzamide, 3-[(dimethylamino)methyl]-4-[4-(trifluoromethoxy)phenoxy]-
(9CI) (CA INDEX NAME)




RN 364322-47-4 CAPLUS

CN Benzamide, 3-[(dimethylamino)methyl]-4-[4-(trifluoromethyl)phenoxy]- (9CI)
(CA INDEX NAME)




RN 364322-48-5 CAPLUS

CN Benzeneacetamide, 3-[(dimethylamino)methyl]-4-[4-(trifluoromethoxy)phenoxy]- (9CI) (CA INDEX NAME)




RN 364322-49-6 CAPLUS


CN Benzamide, 3-[(methylamino)methyl]-4-[4-(methylthio)phenoxy]- (9CI) (CA INDEX NAME)




RN 364322-50-9 CAPLUS
 CN Benzamide, 4-[(dimethylamino)methyl]-3-[4-(trifluoromethoxy)phenoxy]-
 (9CI) (CA INDEX NAME)




RN 364322-51-0 CAPLUS
 CN Benzamide, 4-[(dimethylamino)methyl]-N-methyl-3-[4-(trifluoromethoxy)phenoxy]- (9CI) (CA INDEX NAME)



RN 364322-52-1 CAPLUS
 CN Benzamide, 4-[(dimethylamino)methyl]-N,N-dimethyl-3-[4-(trifluoromethoxy)phenoxy]- (9CI) (CA INDEX NAME)




RN 364322-53-2 CAPLUS
 CN Benzamide, 3-[(dimethylamino)methyl]-N-methyl-4-[4-(trifluoromethoxy)phenoxy]- (9CI) (CA INDEX NAME)





RN 364322-54-3 CAPLUS

CN Benzamide, 3-[(dimethylamino)methyl]-N,N-dimethyl-4-[4-(trifluoromethoxy)phenoxy]- (9CI) (CA INDEX NAME)



RN 364322-55-4 CAPLUS


CN Benzamide, 3-[(dimethylamino)methyl]-N,N-dimethyl-4-[4-(trifluoromethyl)phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 364322-56-5 CAPLUS

CN Benzamide, 3-[(dimethylamino)methyl]-N-methyl-4-[4-(trifluoromethyl)phenoxy]- (9CI) (CA INDEX NAME)




RN 364322-57-6 CAPLUS

CN Benzamide, 4-[(dimethylamino)methyl]-N-methyl-3-[4-(trifluoromethyl)phenoxy]- (9CI) (CA INDEX NAME)





RN 364322-58-7 CAPLUS

CN Benzamide, 4-[(dimethylamino)methyl]-N,N-dimethyl-3-[4-(trifluoromethyl)phenoxy]- (9CI) (CA INDEX NAME)





RN 364322-68-9 CAPLUS

CN Methanesulfonamide, N-[[3-[(dimethylamino)methyl]-4-[4-(trifluoromethyl)phenoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)





RN 364322-69-0 CAPLUS

CN Methanesulfonamide, N-[3-[(dimethylamino)methyl]-4-[4-(trifluoromethoxy)phenoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 364322-70-3 CAPLUS



CN Methanesulfonamide, N-[[3-[(dimethylamino)methyl]-4-[4-(trifluoromethoxy)phenoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 364322-71-4 CAPLUS


CN Methanesulfonamide, N-[3-[(dimethylamino)methyl]-4-[4-

(methylthio)phenoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 364322-72-5 CAPLUS


CN Methanesulfonamide, N-[[3-[(dimethylamino)methyl]-4-[4-(methylthio)phenoxy]phenyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 364322-73-6 CAPLUS

CN Methanesulfonamide, N-[[4-[(dimethylamino)methyl]-3-[4-(trifluoromethoxy)phenoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 364322-74-7 CAPLUS

CN Methanesulfonamide, N-[3-[(methylamino)methyl]-4-[4-(trifluoromethyl)phenoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 364322-76-9 CAPLUS

CN Methanesulfonamide, N-[3-[(dimethylamino)methyl]-4-[4-(trifluoromethyl)phenoxy]phenyl]-N-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)




RN 364322-78-1 CAPLUS

CN Methanesulfonamide, N-[3-(aminomethyl)-4-[4-(methylthio)-3-(trifluoromethyl)phenoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 364322-82-7 CAPLUS


CN Methanesulfonamide, N-[3-[(methylamino)methyl]-4-[4-(methylthio)phenoxy]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 364322-83-8 CAPLUS


CN Methanesulfonamide, N-methyl-N-[3-[(methylamino)methyl]-4-[(4-methylthio)phenoxy]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 364322-84-9 CAPLUS

CN Methanesulfonamide, N-(2-hydroxyethyl)-N-[3-[(methylamino)methyl]-4-[(4-methylthio)phenoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 364322-85-0 CAPLUS

CN Methanesulfonamide, N-[4-[3-methoxy-4-(methylthio)phenoxy]-3-[(methylamino)methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 364322-86-1 CAPLUS


CN Methanesulfonamide, N-[3-[(dimethylamino)methyl]-4-[4-(methylthio)phenoxy]phenyl]-N-(2-hydroxyethyl)-, monohydrochloride (9CI)
(CA INDEX NAME)



● HCl


RN 364322-87-2 CAPLUS

CN Methanesulfonamide, N-[3-[(dimethylamino)methyl]-4-[3-methoxy-4-(methylthio)phenoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 364322-88-3 CAPLUS

CN Methanesulfonamide, N-[3-[(dimethylamino)methyl]-4-[4-(methylthio)-3-(trifluoromethyl)phenoxy]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 364322-89-4 CAPLUS

CN Benzenemethanamine, 5-chloro-N,N-dimethyl-2-[4-(methylthio)phenoxy]- (9CI)
(CA INDEX NAME)

RN 364322-90-7 CAPLUS


CN Methanesulfonamide, N-[3-[(dimethylamino)methyl]-4-[4-(methylthio)phenoxy]phenyl]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 364322-91-8 CAPLUS

CN Ethanesulfonamide, N-[3-[(dimethylamino)methyl]-4-[4-(methylthio)phenoxy]phenyl]-2-methoxy-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 364322-92-9 CAPLUS
 CN Ethanesulfonamide, N-[3-[(dimethylamino)methyl]-4-[4-(methylthio)phenoxy]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 364322-93-0 CAPLUS
 CN 2-Propanesulfonamide, N-[3-[(dimethylamino)methyl]-4-[4-(methylthio)phenoxy]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 364322-94-1 CAPLUS
 CN Methanesulfonamide, N-[3-[(dimethylamino)methyl]-4-[4-(methylthio)phenoxy]phenyl]-1,1,1-trifluoro- (9CI) (CA INDEX NAME)




RN 364322-99-6 CAPLUS

CN Benzenemethanamine, N,N-dimethyl-5-(methylsulfonyl)-2-[4-(trifluoromethoxy)phenoxy]- (9CI) (CA INDEX NAME)




RN 364323-00-2 CAPLUS

CN Benzenemethanamine, N,N-dimethyl-5-(methylsulfinyl)-2-[4-(trifluoromethoxy)phenoxy]- (9CI) (CA INDEX NAME)




RN 364323-01-3 CAPLUS

CN Benzenemethanamine, N,N-dimethyl-5-(methylsulfinyl)-2-[4-(trifluoromethyl)phenoxy]- (9CI) (CA INDEX NAME)




RN 364323-02-4 CAPLUS

CN Benzenemethanamine, 4-(ethylsulfinyl)-N,N-dimethyl-2-[4-(trifluoromethyl)phenoxy]- (9CI) (CA INDEX NAME)




RN 364323-04-6 CAPLUS

CN Benzenemethanamine, N,N-dimethyl-4-(methylsulfinyl)-2-[4-(trifluoromethoxy)phenoxy]- (9CI) (CA INDEX NAME)




RN 364323-05-7 CAPLUS

CN Benzenemethanamine, N,N-dimethyl-4-(methylsulfonyl)-2-[4-(trifluoromethoxy)phenoxy]- (9CI) (CA INDEX NAME)




RN 364323-09-1 CAPLUS

CN Benzenemethanol, 3-[(dimethylamino)methyl]-4-[4-(trifluoromethyl)phenoxy]-
(9CI) (CA INDEX NAME)




RN 364323-10-4 CAPLUS

CN Benzenemethanol, 3-[(dimethylamino)methyl]-4-[4-(methylthio)phenoxy]-
(9CI) (CA INDEX NAME)




RN 364323-11-5 CAPLUS

CN Benzenemethanol, 3-[(methylamino)methyl]-4-[4-(methylthio)phenoxy]- (9CI)
(CA INDEX NAME)




RN 364323-12-6 CAPLUS


CN Benzenemethanol, 3-[(dimethylamino)methyl]-4-[4-(trifluoromethoxy)phenoxy]-
(9CI) (CA INDEX NAME)




RN 364323-14-8 CAPLUS
 CN Benzamide, 3-[(dimethylamino)methyl]-N-methyl-4-[4-(methylthio)phenoxy]-
 (9CI) (CA INDEX NAME)



RN 364323-15-9 CAPLUS
 CN Benzamide, 3-[(dimethylamino)methyl]-N-(2-hydroxyethyl)-4-[4-(methylthio)phenoxy]- (9CI) (CA INDEX NAME)



RN 364323-16-0 CAPLUS
 CN Benzamide, 3-[(dimethylamino)methyl]-N-(2-methoxyethyl)-4-[4-(methylthio)phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)




HCl

RN 364323-17-1 CAPLUS

CN Benzamide, 3-[(dimethylamino)methyl]-N-[(1S)-2-hydroxy-1-methylethyl]-4-[4-(methylthio)phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 364323-18-2 CAPLUS

CN Benzamide, 3-[(dimethylamino)methyl]-N-[(1R)-2-hydroxy-1-methylethyl]-4-[4-(methylthio)phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 364323-20-6 CAPLUS

CN Benzamide, 3-[(dimethylamino)methyl]-N-ethyl-4-[4-(methylthio)phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 364323-22-8 CAPLUS
 CN Benzamide, N-(2-amino-2-oxoethyl)-3-[(dimethylamino)methyl]-4-[4-(methylthio)phenoxy]- (9CI) (CA INDEX NAME)




RN 364323-25-1 CAPLUS
 CN Benzamide, N-(2-methoxyethyl)-3-[(methylamino)methyl]-4-[4-(methylthio)phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 364323-26-2 CAPLUS
 CN Benzamide, N-(2-hydroxyethyl)-3-[(methylamino)methyl]-4-[4-(methylthio)phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 364323-27-3 CAPLUS


CN Benzamide, N-(2-amino-2-oxoethyl)-3-[(methylamino)methyl]-4-[4-(methylthio)phenoxy]- (9CI) (CA INDEX NAME)



RN 364323-28-4 CAPLUS

CN Benzamide, N-[(1R)-2-hydroxy-1-methylethyl]-3-[(methylamino)methyl]-4-[4-(methylthio)phenoxy]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 364323-29-5 CAPLUS


CN Benzamide, N-[(1S)-2-hydroxy-1-methylethyl]-3-[(methylamino)methyl]-4-[4-(methylthio)phenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 364323-30-8 CAPLUS


CN Benzamide, N-methyl-3-[(methylamino)methyl]-4-[4-(methylthio)phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 364323-33-1 CAPLUS

CN Benzamide, 3-[(dimethylamino)methyl]-4-[4-(methylthio)-3-(trifluoromethyl)phenoxy]- (9CI) (CA INDEX NAME)




RN 364323-34-2 CAPLUS

CN Benzamide, 3-[(dimethylamino)methyl]-4-[3-methoxy-4-(methylthio)phenoxy]- (9CI) (CA INDEX NAME)



RN 364323-35-3 CAPLUS

CN Benzamide, 3-[(dimethylamino)methyl]-4-[3-methoxy-4-(methylthio)phenoxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 364323-49-9 CAPLUS

CN Benzenesulfonamide, 3-[(dimethylamino)methyl]-4-[4-(methylthio)phenoxy]-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 364321-71-1

CMF C16 H20 N2 O3 S2




CM 2

CRN 87-69-4

CMF C4 H6 O6

Absolute stereochemistry.




RN 364323-50-2 CAPLUS

CN Benzenesulfonamide, 3-[(dimethylamino)methyl]-4-[4-(methylthio)phenoxy]-, (2S,3S)-2,3-dihydroxybutanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 364321-71-1

CMF C16 H20 N2 O3 S2




CM 2

CRN 147-71-7


CMF C4 H6 O6

Absolute stereochemistry.



RN 364323-51-3 CAPLUS

CN Benzenesulfonamide, 3-[(dimethylamino)methyl]-4-[4-(methylthio)phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 364323-52-4 CAPLUS
 CN Benzenesulfonamide, 3-[(dimethylamino)methyl]-4-[4-(methylthio)phenoxy]-,
 2-hydroxy-1,2,3-propanetricarboxylate (1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 364321-71-1
 CMF C16 H20 N2 O3 S2



CM 2


CRN 77-92-9
 CMF C6 H8 O7



RN 364323-53-5 CAPLUS
 CN Benzenesulfonamide, 3-[(dimethylamino)methyl]-4-[4-(methylthio)phenoxy]-,
 sulfate (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 364321-71-1
 CMF C16 H20 N2 O3 S2



CM 2


CRN 7664-93-9

CMF H2 O4 S



RN 364323-55-7 CAPLUS


CN Benzamide, 3-[(dimethylamino)methyl]-N-methyl-4-[4-(methylthio)phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 364324-32-3 CAPLUS


CN Benzenesulfonamide, 3-[(dimethylamino)methyl]-4-[4-(trifluoromethoxy)phenoxy]- (9CI) (CA INDEX NAME)



RN 364324-33-4 CAPLUS


CN Benzenesulfonamide, 3-[(dimethylamino)methyl]-N-[(2R)-2-hydroxypropyl]-4-[4-(methylthio)phenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 364324-34-5 CAPLUS

CN Benzenesulfonamide, 3-[(dimethylamino)methyl]-N-(2-hydroxyethyl)-4-[4-(methylthio)phenoxy]- (9CI) (CA INDEX NAME)



RN 364324-36-7 CAPLUS

CN Benzamide, N-methyl-3-[(methylamino)methyl]-4-[4-(methylthio)phenoxy]- (9CI) (CA INDEX NAME)



RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 12 OF 21 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 2001:693325 CAPLUS
 DN 135:257243
 TI Preparation of condensed imidazoles as histamine H3 receptor ligands
 IN Andersen, Knud Erik; Doerwald, Florencio Zaragoza; Sidelmann, Ulla Grove;
 Rudolf, Klaus; Stenkamp, Dirk; Hurnaus, Rudolf; Mueller, Stephan Georg;
 Krist, Bernd; Eriksen, Birgitte; Pesche, Bernd
 PA Novo Nordisk A/S, Den.; Boehringer Ingelheim International G.m.b.H.
 SO PCT Int. Appl., 170 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001068652	A1	20010920	WO 2001-DK188	20010316
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW:				
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 2002058659	A1	20020516	US 2001-810237	20010316
	US 6437147	B2	20020820		
	EP 1268484	A1	20030102	EP 2001-916934	20010316
	R:				
	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2003527395	T2	20030916	JP 2001-567743	20010316
	US 2003135056	A1	20030717	US 2002-201865	20020723
PRAI	DK 2000-441	A	20000317		
	DK 2000-1016	A	20000629		
	US 2000-193741P	P	20000331		
	US 2000-216553P	P	20000707		
	US 2001-810237	A1	20010316		
	WO 2001-DK188	W	20010316		

OS MARPAT 135:257243

AB A novel class of imidazo heterocyclic compds. (shown as I (e.g. 4,5,6,7-tetrahydro-1H-benzimidazole-5-carboxylic acid [(1S)-(naphth-1-yl)ethyl]amide) as well as any optical or geometric isomer or tautomeric form thereof including mixts. of these or a pharmaceutically acceptable salt thereof), pharmaceutical compns. comprising them and use thereof in the treatment and/or prevention of diseases and disorders related to the histamine H3 receptor. In I: R1 is H or a functional group, which can be converted to H in vivo. R2 is H, C1-6-alkyl, C1-6-alkoxy, C1-6-alkylthio, halogen, cyano, trifluoromethyl, hydroxy, thiol or amino. R3 and R4 independently are H or C1-6-alkyl, which is optionally substituted with aryl or heteroaryl, which are optionally substituted with one or more substituents selected from nitro, -NR7R8, -S(O)2NR7R8, -C(O)NR7R8, hydroxy, halogen, cyano, trifluoromethyl, -OCF3, -OCHF2, -OCH2CHF2, C1-6-alkyl, C2-6-alkenyl, C2-6-alkynyl, C1-6-alkoxy, C1-6-alkylthio, C1-6-alkylsulfonyl, -C(O)OR7, C1-6-alkylcarbonyl, -C(:NOR7)C1-6-alkyl, C3-10-cycloalkyl, C3-10-cycloalkylcarbonyl, -C(:NOR7)C3-10-cycloalkyl, aryl-C1-6-alkyl, heteroaryl-C1 6-alkyl, arylamino, heteroarylamino, aroyl, heteroaroyl, arylsulfonyl, heteroarylsulfonyl, -C(:NOR7)aryl, -C(:NOR7)heteroaryl, arylthio, heteroarylthio, aryloxy and heteroaryloxy.


R7 and R8 independently are H or C1-6-alkyl. M is 0-2; n is 1-4; X is a valence bond, -O-, -S-, -S(O)-, -S(O)2- or -CF2-; p is 0-3; Y is valence bond, -O-, -S-, or -NR9-, wherein R9 is H or C1-6-alkyl; V is :O, :S, :NR10 (R10 = H, cyano, nitro, C1-6-alkyl); W is valence bond, -O-, -S-, -NR11- (R11 = H, C1-6-alkyl); q is 0-3. Z is heteroaryl, aryl, aryloxy, C3-10-cycloalkyl, C3-8-heterocyclyl or aryl annulated with C3-8-heterocyclyl, C1-6-alkyl, C2-6-alkenyl or C2-6-alkynyl, which are optionally substituted with various provisos. More particularly, the compds. are useful for the treatment and/or prevention of diseases and disorders in which an interaction with the histamine H3 receptor is beneficial. The claimed compds. generally show a high binding affinity to the histamine H3 receptor, most preferably $IC_{50} < 500$ nM. Ninety-two example prepn. are included, but the methods of prepn. are not claimed. Pharmaceutical compns. contg. the compds. are claimed effective for redn. of wt., suppression of appetite and treatment and/or prevention of eating disorders (e.g. bulimia, binge eating), impaired glucose tolerance (IGT), Type 2 diabetes, allergic rhinitis, ulcer, anorexia, diseases and disorders related to the serotonin-3 receptor (5-HT₃; e.g. emesis), diseases and disorders related to the vanilloid receptor (e.g. pain, neurogenic inflammation, obesity), and diseases and disorders related to the alpha-2 adrenergic receptor (e.g. sleep inducing agent).

IT 175136-89-7 361394-40-3

RL: RCT (Reactant); RACT (Reactant or reagent)
(reactant; prepn. of condensed imidazoles as histamine H3 receptor ligands)


RN 175136-89-7 CAPLUS

CN Benzenemethanamine, 2-chloro-6-phenoxy- (9CI) (CA INDEX NAME)



RN 361394-40-3 CAPLUS

CN Benzenemethanamine, 2-fluoro-6-(4-methoxyphenoxy)- (9CI) (CA INDEX NAME)



RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 13 OF 21 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 2001:396851 CAPLUS
 DN 135:19652
 TI 3,4-Dihydro-(1H)-quinazolin-2-ones and their use as CSBP/p38 kinase inhibitors
 IN Adams, Jerry L.; Bower, Michael J.; Hall, Ralph F.; Griswold, Don E.; Underwood, David C.
 PA Smithkline Beecham Corporation, USA
 SO PCT Int. Appl., 54 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001038312	A1	20010531	WO 2000-US31861	20001121
	W:	AE, AL, AU, BA, BB, BG, BR, BZ, CA, CN, CZ, DZ, EE, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, MZ, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, TZ, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	EP 1235814	A1	20020904	EP 2000-980569	20001121
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
	JP 2003514899	T2	20030422	JP 2001-540075	20001121
PRAI	US 1999-166977P	P	19991123		
	WO 2000-US31861	W	20001121		

OS MARPAT 135:19652


AB Novel substituted quinazoline compds. are disclosed, specifically I [R1 = (un)substituted Ph, naphthyl, heterocyclyl or heteroaryl; R2 = (un)substituted alkyl, (hetero)aryl(alkyl), or heterocyclyl(alkyl); X = O or S] and their pharmaceutically acceptable salts. Also disclosed are pharmaceutical compns. contg. I, and use of I in therapy as CSBP/RK/p38 kinase inhibitors. Applications of I as such to a wide variety of arthritic, inflammatory, proliferative, and viral conditions are specifically claimed. Also claimed is use of I in conjunction with various other drugs or drug classes. Three examples of I were prep'd. and specifically claimed. For instance, 2,6-difluorobenzonitrile was coupled first with aniline using NaH in DMSO, and then with phenol using NaH in THF. The resulting 2-phenoxy-6-(phenylamino)benzonitrile underwent redn. of the nitrile to aminomethyl using LiAlH₄, and the product underwent cyclocondensation with 1,1'-carbonyldiimidazole, to give title compd. II. Representative compds. I had IC₅₀ values < 50 .mu.M in a CSBP/p38 kinase assay.

IT 342431-66-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (intermediate; prepn. of dihydroquinazolinones as CSBP/RK/p38 kinase inhibitors)

RN 342431-66-7 CAPLUS

CN Benzenemethanamine, 2-amino-6-phenoxy- (9CI) (CA INDEX NAME)



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 14 OF 21 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 2001:283913 CAPLUS
 DN 134:310974
 TI Preparation of biaryl ether derivatives as monoamine reuptake inhibitors
 IN Howard, Harry Ralph, Jr.; Adam, Mavis Diane
 PA Pfizer Products Inc., USA
 SO PCT Int. Appl., 52 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001027068	A1	20010419	WO 2000-IB1373	20000927
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW:				
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	BR 2000014733	A	20020611	BR 2000-14733	20000927
	EP 1220831	A1	20020710	EP 2000-960916	20000927
	R:				
	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
	JP 2003511434	T2	20030325	JP 2001-530089	20000927
	EE 200200191	A	20030616	EE 2002-191	20000927
	US 6410736	B1	20020625	US 2000-692335	20001019
	NO 2002001659	A	20020408	NO 2002-1659	20020408
	BG 106603	A	20021229	BG 2002-106603	20020410
	US 2003055038	A1	20030320	US 2002-153308	20020522
	US 6596741	B2	20030722		
PRAI	US 1999-159276P	P	19991013		
	US 1999-167761P	P	19991129		
	WO 2000-IB1373	W	20000927		
	US 2000-692335	A3	20001019		

OS MARPAT 134:310974

AB The title compds. [I; rings A and B can be replaced by naphthyl group; n, m = 1-3; R1, R2 = H, alkyl, alkenyl, etc.; NR1R2 = 4-8 membered satd. (un)substituted ring contg. 1-2 heteroatoms, including N atom to which R1 and R2 are attached; R3, R4 = H, alkyl optionally substituted with 1-3 F atoms; CR3R4 = 4-8 membered satd. (un)substituted carbocyclic ring; NR2CR3 = 4-8 membered satd. (un)substituted ring contg. 1-2 heteroatoms, including N atom to which R2 is attached; X = (un)substituted Ph, heteroaryl, heterocyclyl; Y = H, halo, alkyl optionally substituted with 1-3 F atoms, etc.; Z = H, halo, alkoxy, etc.] and their pharmaceutically acceptable salts which exhibit activity as serotonin, norepinephrine, and dopamine reuptake inhibitors and can be used in the treatment of central nervous system and other disorders, were prepd. E.g., a 3-step synthesis of I [R1 = Me; R2-R4 = H; X = 5-Ph; Z = H; Y = 3,4-Cl2] was given. All exemplified compds. I showed IC50 of .ltoreq. 250 nM for serotonin reuptake inhibition, and IC50 of .ltoreq. 1000 nM for dopamine and for norepinephrine reuptake inhibition.

IT 289717-61-9P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU

(Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT
(Reactant or reagent); USES (Uses)

(prepn. of biaryl ether derivs. as monoamine reuptake inhibitors)

RN 289717-61-9 CAPLUS

CN Benzenemethanamine, 5-bromo-2-(3,4-dichlorophenoxy)-N-methyl- (9CI) (CA
INDEX NAME)




IT 334980-95-9P 334980-96-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)

(prepn. of biaryl ether derivs. as monoamine reuptake inhibitors)


RN 334980-95-9 CAPLUS

CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N-methyl-5-nitro- (9CI) (CA
INDEX NAME)




RN 334980-96-0 CAPLUS

CN Carbamic acid, [[2-(3,4-dichlorophenoxy)-5-nitrophenyl]methyl]methyl-,
1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 15 OF 21 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 2000:761658 CAPLUS
 DN 134:162754
 TI Parallel solution-phase syntheses of functionalized bicyclo[2.2.2]octanes:
 generation of a library using orchestrated multi-step sequences of
 polymer-supported reagents and sequesterants
 AU Ley, Steven V.; Massi, Alessandro
 CS Department of Chemistry, University of Cambridge, Cambridge, CB2 1EW, UK
 SO Perkin 1 (2000), (21), 3645-3654
 CODEN: PERKF9; ISSN: 1470-4358
 PB Royal Society of Chemistry
 DT Journal
 LA English
 OS CASREACT 134:162754
 AB An array of bicyclo[2.2.2]octane derivs. was prepd. in high yield using an
 orchestrated multi-step sequence of polymer-supported reagents and
 sequestering agents, without any chromatog. purifn. steps. Nine
 intermediate libraries were synthesized, with the final library possessing
 five sites of diversity. Key steps included an efficient tandem Michael
 addn. reaction of acrylates with cyclohexenones and a subsequent reductive
 amination reaction.
 IT 175136-89-7
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (parallel soln.-phase syntheses of functionalized
 bicyclo[2.2.2]octanes)
 RN 175136-89-7 CAPLUS
 CN Benzenemethanamine, 2-chloro-6-phenoxy- (9CI) (CA INDEX NAME)



RE.CNT 58 THERE ARE 58 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 16 OF 21 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 2000:608708 CAPLUS
 DN 133:207665
 TI Preparation of phenoxybenzylamines as monoamine reuptake inhibitors
 IN Elliott, Mark Leonard; Howard, Harry Ralph, Jr.; Schmidt, Christopher
 Joseph; Seeger, Thomas Francis
 PA Pfizer Products Inc., USA
 SO PCT Int. Appl., 60 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000050380	A1	20000831	WO 2000-IB108	20000202
	W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	EP 1154984	A1	20011121	EP 2000-900785	20000202
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
	BR 2000008958	A	20011127	BR 2000-8958	20000202
	EE 200100441	A	20021216	EE 2001-441	20000202
	AU 763884	B2	20030731	AU 2000-30709	20000202
	US 2002143003	A1	20021003	US 2001-845992	20010430
	HR 2001000585	A1	20021231	HR 2001-585	20010807
	NO 2001004047	A	20011022	NO 2001-4047	20010820
	ZA 2001006890	A	20020923	ZA 2001-6890	20010821
	BG 105858	A	20020430	BG 2001-105858	20010830
PRAI	US 1999-121313P	P	19990223		
	US 2000-529207	A2	20000202		
	WO 2000-IB108	W	20000202		

OS MARPAT 133:207665

AB ROZCR3R4NR1R2 [R = (un)substituted Ph; R1,R2 = H, alk(en)yl, alkynyl; NR1R2 = heterocyclyl; R3,R4 = H or (fluoro)alkyl; R3R4 = (un)substituted alkylene; R2R3 = atoms to complete a heterocyclic ring; Z = (un)substituted phenylene] were prep'd. as monoamine reuptake inhibitors (no data). Thus, 2,5-F(F3C)C6H3CHO was aroxylated by 3,4-Cl2C6H3OH and the product reductively aminated by Me2NH to give title comp'd. I.


IT 289716-74-1P 289716-75-2P 289716-79-6P
 289716-80-9P 289716-89-8P 289716-92-3P
 289716-93-4P 289716-94-5P 289716-95-6P
 289716-96-7P 289716-97-8P 289717-01-7P
 289717-02-8P 289717-09-5P 289717-11-9P
 289717-13-1P 289717-16-4P 289717-17-5P
 289717-18-6P 289717-19-7P 289717-23-3P
 289717-28-8P 289717-29-9P 289717-32-4P
 289717-33-5P 289717-34-6P 289717-35-7P
 289717-36-8P 289717-39-1P 289717-40-4P
 289717-41-5P 289717-42-6P 289717-43-7P
 289717-44-8P 289717-45-9P 289717-46-0P
 289717-47-1P 289717-48-2P 289717-51-7P

289717-52-8P 289717-56-2P 289717-57-3P
 289717-59-5P 289717-60-8P 289717-61-9P
 289717-62-0P 289717-63-1P 289717-64-2P
 289717-65-3P 289717-66-4P 289717-69-7P
 289717-70-0P 289717-71-1P 289717-72-2P
 289719-21-7P 289719-22-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of phenoxybenzylamines as monoamine reuptake inhibitors)


RN 289716-74-1 CAPLUS

CN Benzenemethanamine, 2-fluoro-6-(4-methylphenoxy)- (9CI) (CA INDEX NAME)




RN 289716-75-2 CAPLUS

CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro- (9CI) (CA INDEX NAME)



RN 289716-79-6 CAPLUS

CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N,N-dimethyl-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 289716-80-9 CAPLUS

CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N,N-dimethyl-5-(trifluoromethyl)-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 289716-79-6
CMF C16 H14 Cl2 F3 N O




CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.




RN 289716-89-8 CAPLUS
CN Benzenemethanamine, 2-(4-chlorophenoxy)-5-fluoro-N-methyl-, hydrochloride
(9CI) (CA INDEX NAME)




● HCl

RN 289716-92-3 CAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N,N-dimethyl-,
hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 289716-93-4 CAPLUS
 CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N-methyl-,
 hydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 289716-94-5 CAPLUS
 CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N-methyl- (9CI) (CA
 INDEX NAME)



RN 289716-95-6 CAPLUS
 CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N-methyl-,
 (2Z)-2-butenedioate (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 289716-94-5
 CMF C14 H12 Cl2 F N O




CM 2


CRN 110-16-7

CMF C4 H4 O4

Double bond geometry as shown.




RN 289716-96-7 CAPLUS

CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N,N-dimethyl-5-nitro- (9CI)
(CA INDEX NAME)


RN 289716-97-8 CAPLUS

CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N,N-dimethyl-3-(trifluoromethyl)-, hydrochloride (9CI) (CA INDEX NAME)



HCl


RN 289717-01-7 CAPLUS
 CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N,N-dimethyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 289717-02-8 CAPLUS
 CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N,N-dimethyl-4-(trifluoromethyl)-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 289717-01-7
 CMF C16 H14 Cl2 F3 N O





CM 2

CRN 110-16-7
 CMF C4 H4 O4

Double bond geometry as shown.



RN 289717-09-5 CAPLUS
 CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N,N-dimethyl-6-(trifluoromethyl)-, hydrochloride (9CI) (CA INDEX NAME)



● HCl



RN 289717-11-9 CAPLUS

CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N-methyl-6-(trifluoromethyl)-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 289717-10-8

CMF C15 H12 Cl2 F3 N O




CM 2

CRN 110-16-7

CMF C4 H4 O4


Double bond geometry as shown.



RN 289717-13-1 CAPLUS
 CN Benzenemethanamine, 2-(3,4-dimethylphenoxy)-5-fluoro-N-methyl-,
 (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 289717-12-0
 CMF C16 H18 F N O




CM 2

CRN 110-16-7
 CMF C4 H4 O4

Double bond geometry as shown.



RN 289717-16-4 CAPLUS
 CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N-methyl-4-(trifluoromethyl)-
 (9CI) (CA INDEX NAME)




RN 289717-17-5 CAPLUS
 CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N-methyl-4-(trifluoromethyl)-,

(2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 289717-16-4

CMF C15 H12 Cl2 F3 N O




CM 2

CRN 110-16-7


CMF C4 H4 O4

Double bond geometry as shown.



RN 289717-18-6 CAPLUS

CN Benzenemethanamine, 4-chloro-2-(3,4-dichlorophenoxy)-N-methyl- (9CI) (CA INDEX NAME)




RN 289717-19-7 CAPLUS

CN Benzenemethanamine, 4-chloro-2-(3,4-dichlorophenoxy)-N-methyl-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 289717-18-6

CMF C14 H12 Cl3 N O




CM 2

CRN 110-16-7

CMF C4 H4 O4

Double bond geometry as shown.




RN 289717-23-3 CAPLUS

CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-3-fluoro-N-methyl-,
(2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 289717-22-2

CMF C14 H12 Cl2 F N O




CM 2

CRN 110-16-7

CMF C4 H4 O4


Double bond geometry as shown.



RN 289717-28-8 CAPLUS
 CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-4-fluoro-N-methyl-,
 (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 289717-27-7
 CMF C14 H12 Cl2 F N O




CM 2

CRN 110-16-7
 CMF C4 H4 O4

Double bond geometry as shown.



RN 289717-29-9 CAPLUS
 CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-methoxy-N-methyl-,
 hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 289717-32-4 CAPLUS
 CN Benzenemethanamine, 2-(4-chlorophenoxy)-5-fluoro-N,N-dimethyl-,
 (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 289717-31-3
 CMF C15 H15 Cl F N O




CM 2

CRN 110-16-7
 CMF C4 H4 O4

Double bond geometry as shown.




RN 289717-33-5 CAPLUS
 CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-4,5-dimethoxy-N-methyl-,
 hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 289717-34-6 CAPLUS
 CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N,4,5-trimethyl-,
 hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 289717-35-7 CAPLUS
 CN Benzenemethanamine, 5-bromo-2-(3,4-dichlorophenoxy)-N-methyl-,
 hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 289717-36-8 CAPLUS
 CN Benzenemethanamine, 4-bromo-2-(3,4-dichlorophenoxy)-N-methyl-,
 hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 289717-39-1 CAPLUS
 CN Benzonitrile, 3-(3,4-dichlorophenoxy)-4-[(methylamino)methyl]-,
 monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 289717-40-4 CAPLUS
 CN Benzenesulfonamide, 4-(3,4-dichlorophenoxy)-N-methyl-3-[(methylamino)methyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 289717-41-5 CAPLUS
 CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-4-methoxy-N,N-dimethyl-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 289717-42-6 CAPLUS
 CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N,N,5-trimethyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 289717-43-7 CAPLUS
 CN Benzenemethanamine, 2-fluoro-N,N-dimethyl-6-(4-methylphenoxy)- (9CI) (CA INDEX NAME)



RN 289717-44-8 CAPLUS
 CN Benzenemethanamine, 2-fluoro-N,N-dimethyl-6-(4-methylphenoxy)-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 289717-43-7
 CMF C16 H18 F N O



CM 2


CRN 110-16-7
 CMF C4 H4 O4

Double bond geometry as shown.



RN 289717-45-9 CAPLUS


CN Benzenemethanamine, 5-amino-2-(3,4-dichlorophenoxy)-N,N-dimethyl-,
monohydrochloride (9CI) (CA INDEX NAME)



● HCl



RN 289717-46-0 CAPLUS

CN Benzenemethanamine, 5-amino-2-(3,4-dichlorophenoxy)-N,N-dimethyl- (9CI)
(CA INDEX NAME)



RN 289717-47-1 CAPLUS



CN Acetamide, N-[4-(3,4-dichlorophenoxy)-3-[(dimethylamino)methyl]phenyl]-,
monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 289717-48-2 CAPLUS

CN Acetamide, N-[4-(3,4-dichlorophenoxy)-3-[(dimethylamino)methyl]phenyl]-
(9CI) (CA INDEX NAME)



RN 289717-51-7 CAPLUS


CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-, hydrochloride (9CI)
(CA INDEX NAME)



● HCl


RN 289717-52-8 CAPLUS

CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N,N-dimethyl- (9CI)
(CA INDEX NAME)




RN 289717-56-2 CAPLUS

CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-methoxy-N-methyl- (9CI) (CA
INDEX NAME)




RN 289717-57-3 CAPLUS

CN Benzenemethanamine, 2-(4-chlorophenoxy)-5-fluoro-N-methyl- (9CI) (CA
INDEX NAME)




RN 289717-59-5 CAPLUS

CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N,N,5-trimethyl- (9CI) (CA
INDEX NAME)




RN 289717-60-8 CAPLUS

CN Benzenemethanamine, 4-bromo-2-(3,4-dichlorophenoxy)-N-methyl- (9CI) (CA INDEX NAME)




RN 289717-61-9 CAPLUS

CN Benzenemethanamine, 5-bromo-2-(3,4-dichlorophenoxy)-N-methyl- (9CI) (CA INDEX NAME)




RN 289717-62-0 CAPLUS

CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-4,5-dimethoxy-N-methyl- (9CI) (CA INDEX NAME)




RN 289717-63-1 CAPLUS


CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-4-methoxy-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 289717-64-2 CAPLUS
 CN Benzonitrile, 4-(3,4-dichlorophenoxy)-3-[(methylamino)methyl]- (9CI) (CA INDEX NAME)




RN 289717-65-3 CAPLUS
 CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N,4,5-trimethyl- (9CI) (CA INDEX NAME)



RN 289717-66-4 CAPLUS
 CN Benzonitrile, 3-(3,4-dichlorophenoxy)-4-[(methylamino)methyl]- (9CI) (CA INDEX NAME)




RN 289717-69-7 CAPLUS
 CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-N-methyl-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 289717-70-0 CAPLUS

CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-4-methoxy-N-methyl- (9CI) (CA INDEX NAME)




RN 289717-71-1 CAPLUS

CN Benzenemethanamine, 2-(4-chloro-3-fluorophenoxy)-5-fluoro-N-methyl- (9CI) (CA INDEX NAME)



RN 289717-72-2 CAPLUS


CN Benzenemethanamine, 2-(3-chloro-4-fluorophenoxy)-5-fluoro-N-methyl- (9CI) (CA INDEX NAME)



RN 289719-21-7 CAPLUS

CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-methyl-, hydrochloride (9CI)


(CA INDEX NAME)



● HCl

RN 289719-22-8 CAPLUS

CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-4-methoxy-, hydrochloride
(9CI) (CA INDEX NAME)



● HCl

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 17 OF 21 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1999:225654 CAPLUS
 DN 130:304065
 TI Microcapsules formed from polyisocyanates and thermal recording materials using them
 IN Kodama, Tomohiro; Fujimoto, Kiyoshi; Wakata, Yuichi
 PA Fuji Photo Film Co., Ltd., Japan
 SO Jpn. Kokai Tokkyo Koho, 21 pp.
 CODEN: JKXXAF
 DT Patent
 LA Japanese
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 11092439	A2	19990406	JP 1997-251070	19970916
PRAI	JP 1997-251070		19970916		

AB The microcapsules are formed from polyisocyanates I (R, R1, R2 = H, alkyl, aryl, aralkyl, alkenyl, alkynyl, alkoxy, aryloxy, alkylthio, dialkylamino, acyloxy, arylthio; p = 1-3; q = 3-6; r, s, t = 0, 1; q + r + s + t = 6). The recording material comprises a support and thermal recording layer contg. the microcapsules encapsulating component A and/or component B which reacts with component A, e.g. diazo compds., leuco dyes, etc. The recording material is storage stable and the background of the recorded materials are resistant to light.


IT **223423-70-9P**
 RL: DEV (Device component use); PNU (Preparation, unclassified); PREP (Preparation); USES (Uses)
 (thermal recording materials using color former microcapsules having capsule wall formed from poly(isocyanatoalkyl)benzenes)

RN 223423-70-9 CAPLUS

CN 1,2-Ethanediamine, N-(2-aminoethyl)-, polymer with Takenate D 110N and 1,3,5-tris(isocyanatomethyl)-2-methyl-4-phenoxybenzene (9CI) (CA INDEX NAME)

CM 1

CRN 223423-69-6
 CMF C19 H15 N3 O4



CM 2

CRN 37337-02-3
 CMF Unspecified
 CCI PMS, MAN


*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

10/010,651


CM 3

CRN 111-40-0


CMF C4 H13 N3



L10 ANSWER 18 OF 21 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1984:68778 CAPLUS
 DN 100:68778
 TI Study of the reactivity of alkylaromatic tertiary diamines
 AU Burmistr, M. V.; Svetkin, Yu. V.
 CS USSR
 SO Voprosy Khimii i Khimicheskoi Tekhnologii (1983), 70, 6-10
 CODEN: VKKCAJ; ISSN: 0321-4095
 DT Journal
 LA Russian
 AB The reactivity of 20 alkylarom. tertiary diamines (N,N,N',N'-tetramethyl-p-xylylenediamine [19851-38-8], N,N,N',N'-tetramethyl-m-xylylenediamine [19851-44-6], etc.) was evaluated by MO LCAO calcn. of electron d. on N atoms (assuming that the reactivity increases with increasing electron d. on N atoms) and by detn. of the rate const. in polymn. with p-xylylene dichloride [623-25-6]. The presence of Me substituent in arom. rings of the diamines increased the electron d. on N atoms, and Me groups in the o-position with respect to N were most effective. The presence of CH₂NMe₂ and Cl substituents in arom. rings decreased electron d. on N atoms. The polymn. rate const. did not correlate with electron d. on N atoms indicating the importance of steric factors.
 IT **88847-36-3**
 RL: PRP (Properties)
 (reactivity of, electron d. on N atoms and rate const. in ionene formation in relation to)
 RN 88847-36-3 CAPLUS
 CN 1,3-Benzenedimethanamine, N,N,N',N'-tetramethyl-2-phenoxy- (9CI) (CA INDEX NAME)



L10 ANSWER 19 OF 21 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1983:539732 CAPLUS
 DN 99:139732
 TI Synthesis of phaeantharine, IV: Synthesis of 6,6',7-trimethoxy-7',8-diisoquinolyl ether (unit B)
 AU Knabe, Joachim; Weirich, Wigand
 CS Fachrichtung Pharm. Chem., Univ. Saarlandes, Saarbruecken, 6600, Fed. Rep. Ger.
 SO Archiv der Pharmazie (Weinheim, Germany) (1983), 316(8), 694-6
 CODEN: ARPMAS; ISSN: 0365-6233
 DT Journal
 LA German
 AB Unit B of phaeantharine was prepd. in 3 steps. Refluxing H₂NCH₂CH(OMe)₂ and benzaldehyde I (R = CHO) in EtOH 1 h and hydrogenating the soln. over PtO₂ gave 82% amine I [R = CH₂NHCH₂CH(OMe)₂] which was tosylated in pyridine and the product (89% yield) cyclized in refluxing 6N HCl to give 17% isoquinoline II (12% overall yield).
 IT **87179-88-2P**
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (prepn. and tosylation of)
 RN 87179-88-2 CAPLUS
 CN Benzenemethanamine, N-(2,2-dimethoxyethyl)-2-[5-[(2,2-dimethoxyethyl)amino]methyl]-2-methoxyphenoxy]-3,4-dimethoxy- (9CI) (CA INDEX NAME)



L10 ANSWER 20 OF 21 CAPLUS COPYRIGHT 2003 ACS on STN

AN 1970:466188 CAPLUS

DN 73:66188

TI Macro chelate rings. III. Syntheses and configurations of complexes of new ligands, 4,4'-dimethyl-2,2'-bis(salicylideneaminomethyl)diphenyl ether and 4,4'-dimethyl-2,2'-bis(salicylideneaminomethyl)diphenylamine

AU Okawa, Hisashi; Koyama, Hiroyuki; Inazu, Takahiko; Yoshino, Tamotsu

CS Fac. Sci., Kyushu Univ., Fukuoka, Japan

SO Bulletin of the Chemical Society of Japan (1970), 43(6), 1729-33

CODEN: BCSJA8; ISSN: 0009-2673

DT Journal

LA English


AB Two quadridentate chelating agents, 4,4'-dimethyl-2,2'-bis(salicylideneaminomethyl)diphenyl ether (I) and 4,4'-dimethyl-2,2'-bis(salicylideneaminomethyl)diphenylamine (II), which may form metal complexes with a ten-membered chelate ring, were synthesized and their Co(II), Ni(II), Cu(II), and Zn(II) complexes prepd. The configurations around the central divalent metal ion were explored on the basis of the absorption of the ligand field in a soln. A tetrahedral configuration for Co(II) and Zn(II) complexes, and a pseudotetrahedral configuration for the Ni(II) and Cu complexes, were concluded.

IT 27996-12-9P

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 27996-12-9 CAPLUS

CN Benzylamine, 2,2'-oxybis[5-methyl-, dihydrochloride (8CI) (CA INDEX NAME)



● 2 HCl

L10 ANSWER 21 OF 21 CAPLUS COPYRIGHT 2003 ACS on STN

AN 1961:118547 CAPLUS

DN 55:118547

OREF 55:22321f-i,22322a-b

TI The synthesis of esters of some amino acids having pharmacological importance. I. The synthesis of esters of piperidino carboxylic acids

AU Matkovics, Bela; Foldeak, Sandor; Porszasz, Janos; Sipos, Gyorgy

CS Tudományegyetem, Szeged, Hung.

SO Acta Pharmaceutica Hungarica (1961), 31, 113-21

CODEN: APHGAO; ISSN: 0001-6659

DT Journal


LA Hungarian

AB $\text{RCH}_2\text{CO}_2\text{R}'$ (I), $\text{RCH}_2\text{CH}_2\text{CO}_2\text{R}'$ (II), $\text{BzOCH}_2\text{CH}_2\text{R}$ (III), and $\text{AcOCHMeCH}_2\text{R}$ (IV) were prep'd. I were prep'd. by condensing $\text{ClCH}_2\text{CO}_2\text{R}'$ with a secondary amine, II by boiling $\text{ClCH}_2\text{CH}_2\text{CO}_2\text{R}'$ with the amine, and III by the reaction of an amino alc. with BzCl . The following I were obtained (R, R', b.p..degree./mm., m.p. of picrate, m.p. of HCl salt, and m.p. of methiodide are given): piperidino, Me, 69.degree./5, 115.degree., 214.degree., 163-4.degree.; piperidino, Et, 68.degree./1, 122.degree., 117-17.5.degree., 160-60.3.degree.; piperidino, Bu, 100-1.degree./4, 85.degree., -, 178.degree.; piperidino, PhCH_2 , 134-5.degree./1, 137.degree., 133.degree., 91-6.degree.; morpholino, Me, 77.degree./2, 143.degree., 150.5.degree., 147.5.degree.; morpholino, Et, 86-7.degree./4, 163.degree., 181.degree., 132-3.degree.; morpholino, Bu, 105.5-106.degree./3, -, 127-9.degree., 95-6.degree.; morpholino, PhCH_2 , 164-5.degree./5, 143.degree., 149.degree., -; pyrrolidino, Me, 72-3.degree./8, 104.degree., -, 153.degree.; pyrrolidino, Et, 59-60.degree./2, 119.5.degree., 133-3.5.degree., -; pyrrolidino, Bu, 81-2.degree./3, 109.5.degree., -, -; pyrrolidino, PhCH_2 , 134-5.degree./1, 159-60.degree., 139-40.degree., 156.degree.. The following II were prep'd. (data as above): piperidino, Me, 72.degree./2, 164.degree., 189.degree., 147-8.degree.; piperidino, Et, 102-3.degree./5, 131.5.degree., 169.degree., -; piperidino, Bu, 124-5.degree./6, 108-9.degree., 164.7.degree., -; piperidino, PhCH_2 , 149-50.degree./1, 113.degree., 193.5.degree., -; piperidino, Ph, 114-20.degree./3, -, 192-5.degree., -; piperidino, CPh_3 , 171.degree./1, -, 214.degree., -; morpholino, Me, 82.degree./2, 129.degree., 203.degree., 151.degree.; morpholino, Et, 108.degree./6, 108.degree., 188-9.degree., -; morpholino, Bu, 131-2.degree./6, 150.degree., 173.degree., 115.degree.; morpholino, PhCH_2 , 154.degree./1, 125.degree., 189-90.degree., -; pyrrolidino, Me, 76.degree./5, 147.degree., 128.degree., 166.degree.; pyrrolidino, Et, 85.degree./6, 114.degree., 146.degree., -; pyrrolidino, Bu, 106-8.degree./5, 97.degree., 74-5.degree., 115.degree.; pyrrolidino, PhCH_2 , 145-6.degree./3, 102.degree., 152.degree., 154.degree.. IV (R = pyrrolidino) (V), b3 75.degree., picrate m. 111-12.degree., gave a hygroscopic HCl salt. III (R = piperidino) b2 141.degree.; HCl salt m. 184.degree.; methiodide m. 141.5.degree.. The action of the compds. on blood pressure and on respiration was given. II (R = N-piperidino, R' = CPh_3) and V had strong antinicotinic action. The effect of the piperidino and pyrrolidino propionates was increased by quaternization.

IT 103044-26-4, Veratrylamine, 2,2'-oxybis[N,N-diethyl- (prepn. of)

RN 103044-26-4 CAPLUS

CN Veratrylamine, 2,2'-oxybis[N,N-diethyl- (6CI) (CA INDEX NAME)



=> d his

(FILE 'HOME' ENTERED AT 17:35:47 ON 24 SEP 2003)

FILE 'REGISTRY' ENTERED AT 17:35:52 ON 24 SEP 2003

L1 SCREEN 2016 OR 2026 OR 1840 OR 2039 OR 2040 OR 2045 OR 20
 L2 STRUCTURE UPLOADED
 L3 QUE L2 NOT L1
 L4 19 S L3 SSS SAM
 L5 SCREEN 2016 OR 2026 OR 1840 OR 2039 OR 2040 OR 2045 OR 20
 L6 STRUCTURE UPLOADED
 L7 QUE L6 NOT L5
 L8 19 S L7 SSS SAM
 L9 399 S L7 SSS FUL

FILE 'CAPLUS' ENTERED AT 17:38:24 ON 24 SEP 2003.

L10 21 S L9


FILE 'CAOLD' ENTERED AT 17:39:31 ON 24 SEP 2003

=> s 19

L11 1 L9

=> d l11 bib,hitstr


L11 ANSWER 1 OF 1 CAOLD COPYRIGHT 2003 ACS on STN
 AN CA55:22321e CAOLD
 TI synthesis and halomethylation of bis(3,4-dimethoxyphenyl) ether-reaction
 of halomethyl derivs. with secondary amines and pyridines
 AU Matarasso-Tchiroukhine, Elisabeth
 IT 103044-26-4 116378-59-7
 RN 103044-26-4 CAOLD
 CN Veratrylamine, 2,2'-oxybis[N,N-diethyl- (6CI) (CA INDEX NAME)



RN 116378-59-7 CAOLD
 CN Veratrylamine, 2,2'-oxybis[N,N-diethyl-, dipicrate (6CI) (CA INDEX NAME)


CM 1

CRN 103044-26-4
 CMF C26 H40 N2 O5



CM 2

CRN 88-89-1
 CMF C6 H3 N3 O7



10/010,651

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

3.02

248.67

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

0.00

-13.67

STN INTERNATIONAL LOGOFF AT 17:40:03 ON 24 SEP 2003


=> s 146939-27-7/rn
L1 1 146939-27-7/RN

=> s 11
L2 1-99 L1


=> s 11
L3 59 L1

=> d 13 1-59 bib,ab,hitstr


L3 ANSWER 1 OF 59 USPATFULL on STN
AN 2003:243900 USPATFULL
TI Pharmaceutical compositions containing polymer and drug assemblies
IN Babcock, Walter C., Bend, OR, UNITED STATES
Crew, Marshall D., Bend, OR, UNITED STATES
Friesen, Dwayne T., Bend, OR, UNITED STATES
Rabenstein, Mark D., Bend, OR, UNITED STATES
Shanker, Ravi M., Groton, CT, UNITED STATES
Smithey, Daniel T., Bend, OR, UNITED STATES
PI US 2003170309 A1 20030911
AI US 2002-173945 A1 20020617 (10)
PRAI US 2001-300259P 20010622 (60)
DT Utility
FS APPLICATION
LREP PFIZER INC., PATENT DEPARTMENT, MS8260-1611, EASTERN POINT ROAD, GROTON,
CT, 06340
CLMN Number of Claims: 67
ECL Exemplary Claim: 1
DRWN 5 Drawing Page(s)
LN.CNT 7724
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Solutions containing polymer/drug assemblies of a low-solubility drug
and polymer are disclosed. In addition, solid aggregated polymer/drug
assemblies are disclosed comprising a low-solubility drug and polymer.
IT **146939-27-7**, Ziprasidone
(comps. contg. amphiphilic polymer and low-soly. drug assemblies)
RN 146939-27-7 USPATFULL
CN 2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-
chloro-1,3-dihydro- (9CI) (CA INDEX NAME)




L3 ANSWER 2 OF 59 USPATFULL on STN
AN 2003:225766 USPATFULL
TI Aequorin as a growth marker in yeast
IN Fraissignes, Pauline, Marseille, FRANCE
Guedin, Denis, Montauroux, FRANCE
PI US 2003157578 A1 20030821
AI US 2002-281013 A1 20021025 (10)
PRAI EP 2001-125708 20011027
US 2002-346021P 20020104 (60)
DT Utility
FS APPLICATION
LREP Aventis Pharmaceuticals Inc., Patent Department, Route #202-206 / P.O.
Box 6800, Bridgewater, NJ, 08807-0800
CLMN Number of Claims: 5
ECL Exemplary Claim: 1
DRWN 11 Drawing Page(s)
LN.CNT 484
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A yeast cell containing constitutively expressed aequorin and methods of
using the cells in growth and toxicity assays are disclosed.
IT **146939-27-7**, Ziprasidone
(measuring toxicity of; cloning aequorin gene of Aequoria victoria in
yeast and its use as growth marker in screening for anti-fungal agents
and measuring toxicity of chems.)
RN 146939-27-7 USPATFULL
CN 2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-
chloro-1,3-dihydro- (9CI) (CA INDEX NAME)




L3 ANSWER 3 OF 59 USPATFULL on STN
 AN 2003:188541 USPATFULL
 TI Methods and compositions for the treatment of psychiatric disorders
 IN Muller, Norbert, Munchen, GERMANY, FEDERAL REPUBLIC OF
 PI US 2003130334 A1 20030710
 AI US 2002-157969 A1 20020531 (10)
 PRAI DE 2001-129328 20010619
 US 2002-364904P 20020314 (60)
 DT Utility
 FS APPLICATION
 LREP Teresa Stanek Rea, Esq., BURNS, DOANE, SWECKER & MATHIS, L.L.P., P.O.
 Box 1404, Alexandria, VA, 22313-1404
 CLMN Number of Claims: 37
 ECL Exemplary Claim: 1
 DRWN 5 Drawing Page(s)
 LN.CNT 1802
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB A method for the prevention, treatment, or inhibition of a psychiatric disorder, in particular schizophrenia, is described which comprises administering a COX-2 inhibitor or prodrug thereof to a subject. Moreover, a method for the prevention, treatment, or inhibition of a psychiatric disorder, in particular schizophrenia or depressive disorders, is disclosed comprising administering to a subject a COX-2 inhibitor or prodrug thereof in combination with a neuroleptic drug or an antidepressant. Compositions and kits that are suitable for the practice of the method are also described.
 IT **146939-27-7**, Ziprasidone
 (cyclooxygenase 2 inhibitor for treatment of psychiatric disorders, and use with other agents)
 RN 146939-27-7 USPATFULL
 CN 2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro- (9CI) (CA INDEX NAME)




L3 ANSWER 4 OF 59 USPATFULL on STN
AN 2003:173998 USPATFULL
TI Compounds with 5-HT activity useful for controlling visual field loss
IN Collier Jr, Robert J., Arlington, TX, UNITED STATES
Hellberg, Mark R., Highland Village, TX, UNITED STATES
Dean, Thomas R., Weatherford, TX, UNITED STATES
PI US 2003119846 A1 20030626
AI US 2002-221056 A1 20020909 (10)
WO 2001-US5740 20010223
PRAI US 2000-60190279 20000317
DT Utility
FS APPLICATION
LREP ALCON RESEARCH, LTD., R&D COUNSEL, Q-148, 6201 SOUTH FREEWAY, FORT
WORTH, TX, 76134-2099
CLMN Number of Claims: 13
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 461
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds with 5-HT.sub.1A agonist activity which are useful for
controlling the visual field loss associated with glaucoma are
disclosed.
IT **146939-27-7**, Ziprasidone
(5-HT_{1A} agonist for treating disorder of outer retina)
RN 146939-27-7 USPATFULL
CN 2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-
chloro-1,3-dihydro- (9CI) (CA INDEX NAME)




L3 ANSWER 5 OF 59 USPATFULL on STN
AN 2003:166654 USPATFULL
TI Compounds with 5-HT₂ and 5-HT_{1A} agonist activity for treating glaucoma
IN Collier, Robert J, JR., Arlington, TX, UNITED STATES
Dean, Thomas R, Weatherford, TX, UNITED STATES
Hellberg, Mark R, Highland Village, TX, UNITED STATES
PI US 2003114512 A1 20030619
AI US 2002-221116 A1 20020909 (10)
WO 2001-US5432 20010220
DT Utility
FS APPLICATION
LREP ALCON RESEARCH, LTD., R&D COUNSEL, Q-148, 6201 SOUTH FREEWAY, FORT
WORTH, TX, 76134-2099
CLMN Number of Claims: 14
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 500
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds with both 5-HT₂ and 5-HT_{1A} agonist activity which
are useful for lowering and controlling IOP and the treatment of
glaucomatous optic neuropathy.
IT **146939-27-7**, Ziprasidone
(5-HT_{1A} agonist for treating disorder of outer retina)
RN 146939-27-7 USPATFULL
CN 2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-
chloro-1,3-dihydro- (9CI) (CA INDEX NAME)



L3 ANSWER 6 OF 59 USPTAFULL on STN
 AN 2003:159931 USPTAFULL
 TI Treatment of psychotic disorders comprising co-therapy with
 anticonvulsant derivatives and atypical antipsychotics
 IN Fenton, Wayne S., Rockville, MD, UNITED STATES
 PI US 2003109546 A1 20030612
 AI US 2002-131277 A1 20020423 (10)
 PRAI US 2001-286765P 20010426 (60)
 US 2001-301661P 20010628 (60)
 DT Utility
 FS APPLICATION
 LREP AUDLEY A. CIAMPORCERO JR., JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON
 PLAZA, NEW BRUNSWICK, NJ, 08933-7003
 CLMN Number of Claims: 19
 ECL Exemplary Claim: 1
 DRWN No Drawings
 LN.CNT 749
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB Treatment of psychotic disorders such as schizophrenia, schizophreniform
 and schizoaffective disorders comprising co-therapy with an
 anticonvulsant derivative and a typical antipsychotic.
 IT **146939-27-7**, Ziprasidone
 (anticonvulsant deriv.-atypical antipsychotic co-therapy for psychotic
 disorders)
 RN 146939-27-7 USPTAFULL
 CN 2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-
 chloro-1,3-dihydro- (9CI) (CA INDEX NAME)



L3 ANSWER 7 OF 59 USPATFULL on STN
 AN 2003:126760 USPATFULL
 TI Hydrogel-driven drug dosage form
 IN Appel, Leah E., Bend, OR, UNITED STATES
 Babcock, Walter C., Bend, OR, UNITED STATES
 Beyerinck, Ronald A., Bend, OR, UNITED STATES
 Chidlaw, Mark B., Bend, OR, UNITED STATES
 Curatolo, William J., Niantic, CT, UNITED STATES
 Friesen, Dwayne T., Bend, OR, UNITED STATES
 Herbig, Scott M., East Lyme, CT, UNITED STATES
 Thombre, Avinash G., East Lyme, CT, UNITED STATES
 PI US 2003086972 A1 20030508
 AI US 2001-920056 A1 20010801 (9)
 PRAI US 2000-224199P 20000809 (60)
 DT Utility
 FS APPLICATION
 LREP Gregg C. Benson, Pfizer Inc., Patent Department, MS 4159,, Eastern Point
 Road, Groton, CT, 06340
 CLMN Number of Claims: 111
 ECL Exemplary Claim: 1
 DRWN No Drawings
 LN.CNT 3101
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB A controlled release dosage form has a coated core with the core
 comprising a drug-containing composition and a water-swella-
 ble composition, each occupying separate regions within the core. The
 coating around the core is water-permeable, water-insoluble and has at
 least one delivery port therethrough. A variety of geometric
 arrangements are disclosed.
 IT **146939-27-7**
 (polymeric hydrogel-driven controlled release dosage forms of low-soly.
 drugs)
 RN 146939-27-7 USPATFULL
 CN 2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-
 chloro-1,3-dihydro- (9CI) (CA INDEX NAME)




10/010,651 (Ziprasidone)


L3 ANSWER 8 OF 59 USPATFULL on STN
 AN 2003:113511 USPATFULL
 TI Thiazole derivatives
 IN Sanner, Mark A., Old Saybrook, CT, UNITED STATES
 Helal, Chris J., Mystic, CT, UNITED STATES
 Cooper, Christopher B., Lawrenceville, NJ, UNITED STATES
 PA Pfizer Inc. (U.S. corporation)
 PI US 2003078252 A1 20030424
 AI US 2002-144403 A1 20020513 (10)
 PRAI US 2001-290466P 20010511 (60)
 DT Utility
 FS APPLICATION
 LREP PFIZER INC, 150 EAST 42ND STREET, 5TH FLOOR - STOP 49, NEW YORK, NY,
 10017-5612
 CLMN Number of Claims: 86
 ECL Exemplary Claim: 1
 DRWN No Drawings
 LN.CNT 2788
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB The invention provides compounds of formula 1 ##STR1##

wherein R.sup.1, R.sup.3, and R.sup.4 are as defined, and their
 pharmaceutically acceptable salts. Compounds of formula 1 are indicated
 to have activity inhibiting cdk5, cdk2, and GSK-3. Pharmaceutical
 compositions and methods comprising compounds of formula 1 for treating
 diseases and conditions comprising abnormal cell growth, such as cancer,
 and neurodegenerative diseases and conditions and those affected by
 dopamine neurotransmission are described. Also described are
 pharmaceutical compositions and methods comprising compounds of formula
 1 for treating male fertility and sperm motility; diabetes mellitus;
 impaired glucose tolerance; metabolic syndrome or syndrome X; polycystic
 ovary syndrome; adipogenesis and obesity; myogenesis and frailty, for
 example age-related decline in physical performance; acute sarcopenia,
 for example muscle atrophy and/or cachexia associated with burns, bed
 rest, limb immobilization, or major thoracic, abdominal, and/or
 orthopedic surgery; sepsis; hair loss, hair thinning, and balding; and
 immunodeficiency.

IT 146939-27-7, Ziprasidone
 (therapeutics also contg.; prepn. of thiazole derivs. as cdk
 inhibitors)
 RN 146939-27-7 USPATFULL
 CN 2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-
 chloro-1,3-dihydro- (9CI) (CA INDEX NAME)




L3 ANSWER 9 OF 59 USPATFULL on STN
AN 2003:112497 USPATFULL
TI Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
IN Dugger, Harry A., III, Flemington, NJ, UNITED STATES
PI US 2003077227 A1 20030424
AI US 2002-230060 A1 20020829 (10)
RLI Continuation-in-part of Ser. No. US 2000-537118, filed on 29 Mar 2000, PENDING Continuation-in-part of Ser. No. WO 1997-US17899, filed on 1 Oct 1997, PENDING
DT Utility
FS APPLICATION
LREP PENNIE & EDMONDS LLP, 1667 K STREET NW, SUITE 1000, WASHINGTON, DC, 20006
CLMN Number of Claims: 123
ECL Exemplary Claim: 1
DRWN 1 Drawing Page(s)
LN.CNT 1383
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Buccal aerosol sprays or capsules using polar and non-polar solvent have now been developed which provide biologically active compounds for rapid absorption through the oral mucosa, resulting in fast onset of effect. The buccal polar compositions of the invention comprise formulation I: aqueous polar solvent, active compound, and optional flavoring agent; formulation II: aqueous polar solvent, active compound, optionally flavoring agent, and propellant; formulation III: non-polar solvent, active compound, and optional flavoring agent; and formulation IV: non-polar solvent, active compound, optional flavoring agent, and propellant.
IT **146939-27-7**, Ziprasidone
(buccal sprays or capsule contg. drugs for treating disorders of central nervous system)
RN 146939-27-7 USPATFULL
CN 2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro- (9CI) (CA INDEX NAME)



10/010,651 (Ziprasidone)

L3 ANSWER 10 OF 59 USPATFULL on STN
 AN 2003:105890 USPATFULL
 TI Pharmaceutical compositions comprising drug and concentration-enhancing polymers
 IN Curatolo, William J., Niantic, CT, UNITED STATES
 Friesen, Dwayne T., Bend, OR, UNITED STATES
 PA Pfizer Inc. (U.S. corporation)
 PI US 2003072801 A1 20030417
 AI US 2002-176462 A1 20020620 (10)
 PRAI US 2001-300314P 20010622 (60)
 DT Utility
 FS APPLICATION
 LREP PFIZER INC., PATENT DEPARTMENT, MS8260-1611, EASTERN POINT ROAD, GROTON, CT, 06340
 CLMN Number of Claims: 15
 ECL Exemplary Claim: 1
 DRWN No Drawings
 LN.CNT 7618
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB A solubility-improved drug form is combined with a concentration-enhancing polymer in a sufficient amount so that the combination provides substantially enhanced drug concentration in a use environment relative to a control comprising the same amount of the same drug form without the concentration-enhancing polymer.
 IT **146939-27-7**, Ziprasidone
 (pharmaceutical compns. comprising drug and concn.-enhancing polymers)
 RN 146939-27-7 USPATFULL
 CN 2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro- (9CI) (CA INDEX NAME)




L3 ANSWER 11 OF 59 USPTAFULL on STN
 AN 2003:100586 USPTAFULL
 TI Method and system for predicting pharmacokinetic properties
 IN Uchiyama, Mamoru, Aichi-ken, JAPAN
 Hattori, Kazunari, Aichi-ken, JAPAN
 Shimada, Kaoru, Aichi-ken, JAPAN
 PI US 2003069698 A1 20030410
 AI US 2001-876767 A1 20010607 (9)
 PRAI US 2000-211864P 20000614 (60)
 DT Utility
 FS APPLICATION
 LREP Gregg C. Benson, Pfizer Inc., Patent Department, MS 4159, Eastern Point
 Road, Groton, CT, 06340
 CLMN Number of Claims: 7
 ECL Exemplary Claim: 1
 DRWN No Drawings
 LN.CNT 717
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB This invention provides a method for predicting pharmacokinetic
 properties of molecules comprising the steps of:


- (a) preparing 2D-structures of molecules used as a training set;
- (b) constructing a 2D-fingerprint by counting the number of structural
 descriptors that potentially relate to a pharmacokinetic property,
 either manually or automatically using internally developed macro;
 wherein said structural descriptors consist of predefined 20 to 80
 atoms/fragments or substructures;
- (c) analyzing the obtained 2D-fingerprint by a statistical analysis
 method to correlate with the pharmacokinetic property of the molecule to
 yield a quantitative structure-property relationship (QSPR) model; and
- (d) calculating the pharmacokinetic property of a trial molecule using
 the above obtained QSPR model.

A system for this invention is also provided. According to this method
 and system, it is possible to predict pharmacokinetic properties of
 molecules prior to synthesis, without labor-intensive and time-consuming
 experimentation.

IT **146939-27-7**, Ziprasidone
 (method and system for predicting pharmacokinetic properties)
 RN 146939-27-7 USPTAFULL
 CN 2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-
 chloro-1,3-dihydro- (9CI) (CA INDEX NAME)




L3 ANSWER 12 OF 59 USPTAFULL on STN
 AN 2003:78121 USPTAFULL
 TI Modified release formulations containing a hypnotic agent
 IN Lemmens, Jacobus M., Mook, NETHERLANDS
 van den Heuvel, Dennie J.M., Boxmeer, NETHERLANDS
 Platteeuw, Johannes J., s'Hertogenbosch, NETHERLANDS
 van Dalen, Frans, Nijmegen, NETHERLANDS
 PI US 2003054041 A1 20030320
 AI US 2001-833662 A1 20010413 (9)
 PRAI US 2000-196939P 20000413 (60)
 DT Utility
 FS APPLICATION
 LREP SYNTHON PHARMACEUTICALS, LTD., PATENT DEPT., P.O. BOX 161, CATHARPIN,
 VA, 20143
 CLMN Number of Claims: 57
 ECL Exemplary Claim: 1
 DRWN 6 Drawing Page(s)
 LN.CNT 971
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB Hypnotic pharmaceutical compositions are made from pellets and exhibit a
 modified release. Zolpidem or a pharmaceutically acceptable salt thereof
 is a typical hypnotic. The pellets are preferably spherical and exhibit
 a dissolution profile that includes 60% of the hypnotic agent being
 release from the pellet not earlier than 5 minutes from the start of a
 specified in vitro dissolution test. Although the modified release
 profile can include 50% of the hypnotic agent being released not earlier
 than 15 minutes after the start of the dissolution test, the pellet
 preferably does not contain a release rate controlling excipient or
 coating. Instead, microcrystalline cellulose and the active constitute
 the majority of the pellet, e.g. 90% or more. Spherical pellets are also
 made by a convenient method that is applicable to any pharmaceutically
 active agent.
 IT **146939-27-7**, Ziprasidone
 (modified-release formulations contg. hypnotic agent)
 RN 146939-27-7 USPTAFULL
 CN 2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-
 chloro-1,3-dihydro- (9CI) (CA INDEX NAME)




10/010,651 (Ziprasidone)

L3 ANSWER 13 OF 59 USPATFULL on STN
AN 2003:38170 USPATFULL
TI Combination therapy for treatment of bipolar disorders
IN Tollefson, Gary Dennis, Indianapolis, IN, UNITED STATES
PI US 2003027817 A1 20030206
AI US 2002-165850 A1 20020607 (10)
RLI Continuation of Ser. No. US 2000-700446, filed on 9 Nov 2000, ABANDONED
A 371 of International Ser. No. WO 1999-US11314, filed on 21 May 1999,
UNKNOWN
PRAI US 1998-87126P 19980529 (60)
DT Utility
FS APPLICATION
LREP ELI LILLY AND COMPANY, PATENT DIVISION, P.O. BOX 6288, INDIANAPOLIS, IN,
46206-6288
CLMN Number of Claims: 14
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 887
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides methods and compositions for the treatment of
Bipolar Disorder, Bipolar Depression or Unipolar Depression, all with or
without psychotic features. This method employs a compound having
activity as an atypical antipsychotic and a serotonin reuptake
inhibitor.
IT **146939-27-7**, Ziprasidone
(combination therapy for treatment of bipolar disorders)
RN 146939-27-7 USPATFULL
CN 2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-
chloro-1,3-dihydro- (9CI) (CA INDEX NAME)




L3 ANSWER 14 OF 59 USPATFULL on STN
AN 2003:17935 USPATFULL
TI Method for treating pain
IN Helton, David Reed, Irvine, CA, UNITED STATES
Shannon, Harlan E., Carmel, IN, UNITED STATES
Womer, Daniel E., Thornton, CO, UNITED STATES
Kallman, Mary Jeanne, Greenfield, IN, UNITED STATES
PI US 2003013689 A1 20030116
AI US 2002-224224 A1 20020815 (10)
RLI Division of Ser. No. US 2000-498047, filed on 4 Feb 2000, GRANTED, Pat.
No. US 6444665 Continuation of Ser. No. US 1997-823458, filed on 24 Mar
1997, ABANDONED
PRAI US 1996-14152P 19960325 (60)
DT Utility
FS APPLICATION
LREP ELI LILLY AND COMPANY, PATENT DIVISION, P.O. BOX 6288, INDIANAPOLIS, IN,
46206-6288
CLMN Number of Claims: 26
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 570
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides a method for treating pain using an
atypical antipsychotic compound.
IT **146939-27-7**, Ziprasidone
(treating pain with an atypical antipsychotic compd.)
RN 146939-27-7 USPATFULL
CN 2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-
chloro-1,3-dihydro- (9CI) (CA INDEX NAME)




L3 ANSWER 15 OF 59 USPATFULL on STN
 AN 2003:11193 USPATFULL
 TI Method of controlling weight gain associated with therapeutic drugs
 IN Mendel, Carl M., Short Hills, NJ, UNITED STATES
 Seaton, Timothy B., Far Hills, NJ, UNITED STATES
 Weinstein, Steve P., Hartsdale, NY, UNITED STATES
 PI US 2003008897 A1 20030109
 AI US 2000-527813 A1 20000317 (9)
 DT Utility
 FS APPLICATION
 LREP JOHN D. CONWAY, ABBOTT BIORESEARCH CENTER, 100 RESEARCH DRIVE,
 WORCESTER, MA, 01605-4314
 CLMN Number of Claims: 20
 ECL Exemplary Claim: 1
 DRWN No Drawings
 LN.CNT 382
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB A compound of formula I ##STR1##

or a pharmaceutically acceptable salt thereof in which R.sub.1 and R.sub.2 are independently H or methyl (for example N,N-dimethyl-1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl amine hydrochloride optionally in the form of its monohydrate) is used for treating weight gain associated with treatment with certain drug therapy, including the use of tricyclic antidepressants, lithium, sulphonylureas, beta-adrenergic blockers, certain steroid contraceptives, corticosteroids, insulin, cyproheptadine, sodium valproate, neuroleptics, phenothiazine or piztifin.

IT **146939-27-7**, Ziprasidone
 (method of controlling wt. gain assocd. with therapeutic drugs)
 RN 146939-27-7 USPATFULL
 CN 2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro- (9CI) (CA INDEX NAME)




L3 ANSWER 16 OF 59 USPTAFULL on STN
AN 2002:338071 USPTAFULL
TI Highly purified ethyl EPA and other EPA derivatives for psychiatric and neurological disorders
IN Peet, Malcolm, Sheffield, UNITED KINGDOM
Vaddadi, Krishna S., Melbourne, AUSTRALIA
PA Laxdale Limited (non-U.S. corporation)
PI US 2002193439 A1 20021219
AI US 2002-191430 A1 20020710 (10)
RLI Continuation of Ser. No. US 2001-14603, filed on 14 Dec 2001, PENDING
Division of Ser. No. US 2000-492741, filed on 27 Jan 2000, GRANTED, Pat.
No. US 6384077
PRAI GB 1999-1809 19990127
DT Utility
FS APPLICATION
LREP JACOBSON HOLMAN PLLC, 400 SEVENTH STREET N.W., SUITE 600, WASHINGTON,
DC, 20004
CLMN Number of Claims: 27
ECL Exemplary Claim: 1
DRWN 3 Drawing Page(s)
LN.CNT 1151
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A pharmaceutical preparation comprising EPA in an appropriately
assimilable form where of all the fatty acids present in the preparation
at least 90%, and preferably at least 95%, is in the form of EPA and
where less than 5%, and preferably less than 3%, is in the form of DHA
is provided for the treatment of a psychiatric or central nervous
disorder. The preparation may be administered with conventional drugs to
treat psychiatric or central nervous disorders to improve their efficacy
or reduce their side effects.
IT **146939-27-7**, Ziprasidone
(highly purified eicosapentaenoic acid derivs. for psychiatric and
neurol. disorders)
RN 146939-27-7 USPTAFULL
CN 2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-
chloro-1,3-dihydro- (9CI) (CA INDEX NAME)




10/010,651 (Ziprasidone)

L3 ANSWER 17 OF 59 USPATFULL on STN
 AN 2002:338062 USPATFULL
 TI Methods for treating neuropsychiatric disorders
 IN Tsai, Guochuan, Cambridge, MA, UNITED STATES
 Covle, Joseph, Belmont, MA, UNITED STATES
 PI US 2002193429 A1 20021219
 AI US 2002-196686 A1 20020715 (10)
 RLI Continuation of Ser. No. US 2001-834351, filed on 13 Apr 2001, GRANTED,
 Pat. No. US 6420351 Continuation of Ser. No. US 1999-291296, filed on 14
 Apr 1999, GRANTED, Pat. No. US 6228875
 PRAI US 1998-81645P 19980414 (60)
 DT Utility
 FS APPLICATION
 LREP JANIS K. FRASER, PH.D., J.D., Fish & Richardson P.C., 225 Franklin
 Street, Boston, MA, 02110-2804
 CLMN Number of Claims: 38
 ECL Exemplary Claim: 1
 DRWN No Drawings
 LN.CNT 692
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB The invention provides methods for treating neuropsychiatric disorders
 such as schizophrenia, Alzheimer's Disease, autism, depression, benign
 forgetfulness, childhood learning disorders, close head injury, and
 attention deficit disorder. The methods entail administering to a
 patient diagnosed as having a neuropsychiatric disorder a pharmaceutical
 composition containing (i) a therapeutically effective amount of
 D-alanine (or a modified form thereof), provided that the composition is
 substantially free of D-cycloserine, and/or (ii) D-serine (or a modified
 form thereof), and/or (iii) 105 to 500 mg of D-cycloserine (or a
 modified form thereof), and/or (iv) N-methylglycine (or a modified form
 thereof).
 IT **146939-27-7**, Ziprasidone
 (methods for treating neuropsychiatric disorders)
 RN 146939-27-7 USPATFULL
 CN 2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-
 chloro-1,3-dihydro- (9CI) (CA INDEX NAME)




10/010,651 (Ziprasidone)

L3 ANSWER 18 OF 59 USPATFULL on STN
 AN 2002:323220 USPATFULL
 TI Highly purified EPA and other EPA derivatives for psychiatric and neurological disorders
 IN Peet, Malcolm, Sheffield, UNITED KINGDOM
 Vaddadi, Krishna S., Melbourne, AUSTRALIA
 PA Laxdale Limited (non-U.S. corporation)
 PI US 2002183389 A1 20021205
 AI US 2002-173622 A1 20020619 (10)
 RLI Continuation of Ser. No. US 2001-14603, filed on 14 Dec 2001, PENDING
 Division of Ser. No. US 2000-492741, filed on 27 Jan 2000, GRANTED, Pat. No. US 6384077
 PRAI GB 1999-1809 19990127
 DT Utility
 FS APPLICATION
 LREP JACOBSON HOLMAN PLLC, 400 SEVENTH STREET N.W., SUITE 600, WASHINGTON, DC, 20004
 CLMN Number of Claims: 27
 ECL Exemplary Claim: 1
 DRWN 3 Drawing Page(s)
 LN.CNT 1151
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB A pharmaceutical preparation comprising EPA in an appropriately assimilable form where of all the fatty acids present in the preparation at least 90%, and preferably at least 95%, is in the form of EPA and where less than 5%, and preferably less than 3%, is in the form of DHA is provided for the treatment of a psychiatric or central nervous disorder. The preparation may be administered with conventional drugs to treat psychiatric or central nervous disorders to improve their efficacy or reduce their side effects.
 IT **146939-27-7**, Ziprasidone
 (highly purified eicosapentaenoic acid derivs. for psychiatric and neurol. disorders)
 RN 146939-27-7 USPATFULL
 CN 2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro- (9CI) (CA INDEX NAME)



10/010,651 (Ziprasidone)


L3 ANSWER 19 OF 59 USPTAFULL on STN
 AN 2002:323146 USPTAFULL
 TI Combination of cyamemazine and an atypical neuroleptic
 IN Dib, Michel, Paris, FRANCE
 Leperlier, Cyrille, Fontainebleau, FRANCE
 PI US 2002183312 A1 20021205
 AI US 2002-164771 A1 20020607 (10)
 RLI Continuation of Ser. No. WO 2000-FR3446, filed on 8 Dec 2000, UNKNOWN
 PRAI FR 1999-15632 19991210
 DT Utility
 FS APPLICATION
 LREP ROSS J. OEHLER, AVENTIS PHARMACEUTICALS INC., ROUTE 202-206, MAIL CODE:
 D-303A, BRIDGEWATER, PA, 08807
 CLMN Number of Claims: 21
 ECL Exemplary Claim: 1
 DRWN No Drawings
 LN.CNT 257
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB The present invention relates to the combination of cyamemazine and an
 atypical neuroleptic, or a pharmaceutically acceptable salt thereof, and
 to the use thereof in the treatment of schizophrenia, and in particular
 of acute episodes of schizophrenia.
 IT **146939-27-7**, Ziprasidone
 (combination of cyamemazine and atypical neuroleptic)
 RN 146939-27-7 USPTAFULL
 CN 2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-
 chloro-1,3-dihydro- (9CI) (CA INDEX NAME)




L3 ANSWER 20 OF 59 USPATFULL on STN
AN 2002:280621 USPATFULL
TI New drug combinations
IN Wong, Erik Ho Fong, Portage, MI, UNITED STATES
Gallen, Christopher C., Wynnewood, PA, UNITED STATES
Svensson, Torgny, Lidingo, SWEDEN
PI US 2002156067 A1 20021024
AI US 2001-35100 A1 20011228 (10)
PRAI US 2001-259286P 20010102 (60)
DT Utility
FS APPLICATION
LREP PHARMACIA & UPJOHN, 301 HENRIETTA ST, 0228-32-LAW, KALAMAZOO, MI, 49007
CLMN Number of Claims: 22
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 704
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A composition comprising:

(a) a pharmaceutically effective amount of one or more norepinephrine reuptake inhibitors or a pharmaceutically effective salt thereof; and


(b) a pharmaceutically effective amount of one or more neuroleptic agents or a pharmaceutically effective salt thereof is provided. The composition is useful in treating disorders or diseases of the central nervous system, and particularly useful in treating schizophrenia.
IT **146939-27-7**, Ziprasidone
(pharmaceuticals contg. combination of norepinephrine reuptake inhibitors and neuroleptics)
RN 146939-27-7 USPATFULL
CN 2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro- (9CI) (CA INDEX NAME)



L3 ANSWER 21 OF 59 USPATFULL on STN
AN 2002:228330 USPATFULL
TI Combination treatment for anxiety, depression, obsessive compulsive disorder and psychosis
IN Howard, Harry R., JR., Bristol, CT, UNITED STATES
PA Pfizer Inc. (U.S. corporation)
PI US 2002123490 A1 20020905
AI US 2001-10651 A1 20011206 (10)
PRAI US 2001-272619P 20010301 (60)
DT Utility
FS APPLICATION
LREP PFIZER INC, 150 EAST 42ND STREET, 5TH FLOOR - STOP 49, NEW YORK, NY, 10017-5612
CLMN Number of Claims: 30
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1659
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to a method of treating depression, obsessive compulsive disorder and psychosis in a mammal, including a human, by administering to the mammal an atypical antipsychotic in combination with an antidepressant agent with improvement in efficiency. It also relates to pharmaceutical compositions containing a pharmaceutically acceptable carrier, an atypical antipsychotic, and an SRI.
IT **146939-27-7**, Ziprasidone
(atypical antipsychotic-antidepressant combination for treatment of depression, obsessive compulsive disorder, and psychosis)
RN 146939-27-7 USPATFULL
CN 2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro- (9CI) (CA INDEX NAME)



L3 ANSWER 22 OF 59 USPTAFULL on STN
AN 2002:224609 USPTAFULL
TI Method for treating pain
IN Helton, David R., Greenfield, IN, United States
Shannon, Harlan E., Carmel, IN, United States
Womer, Daniel E., Thornton, CO, United States
Kallman, Mary Jeanne, Greenfield, IN, United States
PA Eli Lilly and Company, Indianapolis, IN, United States (U.S.
corporation)
PI US 6444665 B1 20020903
AI US 2000-498047 20000204 (9)
RLI Continuation of Ser. No. US 1997-823458, filed on 24 Mar 1997, now
abandoned
PRAI US 1996-14152P 19960325 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Jarvis, William R. A.
LREP Lentz, Nelsen L., Palmberg, Arleen
CLMN Number of Claims: 42
ECL Exemplary Claim: 1
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
LN.CNT 642
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides a method for treating pain using an
atypical antipsychotic compound.
IT **146939-27-7**, Ziprasidone
(treating pain with an atypical antipsychotic compd.)
RN 146939-27-7 USPTAFULL
CN 2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-
chloro-1,3-dihydro- (9CI) (CA INDEX NAME)




L3 ANSWER 23 OF 59 USPATFULL on STN
 AN 2002:221820 USPATFULL
 TI Imidazole derivatives
 IN Sanner, Mark A., Old Saybrook, CT, UNITED STATES
 Helal, Chris J., Mystic, NJ, UNITED STATES
 Cooper, Christoper B., Lawrenceville, NJ, UNITED STATES
 Menniti, Frank S., Mystic, CT, UNITED STATES
 Ahlijanian, Michael K., Mystic, CT, UNITED STATES
 Villalobos, Anabella, Niantic, CT, UNITED STATES
 Lau, Lit-Fui, Mystic, CT, UNITED STATES
 Seymour, Patricia A., Westerly, RI, UNITED STATES
 PI US 2002119963 A1 20020829
 AI US 2001-919630 A1 20010731 (9)
 PRAI US 2000-221724P 20000731 (60)
 US 2000-228394P 20000828 (60)
 US 2000-229437P 20000831 (60)
 DT Utility
 FS APPLICATION
 LREP PFIZER INC, 150 EAST 42ND STREET, 5TH FLOOR - STOP 49, NEW YORK, NY,
 10017-5612
 CLMN Number of Claims: 57
 ECL Exemplary Claim: 1
 DRWN No Drawings
 LN.CNT 3078
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB The invention provides compounds of formula 1 ##STR1##

 wherein R.sup.1, R.sup.2, R.sup.3, and R.sup.4 are as defined, and their
 pharmaceutically acceptable salts. Compounds of formula 1 are indicated
 to have activity inhibiting cdk5, cdk2, and GSK-3. Pharmaceutical
 compositions and methods comprising compounds of formula 1 for treating
 and preventing diseases and conditions comprising abnormal cell growth,
 such as cancer, and neurodegenerative diseases and conditions and those
 affected by dopamine neurotransmission. Also described are
 pharmaceutical compositions and methods comprising compounds of formula
 1 for treating male fertility and sperm motility; diabetes mellitus;
 impaired glucose tolerance; metabolic syndrome or syndrome X; polycystic
 ovary syndrome; adipogenesis and obesity; myogenesis and frailty, for
 example age-related decline in physical performance; acute sarcopenia,
 for example muscle atrophy and/or cachexia associated with burns, bed
 rest, limb immobilization, or major thoracic, abdominal, and/or
 orthopedic surgery; sepsis; hair loss, hair thinning, and balding; and
 immunodeficiency.
 IT 146939-27-7, Ziprasidone
 (coadministration; prepn. of acylaminoimidazoles as inhibitors of cdk5,
 cdk2, and GSK-3)
 RN 146939-27-7 USPATFULL
 CN 2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-
 chloro-1,3-dihydro- (9CI) (CA INDEX NAME)


L3 ANSWER 24 OF 59 USPATFULL on STN
 AN 2002:192114 USPATFULL
 TI Pyrazole derivatives
 IN Sanner, Mark A., Old Saybrook, CT, UNITED STATES
 Helal, Chris J., Mystic, CT, UNITED STATES
 Cooper, Christopher B., Lawrenceville, NJ, UNITED STATES
 Wager, Travis T., New London, CT, UNITED STATES
 PI US 2002103185 A1 20020801
 AI US 2001-941001 A1 20010828 (9)
 PRAI US 2000-229415P 20000831 (60)
 US 2000-232032P 20000912 (60)
 DT Utility
 FS APPLICATION
 LREP PFIZER INC, 150 EAST 42ND STREET, 5TH FLOOR - STOP 49, NEW YORK, NY,
 10017-5612
 CLMN Number of Claims: 43
 ECL Exemplary Claim: 1
 DRWN No Drawings
 LN.CNT 4457
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB The invention provides compounds of formula 1 ##STR1##

 wherein R.sup.1, R.sup.2, R.sup.3, and R.sup.4 are as defined, and their
 pharmaceutically acceptable salts. Compounds of formula 1 are indicated
 to have activity inhibiting cdk5, cdk2, and GSK-3. Pharmaceutical
 compositions and methods comprising compounds of formula 1 for treating
 and preventing diseases and conditions comprising abnormal cell growth,
 such as cancer, and neurodegenerative diseases and conditions and those
 affected by dopamine neurotransmission. Also described are
 pharmaceutical compositions and methods comprising compounds of formula
 1 for treating male fertility and sperm motility; diabetes mellitus;
 impaired glucose tolerance; metabolic syndrome or syndrome X; polycystic
 ovary syndrome; adipogenesis and obesity; myogenesis and frailty, for
 example age-related decline in physical performance; acute sarcopenia,
 for example muscle atrophy and/or cachexia associated with burns, bed
 rest, limb immobilization, or major thoracic, abdominal, and/or
 orthopedic surgery; sepsis; hair loss, hair thinning, and balding; and
 immunodeficiency.
 IT **146939-27-7**, Ziprasidone
 (coadministration; prepn. of pyrazole derivs. and use as protein kinase
 inhibitors)
 RN 146939-27-7 USPATFULL
 CN 2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-
 chloro-1,3-dihydro- (9CI) (CA INDEX NAME)




L3 ANSWER 25 OF 59 USPTAFULL on STN
 AN 2002:165235 USPTAFULL
 TI Use of growth hormone secretagogues for stimulating or increasing appetite
 IN Friedman, Hylar L., Marlboro, VT, UNITED STATES
 Gardner, Mark J., Wakefield, RI, UNITED STATES
 Landshulz, William H., East Lyme, CT, UNITED STATES
 Pan, Lydia C., Mystic, CT, UNITED STATES
 PI US 2002086865 A1 20020704
 AI US 2001-893014 A1 20010627 (9)
 PRAI US 2000-214979P 20000629 (60)
 DT Utility
 FS APPLICATION
 LREP Gregg C. Benson, Pfizer Inc., Patent Department, Eastern Point Road, MS 4159, Groton, CT, 06340
 CLMN Number of Claims: 41
 ECL Exemplary Claim: 1
 DRWN No Drawings
 LN.CNT 2690
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB This invention is directed to methods for increasing or stimulating appetite in a patient which comprises administering certain growth hormone secretagogues, prodrugs thereof or pharmaceutically acceptable salts of said secretagogues or said prodrugs. More preferably, the present invention provides such methods wherein the growth hormone secretagogue is a compound of Formula I: ##STR1##

 a prodrug thereof or a pharmaceutically acceptable salt of said secretagogue or said prodrug.
 IT 146939-27-7, Ziprasidone
 (use of growth hormone secretagogues for stimulating or increasing appetite in combination with an antipsychotic)
 RN 146939-27-7 USPTAFULL
 CN 2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro- (9CI) (CA INDEX NAME)




10/010,651 (Ziprasidone)

L3 ANSWER 26 OF 59 USPTAFULL on STN
 AN 2002:149205 USPTAFULL
 TI Highly purified ethyl EPA and other EPA derivatives for psychiatric and neurological disorders
 IN Peet, Malcolm, Sheffield, UNITED KINGDOM
 Vaddadi, Krishna S., Melbourne, AUSTRALIA
 PA Laxdale Limited (non-U.S. corporation)
 PI US 2002077361 A1 20020620
 AI US 2001-14603 A1 20011214 (10)
 RLI Division of Ser. No. US 2000-492741, filed on 27 Jan 2000, PENDING
 PRAI GB 1999-1809 19990127
 DT Utility
 FS APPLICATION
 LREP JACOBSON HOLMAN PLLC, 400 SEVENTH STREET N.W., SUITE 600, WASHINGTON, DC, 20004
 CLMN Number of Claims: 27
 ECL Exemplary Claim: 1
 DRWN 3 Drawing Page(s)
 LN.CNT 1149
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB A pharmaceutical preparation comprising EPA in an appropriately assimilable form where of all the fatty acids present in the preparation at least 90%, and preferably at least 95%, is in the form of EPA and where less than 5%, and preferably less than 3%, is in the form of DHA is provided for the treatment of a psychiatric or central nervous disorder. The preparation may be administered with conventional drugs to treat psychiatric or central nervous disorders to improve their efficacy or reduce their side effects.
 IT **146939-27-7**, Ziprasidone
 (highly purified eicosapentaenoic acid derivs. for psychiatric and neurol. disorders)
 RN 146939-27-7 USPTAFULL
 CN 2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro- (9CI) (CA INDEX NAME)




L3 ANSWER 27 OF 59 USPTAFULL on STN
 AN 2002:122628 USPTAFULL
 TI Method of treating Bulimia Nervosa and related eating disorders by
 administration of atypical antipsychotic medications
 IN Guadagno, Gina, Cincinnati, OH, United States
 Star, Jodi M., Cincinnati, OH, United States
 PA The Cincinnati Children's Hospital Research Foundation, Cincinnati, OH,
 United States (U.S. corporation)
 PI US 6395727 B1 20020528
 AI US 2000-531129 20000317 (9)
 PRAI US 1999-124952P 19990318 (60)
 DT Utility
 FS GRANTED
 EXNAM Primary Examiner: Criares, Theodore J.
 LREP White, Loy M., Goldstein, Steven J.
 CLMN Number of Claims: 20
 ECL Exemplary Claim: 1
 DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
 LN.CNT 560
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB The invention relates to a method of treating non-psychotic disorders by
 administration of atypical antipsychotic medications, in particular,
 risperidone. More specifically, the invention relates to a method of
 treating the eating disorder Bulimia Nervosa and Bulimia-related eating
 disorders, by administration of antipsychotic medications from the group
 of compounds designated as atypical antipsychotic medications. Typical
 dosage amounts may range from 0.1 milligrams to 4 milligrams per day and
 may be administered in any dosage forms known in the art, including, but
 not limited to oral, intramuscular, rectal, transdermal, sustained
 release forms, controlled release forms, delayed release forms, and
 response release forms.
 IT **146939-27-7**, Ziprasidone
 (method of treating bulimia nervosa and related eating disorders by
 administration of atypical antipsychotic medications)
 RN 146939-27-7 USPTAFULL
 CN 2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-
 chloro-1,3-dihydro- (9CI) (CA INDEX NAME)



10/010,651 (Ziprasidone)

L3 ANSWER 28 OF 59 USPATFULL on STN
AN 2002:102526 USPATFULL
TI Highly purified EPA for treatment of schizophrenia and related disorders
IN Peet, Malcolm, Sheffield, UNITED KINGDOM
Vaddadi, Krishna S, Melbourne, AUSTRALIA
PA Laxdale Limited, Stirling, UNITED KINGDOM (non-U.S. corporation)
PI US 6384077 B1 20020507
AI US 2000-492741 20000127 (9)
PRAI GB 1999-1809 19990127
DT Utility
FS GRANTED
EXNAM Primary Examiner: Jarvis, William R. A.
LREP Jacobson Holman, PLLC
CLMN Number of Claims: 21
ECL Exemplary Claim: 1
DRWN 3 Drawing Figure(s); 3 Drawing Page(s)
LN.CNT 1157
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A pharmaceutical preparation comprising EPA in an appropriately assimilable form where of all the fatty acids present in the preparation at least 90%, and preferably at least 95%, is in the form of EPA and where less than 5%, and preferably less than 3%, is in the form of DHA is provided for the treatment of a psychiatric or central nervous disorder. The preparation may be administered with conventional drugs to treat psychiatric or central nervous disorders to improve their efficacy or reduce their side effects.
IT **146939-27-7**, Ziprasidone
(highly purified eicosapentaenoic acid derivs. for psychiatric and neurol. disorders)
RN 146939-27-7 USPATFULL
CN 2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro- (9CI) (CA INDEX NAME)



L3 ANSWER 29 OF 59 USPATFULL on STN
AN 2002:98912 USPATFULL
TI Osmotic device containing alprazolam and an antipsychotic agent
IN Faour, Joaquina, Buenos Aires, ARGENTINA
Vergez, Juan A., Buenos Aires, ARGENTINA
PI US 2002051807 A1 20020502
US 6599532 B2 20030729
AI US 2001-756497 A1 20010108 (9)
PRAI US 2000-175827P 20000113 (60)
DT Utility
FS APPLICATION
LREP INNOVAR, LLC, P O BOX 250647, PLANO, TX, 75025
CLMN Number of Claims: 18
ECL Exemplary Claim: 1
DRWN 3 Drawing Page(s)
LN.CNT 1199

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


AB The present invention provides an osmotic device containing controlled release alprazolam in the core optionally in combination with an anti-psychotic agent, in a rapid release external coat. A wide range of anti-psychotic agents can be used in this device. Particular embodiments of the invention provide osmotic devices having predetermined release profiles. One preferred embodiment of the osmotic device includes an external coat that has been spray coated rather compression coated onto the device. The device with spray coated external core is smaller and easier to swallow than the similar device having a compression coated external coat. The device is useful for the treatment of depression, anxiety or psychosis related disorders.

IT 146939-27-7, Ziprasidone

(osmotic device contg. alprazolam and antipsychotic agent)

RN 146939-27-7 USPATFULL


CN 2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro- (9CI) (CA INDEX NAME)



L3 ANSWER 30 OF 59 USPATFULL on STN
 AN 2002:88532 USPATFULL
 TI Treatment of gallstones
 IN Mendel, Carl M., Short Hills, NJ, United States
 Seaton, Timothy B., Far Hills, NJ, United States
 Weinstein, Steve P., Hartsdale, NY, United States
 PA Knoll Pharmaceutical Company, Mount Olive, NJ, United States (U.S. corporation)
 PI US 6376552 B1 20020423
 AI US 2000-527962 20000317 (9)
 PRAI US 1999-125340P 19990319 (60)
 DT Utility
 FS GRANTED
 EXNAM Primary Examiner: Cook, Rebecca
 LREP Conway, John D.
 CLMN Number of Claims: 13
 ECL Exemplary Claim: 1
 DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
 LN.CNT 316
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB A compound of formula I ##STR1##

or a pharmaceutically acceptable salt thereof in which R.sub.1 and R.sub.2 are independently H or methyl (for example N,N-dimethyl-1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl amine hydrochloride optionally in the form of its monohydrate) is used for treating gallstones, particularly gallstones associated with weight loss or associated with gall bladder disease related to obesity.

IT **146939-27-7**, Ziprasidone
 (sibutramine and N-demethyl derivs. for controlling wt. gain assocd. with drug therapy)
 RN 146939-27-7 USPATFULL
 CN 2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro- (9CI) (CA INDEX NAME)



10/010,651 (Ziprasidone)

L3 ANSWER 31 OF 59 USPATFULL on STN
 AN 2002:61309 USPATFULL
 TI Methods for treating neuropsychiatric disorders'
 IN Tsai, Guochuan, Cambridge, MA, UNITED STATES
 Coyle, Joseph, Belmont, MA, UNITED STATES
 PA The General Hospital Corporation (U.S. corporation)
 PI US 2002035145 A1 20020321
 US 6420351 B2 20020716
 AI US 2001-834351 A1 20010413 (9)
 RLI Continuation of Ser. No. US 1999-291296, filed on 14 Apr 1999, GRANTED,
 Pat. No. US 6228875
 PRAI US 1998-81645P 19980414 (60)
 DT Utility
 FS APPLICATION
 LREP JANIS K. FRASER, PH.D., J.D., Fish & Richardson P.C., 225 Franklin
 Street, Boston, MA, 02110-2804
 CLMN Number of Claims: 38
 ECL Exemplary Claim: 1
 DRWN No Drawings
 LN.CNT 691

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


AB The invention provides methods for treating neuropsychiatric disorders
 such as schizophrenia, Alzheimer's Disease, autism, depression, benign
 forgetfulness, childhood learning disorders, close head injury, and
 attention deficit disorder. The methods entail administering to a
 patient diagnosed as having a neuropsychiatric disorder a pharmaceutical
 composition containing (i) a therapeutically effective amount of
 D-alanine (or a modified form thereof), provided that the composition is
 substantially free of D-cycloserine, and/or (ii) D-serine (or a modified
 form thereof), and/or (iii) 105 to 500 mg of D-cycloserine (or a
 modified form thereof), and/or (iv) N-methylglycine (or a modified form
 thereof).

IT **146939-27-7**, Ziprasidone

(methods for treating neuropsychiatric disorders)


RN 146939-27-7 USPATFULL

CN 2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-
 chloro-1,3-dihydro- (9CI) (CA INDEX NAME)




10/010,651 (Ziprasidone)

L3 ANSWER 32 OF 59 USPATFULL on STN
AN 2002:27650 USPATFULL
TI Reactive crystallization method to improve particle size
IN Am Ende, David J., Waterford, CT, UNITED STATES
Crawford, Thomas C., Essex, CT, UNITED STATES
Weston, Neil P., Groton, CT, UNITED STATES
PI US 2002016498 A1 20020207
US 6558435 B2 20030506
AI US 2001-863492 A1 20010523 (9)
PRAI US 2000-207629P 20000526 (60)
DT Utility
FS APPLICATION
LREP Paul H. Ginsburg, Pfizer Inc, 20th Floor, 235 East 42nd Street, New York, NY, 10017-5755
CLMN Number of Claims: 19
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 523
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention provides a method of conducting a simultaneous chemical reaction and controlled crystallization of the product employing impinging fluid jet streams containing reactants capable of producing the product with desired particle size characteristics.
IT **146939-27-7**, Ziprasidone
(reactive crystn. method to improve particle size)
RN 146939-27-7 USPATFULL
CN 2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro- (9CI) (CA INDEX NAME)




L3 ANSWER 33 OF 59 USPATFULL on STN
 AN 2002:26886 USPATFULL
 TI Hydrogel-Driven Drug Dosage Form
 IN Appel, Leah E., Bend, OR, UNITED STATES
 Beyerinck, Ronald A., Bend, OR, UNITED STATES
 Chidlaw, Mark B., Bend, OR, UNITED STATES
 Curatolo, William J., Niantic, CT, UNITED STATES
 Friesen, Dwayne T., Bend, OR, UNITED STATES
 Smith, Kelly L., Bend, OR, UNITED STATES
 Thombre, Avinash G., East Lyme, CT, UNITED STATES
 PI US 2002015731 A1 20020207
 AI US 2000-745095 A1 20001220 (9)
 PRAI US 1999-171968P 19991223 (60)
 DT Utility
 FS APPLICATION
 LREP Gregg C. Benson, Pfizer Inc. MS 4159, Eastern Point Road, Groton, CT, 06340
 CLMN Number of Claims: 131
 ECL Exemplary Claim: 1
 DRWN 1 Drawing Page(s)
 LN.CNT 3074
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB A controlled release dosage form has a coated core with the core comprising a drug-containing composition and a water-swellaable composition, each occupying separate regions within the core. The drug-containing composition comprises a low-solubility drug and a drug-entraining agent. The coating around the core is water-permeable, water-insoluble and has at least one delivery port therethrough. A variety of formulations having specific drug release profiles are disclosed.
 IT **146939-27-7**
 (hydrogel-driven drug dosage forms comprising water-swellaable compns.)
 RN 146939-27-7 USPATFULL
 CN 2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro- (9CI) (CA INDEX NAME)




10/010,651 (Ziprasidone)


L3 ANSWER 34 OF 59 USPATFULL on STN
 AN 2002:16618 USPATFULL
 TI Solid pharmaceutical dispersions with enhanced bioavailability
 IN Curatolo, William J., Niantic, CT, UNITED STATES
 Herbig, Scott M., East Lyme, CT, UNITED STATES
 Nightingale, James A.S., Bend, OR, UNITED STATES
 PI US 2002009494 A1 20020124
 AI US 2001-770562 A1 20010126 (9)
 RLI Continuation of Ser. No. US 1998-131019, filed on 7 Aug 1998, ABANDONED
 PRAI US 1997-55221P 19970811 (60)
 DT Utility
 FS APPLICATION
 LREP Gregg C. Benson, Pfizer Inc., Patent Department, MS 4159, Eastern Point
 Road, Groton, CT, 06340
 CLMN Number of Claims: 38
 ECL Exemplary Claim: 1
 DRWN 1 Drawing Page(s)
 LN.CNT 1549
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB Spray dried solid dispersions comprising a sparingly soluble drug and
 hydroxypropylmethylcellulose acetate succinate (HPMCAS) provide
 increased aqueous solubility and/or bioavailability in a use environment.
 IT **146939-27-7**, Ziprasidone
 (solid pharmaceutical dispersions with enhanced bioavailability)
 RN 146939-27-7 USPATFULL
 CN 2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-
 chloro-1,3-dihydro- (9CI) (CA INDEX NAME)



L3 ANSWER 35 OF 59 USPATFULL on STN
AN 2001:223726 USPATFULL
TI Osmotic device containing venlafaxine and an anti-psychotic agent
IN Faour, Joaquina, Buenos Aires, Argentina
Vergez, Juan, Buenos Aires, Argentina
PI US 2001048943 A1 20011206
US 6572890 B2 20030603
AI US 2000-728276 A1 20001130 (9)
PRAI US 2000-175822P 20000113 (60)
DT Utility
FS APPLICATION
LREP INNOVAR, LLC, P O BOX 250647, PLANO, TX, 75025
CLMN Number of Claims: 21
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 1253
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides an osmotic device containing controlled release venlafaxine in the core in combination with an anti-psychotic agent in a rapid release external coat. A wide range of anti-psychotic agents can be used in this device. Particular embodiments of the invention provide osmotic devices having predetermined release profiles. One embodiment of the osmotic device includes an external coat that has been spray-coated rather compression-coated onto the device. The device with spray-coated external core is smaller and easier to swallow than the similar device having a compression-coated external coat. The device is useful for the treatment of depression, anxiety or psychosis related disorders.
IT **146939-27-7**, Ziprasidone
(osmotic device contg. venlafaxine and anti-psychotic agent)
RN 146939-27-7 USPATFULL
CN 2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro- (9CI) (CA INDEX NAME)




L3 ANSWER 36 OF 59 USPTAFULL on STN
 AN 2001:182596 USPTAFULL
 TI Inclusion complexes of aryl-heterocyclic salts
 IN Kim, Yesook, Branford, CT, United States
 Johnson, Kevin C., Niantic, CT, United States
 Shanker, Ravi M., Groton, CT, United States
 PI US 2001031756 A1 20011018
 US 6399777 B2 20020604
 AI US 2001-850658 A1 20010507 (9)
 RLI Division of Ser. No. US 1998-147239, filed on 5 Nov 1998, GRANTED, Pat.
 No. US 6232304 A 371 of International Ser. No. WO 1997-IB321, filed on 1
 Apr 1997, UNKNOWN
 PRAI US 1996-19204P 19960507 (60)
 DT Utility
 FS APPLICATION
 LREP Gregg C. Benson, Pfizer Inc., Patent Department, MS 4159, Eastern Point
 Road, Groton, CT, 06340
 CLMN Number of Claims: 40
 ECL Exemplary Claim: 1
 DRWN 1 Drawing Page(s)
 LN.CNT 726
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB Compositions of matter comprising a pharmaceutically acceptable salt of
 an arylheterocyclic compound, such as ziprasidone, in a cyclodextrin.
 Preferred cyclodextrins are SBECd and HPBCD. The composition can
 comprise a dry mixture, a dry inclusion complex or an aqueous solution.
 The salt/cyclodextrin inclusion complex preferably provides an amount of
 ziprasidone of at least 2.5 mgA/ml when the complex is dissolved in
 water at 40% w/v. A variety of ziprasidone salts are preferred,
 including the mesylate, esylate, besylate, tartrate, napsylate, and
 tosylate.
 IT **146939-27-7D**, Ziprasidone, complexes with cyclodextrin derivs.
 (inclusion complexes of aryl heterocyclic salts)
 RN 146939-27-7 USPTAFULL
 CN 2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-
 chloro-1,3-dihydro- (9CI) (CA INDEX NAME)




10/010,651 (Ziprasidone)

L3 ANSWER 37 OF 59 USPATFULL on STN
AN 2001:109980 USPATFULL
TI METHOD OF SELECTING A SALT FOR MAKING AN INCLUSION COMPLEX
IN KIM, YESOOK, BRANFORD, CT, United States
PI US 2001007862 A1 20010712
AI US 1997-850353 A1 19970502 (8)
PRAI US 1996-16866P 19960507 (60)
DT Utility
FS APPLICATION
LREP GREGG C BENSON, PFIZER INC, PATENT DEPARTMENT, EASTERN POINT ROAD,
GROTON, CT, 06340
CLMN Number of Claims: 15
ECL Exemplary Claim: 1
DRWN 1 Drawing Page(s)
LN.CNT 640
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method of locating one or more salts of a compound, said salts having
a solubility in a cyclodextrin equal to or greater than a desired target
solubility, comprising obtaining a series of salts of said compound,
measuring the equilibrium solubility of each salt in said series in said
cyclodextrin, and comparing each measured solubility with said target
solubility.
IT **146939-27-7**, Ziprasidone
(prepn. of cyclodextrin inclusion complexes with drug salts)
RN 146939-27-7 USPATFULL
CN 2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-
chloro-1,3-dihydro- (9CI) (CA INDEX NAME)



L3 ANSWER 38 OF 59 USPTAFULL on STN
 AN 2001:86466 USPTAFULL
 TI Mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2(1H)-indol-2-one (=ziprasidone), its preparation and its use as dopamine D2 antagonist
 IN Busch, Frank R., Gales Ferry, CT, United States
 Rose, Carol A., Ledyard, CT, United States
 Shine, Russell J., Waterford, CT, United States
 PA Pfizer Inc, New York, NY, United States (U.S. corporation)
 PI US 6245765 B1 20010612
 WO 9742191 19971113
 AI US 1999-180455 19990830 (9)
 WO 1997-IB393 19970410
 19990830 PCT 371 date
 19990830 PCT 102(e) date
 PRAI US 1996-16757P 19960507 (60)
 DT Utility
 FS GRANTED
 EXNAM Primary Examiner: Shah, Mukund J.; Assistant Examiner: Patel, Sudhaker B.
 LREP Richardson, Peter C., Ginsburg, Paul H., Konstas, Kristina L.
 CLMN Number of Claims: 9
 ECL Exemplary Claim: 1
 DRWN 6 Drawing Figure(s); 6 Drawing Page(s)
 LN.CNT 455
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB The invention is directed to the mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one, pharmaceutical compositions containing said ziprasidone mesylate dihydrates, and methods of administering the ziprasidone mesylate dihydrates to treat psychotic diseases.
 IT **146939-27-7P**
 (prepn. of mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-2(1H)-indol-2-one for treatment of psychotic disorders)
 RN 146939-27-7 USPTAFULL
 CN 2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro- (9CI) (CA INDEX NAME)



L3 ANSWER 39 OF 59 USPATFULL on STN
 AN 2001:71539 USPATFULL
 TI Inclusion complexes of aryl-heterocyclic salts
 IN Kim, Yesook, Branford, CT, United States
 Johnson, Kevin C., Niantic, CT, United States
 Shanker, Ravi M., Groton, CT, United States
 PA Pfizer Inc., New York, NY, United States (U.S. corporation)
 PI US 6232304 B1 20010515
 WO 9741896 19971113
 AI US 1998-147239 19981105 (9)
 WO 1997-IB321 19970401
 19981105 PCT 371 date
 19981105 PCT 102(e) date
 PRAI US 1996-19204P 19960507 (60)
 DT Utility
 FS Granted
 EXNAM Primary Examiner: Gerstl, Robert
 LREP Richardson, Peter C., Benson, Gregg C., Jones, James T.
 CLMN Number of Claims: 36
 ECL Exemplary Claim: 1
 DRWN 1 Drawing Figure(s); 1 Drawing Page(s)
 LN.CNT 719


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions of matter comprising a pharmaceutically acceptable salt of an aryl-heterocyclic compound, such as ziprasidone, in a cyclodextrin. Preferred cyclodextrins are SBECd and HPBCD. The composition can comprise a dry mixture, a dry inclusion complex or an aqueous solution. The salt/cyclodextrin inclusion complex preferably provides an amount of ziprasidone of at least 2.5 mgA/ml when the complex is dissolved in water at 40% w/v. A variety of ziprasidone salts are preferred, including the mesylate, esylate, besylate, tartrate, napsylate, and tosylate.

IT **146939-27-7D**, Ziprasidone, complexes with cyclodextrin derivs.
 (inclusion complexes of aryl heterocyclic salts)

RN 146939-27-7 USPATFULL

CN 2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro- (9CI) (CA INDEX NAME)



L3 ANSWER 40 OF 59 USPATFULL on STN
AN 2001:67686 USPATFULL
TI Methods for treating neuropsychiatric disorders
IN Tsai, Guochuan, Cambridge, MA, United States
Coyle, Joseph, Belmont, MA, United States
PA The General Hospital Corporation, Boston, MA, United States (U.S. corporation)
PI US 6228875 B1 20010508
AI US 1999-291296 19990414 (9)
PRAI US 1998-81645P 19980414 (60)
DT Utility
FS Granted
EXNAM Primary Examiner: Henley, III, Raymond
LREP Fish & Richardson P.C.
CLMN Number of Claims: 56
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 864

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


AB The invention provides methods for treating neuropsychiatric disorders such as schizophrenia, Alzheimer's Disease, autism, depression, benign forgetfulness, childhood learning disorders, close head injury, and attention deficit disorder. The methods entail administering to a patient diagnosed as having a neuropsychiatric disorder a pharmaceutical composition containing (i) a therapeutically effective amount of D-alanine (or a modified form thereof), provided that the composition is substantially free of D-cycloserine, and/or (ii) D-serine (or a modified form thereof), and/or (iii) 105 to 500 mg of D-cycloserine (or a modified form thereof), and/or (iv) N-methylglycine (or a modified form thereof).

IT 146939-27-7, Ziprasidone

(methods for treating neuropsychiatric disorders)


RN 146939-27-7 USPATFULL

CN 2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro- (9CI) (CA INDEX NAME)




10/010,651 (Ziprasidone)

L3 ANSWER 41 OF 59 USPATFULL on STN
 AN 2001:8053 USPATFULL
 TI Antipsychotic use of triazolo-pyridazine derivatives
 IN Pineiro, Jose Luis Castro, Bishops Stortford, United Kingdom
 McKernan, Ruth, Saffron Walden, United Kingdom
 Whiting, Paul John, Stansted, United Kingdom
 PA Merck Sharp & Dohme Ltd., Hoddesdon, United Kingdom (non-U.S. corporation)
 PI US 6174886 B1 20010116
 AI US 1998-191304 19981112 (9)
 PRAI GB 1997-23999 19971113
 DT Utility
 FS Granted
 EXNAM Primary Examiner: Wilson, James O.; Assistant Examiner: Owens, Howard
 LREP Lee, Shu M., Rose, David L.
 CLMN Number of Claims: 9
 ECL Exemplary Claim: 1
 DRWN No Drawings
 LN.CNT 1616
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB A class of substituted or 7,8-ring fused 1,2,4-triazolo[4,3-b]pyridazine derivatives, possessing an optionally substituted cycloalkyl, phenyl or heteroaryl substituent at the 3-position and a substituted alkoxy moiety at the 6-position, are selective ligands for GABA.sub.A receptors, in particular having high affinity for the .alpha.2 and/or .alpha.3 subunit thereof, and are accordingly of benefit in the treatment and/or prevention of psychotic disorders including schizophrenia.
 IT **146939-27-7**, Ziprasidone
 (triazolo-pyridazine deriv. GABAA ligands and therapeutic use, alone or with other compds.)
 RN 146939-27-7 USPATFULL
 CN 2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro- (9CI) (CA INDEX NAME)



L3 ANSWER 42 OF 59 USPATFULL on STN
 AN 2000:174635 USPATFULL
 TI Treatment of schizophrenia with ampakines and neuroleptics
 IN Johnson, Steven A., Costa Mesa, CA, United States
 Lynch, Gary S., Irvine, CA, United States
 Rogers, Gary A., Santa Barbara, CA, United States
 PA Cortex Pharmaceuticals, Inc., Irvine, CA, United States (U.S. corporation)
 The Regents of the University of California, Oakland, CA, United States (U.S. corporation)
 PI US 6166008 20001226
 AI US 1998-179341 19981026 (9)
 PRAI US 1997-63627P 19971027 (60)
 DT Utility
 FS Granted
 EXNAM Primary Examiner: Jones, Dwayne C.
 LREP Townsend and Townsend and Crew LLP
 CLMN Number of Claims: 26
 ECL Exemplary Claim: 1
 DRWN 4 Drawing Figure(s); 4 Drawing Page(s)
 LN.CNT 1447
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB This invention relates to treatment of schizophrenia and related psychotic disorders, including enhancement of receptor functioning in synapses in brain networks responsible for higher order behaviors. In a particular aspect, the invention relates to methods for the use of AMPA receptor up-modulators in conjunction with antipsychotics for the treatment of schizophrenia. Kits containing the compositions in appropriate form for administration are also provided.
 IT **146939-27-7**, Ziprasidone
 (AMPAkines and antipsychotic agents for treatment of schizophrenia)
 RN 146939-27-7 USPATFULL
 CN 2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro- (9CI) (CA INDEX NAME)



L3 ANSWER 43 OF 59 USPTAFULL on STN
 AN 2000:157417 USPTAFULL
 TI Ziprasidone formulations
 IN Arenson, Daniel R., East Lyme, CT, United States
 Busch, Frank Robert, Gales Ferry, CT, United States
 Hausberger, Angela G., East Lyme, CT, United States
 Rasadi, Bijan, Groton, CT, United States
 PA Pfizer Inc., New York, NY, United States (U.S. corporation)
 PI US 6150366 20001121
 AI US 1999-320985 19990527 (9)
 PRAI US 1998-89229P 19980615 (60)
 DT Utility
 FS Granted
 EXNAM Primary Examiner: Rose, Shep K.
 LREP Richardson, Peter C., Benson, Gregg C., Jones, James T.
 CLMN Number of Claims: 34
 ECL Exemplary Claim: 1
 DRWN No Drawings
 LN.CNT 715


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions comprising crystalline ziprasidone free base or crystalline ziprasidone hydrochloride particles having a mean particle size less than 85 .mu.m, and a pharmaceutically acceptable carrier, are substantially bioequivalent and can be used to treat psychoses such as schizophrenia.


IT **146939-27-7**, Ziprasidone
 (ziprasidone formulations with improved dissoln. rate)

RN 146939-27-7 USPTAFULL


CN 2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro- (9CI) (CA INDEX NAME)




L3 ANSWER 44 OF 59 USPTAFULL on STN
 AN 2000:157404 USPTAFULL
 TI Therapeutic combinations of mirtazapine and antipsychotic agents, for the treatment or prophylaxis of psychotic disorders
 IN Broekkamp, Christophorus Louis Eduard, Oss, Netherlands
 Berendsen, Hermanus Henricus Gerardus, Geffen, Netherlands
 Pinder, Roger Martin, Oss, Netherlands
 PA Akzo Nobel N.V., Arnhem, Netherlands (non-U.S. corporation)
 PI US 6150353 20001121
 WO 9843646 19981008
 AI US 1999-380723 19990907 (9)
 WO 1998-EP1920 19980325
 19990907 PCT 371 date
 19990907 PCT 102(e) date
 PRAI EP 1997-200881 19970327
 DT Utility
 FS Granted
 EXNAM Primary Examiner: Jarvis, William R. A.
 LREP Gormley, Mary E.
 CLMN Number of Claims: 10
 ECL Exemplary Claim: 1
 DRWN 2 Drawing Figure(s); 2 Drawing Page(s)
 LN.CNT 327
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB This application relates to a combination of the antidepressant mirtazapine and an antipsychotic agent such as haloperidol for the treatment of psychotic disorders.
 IT **146939-27-7**, Ziprasidone
 (mirtazapine-antipsychotic agent combinations for treatment or prophylaxis of psychotic disorders)
 RN 146939-27-7 USPTAFULL
 CN 2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro- (9CI) (CA INDEX NAME)



L3 ANSWER 45 OF 59 USPTAFULL on STN
 AN 2000:153705 USPTAFULL
 TI Combination therapy for treatment of psychoses
 IN Bymaster, Franklin P., Brownsburg, IN, United States
 Perry, Kenneth W., Indianapolis, IN, United States
 Tollefson, Gary D., Indianapolis, IN, United States
 PA Eli Lilly and Company, Indianapolis, IN, United States (U.S. corporation)
 PI US 6147072 20001114
 AI US 1997-935872 19970923 (8)
 PRAI US 1996-26884P 19960923 (60)
 DT Utility
 FS Granted
 EXNAM Primary Examiner: Jarvis, William R. A.
 LREP Titus, Robert D.
 CLMN Number of Claims: 22
 ECL Exemplary Claim: 1
 DRWN No Drawings
 LN.CNT 836
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB The invention relates to a method of treating psychosis, acute mania, mild anxiety states or depression in combination with psychotic episodes by administering to a patient a combination of an atypical antipsychotic and a serotonin reuptake inhibitor.
 IT **146939-27-7**, Ziprasidone
 (pharmaceutical compn. contg. combination of atypical antipsychotic and serotonin reuptake inhibitor for treatment of psychoses)
 RN 146939-27-7 USPTAFULL
 CN 2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro- (9CI) (CA INDEX NAME)




L3 ANSWER 46 OF 59 USPATFULL on STN
AN 2000:153281 USPATFULL
TI Kokori fruit-based cosmetic system
IN Yusuf, Fatimat, 2421 Foothill Blvd. #21H, La Verne, CA, United States
91750
PI US 6146646 20001114
AI US 1998-86444 19980528 (9)
DT Utility
FS Granted
EXNAM Primary Examiner: Page, Thurman K.; Assistant Examiner: Howard, S.
CLMN Number of Claims: 5
ECL Exemplary Claim: 1
DRWN 1 Drawing Figure(s); 1 Drawing Page(s)
LN.CNT 205
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method is provided for generating a cosmetic product for improving the cosmetic appearance of a person. The method comprises the steps of collecting Kokori fruit; removing an outer peel from the Kokori fruit; crushing the Kokori fruit into a pulp; and extracting Kokori liquid from the pulp of the Kokori fruit for the purpose of applying the same about eyes of a user.
IT **146939-27-7, Ziprasidone**
(atypical antipsychotic agent-serotonin reuptake inhibitor combinations for therapy of refractory depression)
RN 146939-27-7 USPATFULL
CN 2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro- (9CI) (CA INDEX NAME)




L3 ANSWER 47 OF 59 USPATFULL on STN
 AN 2000:113945 USPATFULL
 TI Mesylate trihydrate salt of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-2(1H)-indol-2-one (=ziprasidone), its preparation and its use as dopamine D2 antagonist
 IN Busch, Frank R., Gales Ferry, CT, United States
 Rose, Carol A., Ledyard, CT, United States
 PA Pfizer Inc, New York, NY, United States (U.S. corporation)
 PI US 6110918 20000829
 WO 9742190 19971113
 AI US 1999-180456 19990302 (9)
 WO 1997-IB306 19970326
 19990302 PCT 371 date
 19990302 PCT 102(e) date
 PRAI US 1996-16537P 19960507 (60)
 DT Utility
 FS Granted
 EXNAM Primary Examiner: Jones, Dwayne C.
 LREP Richardson, Peter C., Ginsburg, Paul H., Konstas, Kristina L.
 CLMN Number of Claims: 7
 ECL Exemplary Claim: 1
 DRWN 3 Drawing Figure(s); 3 Drawing Page(s)
 LN.CNT 387
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB Mesylate Trihydrate Salt of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-2(1H)-indol-2-one (=Ziprasidone), Its Preparation and Its Use as Dopamine D2 Antagonist


 The invention relates to the mesylate trihydrate salt of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-2(1H)-indol-2-one ("ziprasidone mesylate trihydrate"), to pharmaceutical compositions containing ziprasidone mesylate trihydrate, and to methods of administering ziprasidone mesylate trihydrate to treat psychotic diseases.
 IT **146939-27-7P**
 (prepn. of mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-2(1H)-indol-2-one for treatment of psychotic disorders)
 RN 146939-27-7 USPATFULL
 CN 2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro- (9CI) (CA INDEX NAME)




L3 ANSWER 48 OF 59 USPATFULL on STN
 AN 2000:113942 USPATFULL
 TI Antiemetic use of triazolo-pyridazine derivatives
 IN Castro Pineiro, Jose Luis, Bishops Stortford, United Kingdom
 Tattersall, Frederick David, Bishops Stortford, United Kingdom
 PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
 PI US 6110915 20000829
 AI US 1998-208288 19981208 (9)
 PRAI GB 1997-26700 19971218
 GB 1998-1581 19980123
 DT Utility
 FS Granted
 EXNAM Primary Examiner: Shah, Mukund J.; Assistant Examiner: Liu, Hong
 LREP Lee, Shu M., Rose, David L.
 CLMN Number of Claims: 6
 ECL Exemplary Claim: 1
 DRWN No Drawings
 LN.CNT 1659
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB A class of substituted 7,8-ring fused 1,2,4-triazolo[4,3-b]pyridazine derivatives, as shown in Formula I, possessing an optionally substituted cycloalkyl, phenyl or heteroaryl substituent at the 3-position and a substituted alkoxy moiety at the 6-position, are selective ligands for GABA.sub.A receptors, in particular having high affinity for the .alpha.2 and/or .alpha.3 subunit thereof, and are accordingly of benefit in the treatment and/or prevention of emesis. ##STR1##
 IT **146939-27-7**, Ziprasidone
 (triazolo-pyridazine deriv. GABAA ligands and therapeutic use, alone or with other compds.)
 RN 146939-27-7 USPATFULL
 CN 2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro- (9CI) (CA INDEX NAME)




L3 ANSWER 49 OF 59 USPATFULL on STN
 AN 2000:109801 USPATFULL
 TI Neuroprotective use of triazolo-pyridazine derivatives
 IN Pineiro, Jose Luis Castro, Bishops Stortford, United Kingdom
 PA Merck Sharp & Dohme, Ltd., Hoddesdon, United Kingdom (non-U.S. corporation)
 PI US 6107296 20000822
 AI US 1998-206416 19981207 (9)
 PRAI GB 1997-26702 19971218
 DT Utility
 FS Granted
 EXNAM Primary Examiner: Jones, Dwayne C.
 LREP Lee, Shu M., Rose, David L.
 CLMN Number of Claims: 9
 ECL Exemplary Claim: 1
 DRWN No Drawings
 LN.CNT 1350
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB A class of substituted 7,8-ring fused 1,2,4-triazolo[4,3-b]pyridazine derivatives as shown in Formula I, possessing an optionally substituted cycloalkyl, phenyl or heteroaryl substituent at the 3-position and a substituted alkoxy moiety at the 6-position, are selective ligands for GABA.sub.A receptors, in particular having high affinity for the .alpha.2 and/or .alpha.3 subunit thereof, and are accordingly of benefit in the treatment and/or prevention of neurodegeneration arising from cerebral ischemia. ##STR1##
 IT **146939-27-7**, Ziprasidone
 (triazolo-pyridazine deriv. GABAA ligands and therapeutic use, alone or with other compds.)
 RN 146939-27-7 USPATFULL
 CN 2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro- (9CI) (CA INDEX NAME)



L3 ANSWER 50 OF 59 USPATFULL on STN
 AN 2000:102289 USPATFULL
 TI Use of NK-1 receptors antagonists for treating schizophrenic disorders
 IN Baker, Raymond, Dursley, United Kingdom
 Curtis, Neil Roy, Puckeridge, United Kingdom
 Elliott, Jason Matthew, Felsted, United Kingdom
 Harrison, Timothy, Great Dunmow, United Kingdom
 Hollingworth, Gregory John, Basildon, United Kingdom
 Jackson, Philip Stephen, Harlow, United Kingdom
 Kulagowski, Janusz Jozef, Sawbridgeworth, United Kingdom
 Rupniak, Nadia Melanie, Bishops Stortford, United Kingdom
 Seward, Eileen May, Bishops Stortford, United Kingdom
 Swain, Christopher John, Duxford, United Kingdom
 Williams, Brian John, Great Dunmow, United Kingdom
 PA Merck Sharp & Dohme Ltd., Hoddesdon, United Kingdom (non-U.S. corporation)
 PI US 6100256 20000808
 AI US 1998-95782 19980611 (9)
 RLI Continuation-in-part of Ser. No. US 1997-980930, filed on 1 Dec 1997, now abandoned
 PRAI GB 1996-25051 19961202
 GB 1997-1459 19970124
 GB 1997-13715 19970627
 GB 1997-16491 19970804
 GB 1997-21191 19971007
 DT Utility
 FS Granted
 EXNAM Primary Examiner: Weddington, Kevin E.
 LREP Thies, J. Eric, Rose, David L.
 CLMN Number of Claims: 11
 ECL Exemplary Claim: 1
 DRWN No Drawings
 LN.CNT 1454
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB The present invention provides a method for the treatment or prevention of schizophrenic disorders using an orally active, long acting, CNS-penetrant NK-1 receptor antagonist and pharmaceutical compositions comprising such a NK-1 receptor antagonist.
 IT **146939-27-7**, Ziprasidone
 (NK-1 receptor antagonists for treating schizophrenic disorders, and compd. prepn.)
 RN 146939-27-7 USPATFULL
 CN 2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro- (9CI) (CA INDEX NAME)



L3 ANSWER 51 OF 59 USPATFULL on STN
 AN 2000:61599 USPATFULL
 TI Analgesic use of triazolo-pyridazine derivatives
 IN Pineiro, Jose Luis Castro, Bishops Stortford, United Kingdom
 Hill, Raymond George, Royston, United Kingdom
 PA Merck Sharp & Dohme Ltd., Hoddesdon, United Kingdom (non-U.S.
 corporation)
 PI US 6063783 20000516
 AI US 1998-209071 19981210 (9)
 PRAI GB 1997-26701 19971218
 DT Utility
 FS Granted
 EXNAM Primary Examiner: Jarvis, William R. A.
 LREP Lee, Shu M., Rose, David L., Durette, Philippe L.
 CLMN Number of Claims: 12
 ECL Exemplary Claim: 1
 DRWN 1 Drawing Figure(s); 1 Drawing Page(s)
 LN.CNT 1634
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB A class of substituted 7,8-ring fused 1,2,4-triazolo[4,3-b]pyridazine
 derivatives as shown in Formula I, possessing an optionally substituted
 cycloalkyl, phenyl or heteroaryl substituent at the 3-position and a
 substituted alkoxy moiety at the 6-position, are selective ligands for
 GABA.sub.A receptors, in particular having high affinity for the
 .alpha.2 and/or .alpha.3 subunit thereof, and are accordingly of benefit
 in the treatment and/or prevention of pain. ##STR1##
 IT **146939-27-7**, Ziprasidone
 (triazolo-pyridazine deriv. GABAA ligands and therapeutic use, alone or
 with other compds.)
 RN 146939-27-7 USPATFULL
 CN 2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-
 chloro-1,3-dihydro- (9CI) (CA INDEX NAME)



L3 ANSWER 52 OF 59 USPATFULL on STN
 AN 2000:41041 USPATFULL
 TI Antispastic use of triazolo-pyridazine derivatives
 IN Hefti, Franz Fridolin, Much Hadham, United Kingdom
 PA Merck Sharp & Dohme Ltd., Hertfordshire, United Kingdom (non-U.S. corporation)
 PI US 6046196 20000404
 AI US 1998-208291 19981209 (9)
 PRAI GB 1997-26699 19971218
 DT Utility
 FS Granted
 EXNAM Primary Examiner: Jarvis, William R. A.
 LREP Lee, Shu M., Rose, David L.
 CLMN Number of Claims: 9
 ECL Exemplary Claim: 1
 DRWN No Drawings
 LN.CNT 1538


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A class of substituted 7,8-ring fused 1,2,4-triazolo[4,3-b]pyridazine derivatives, as shown in Formula I possessing an optionally substituted cycloalkyl, phenyl or heteroaryl substituent at the 3-position and a substituted alkoxy moiety at the 6-position, are selective ligands for GABA.sub.A receptors, in particular having high affinity for the .alpha.2 and/or .alpha.3 subunit thereof, and are accordingly of benefit in the treatment and/or prevention of muscle spasm or spasticity, e.g. in paraplegic patients. ##STR1##


IT **146939-27-7**, Ziprasidone
 (triazolo-pyridazine deriv. GABAA ligands and therapeutic use, alone or with other compds.)

RN 146939-27-7 USPATFULL


CN 2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro- (9CI) (CA INDEX NAME)



L3 ANSWER 53 OF 59 USPATFULL on STN
 AN 2000:28261 USPATFULL
 TI Biasing arrangement for linear detector array
 IN Waczynski, Augustyn, Indiana, PA, United States
 Mazurowski, John S., Indiana, PA, United States
 Grinch, Dean S., Dublin, OH, United States
 PA Diasense, Inc., Pittsburgh, PA, United States (U.S. corporation)
 PI US 6034367 20000307
 WO 9707528 19970227
 AI US 1998-11568 19980924 (9)
 WO 1996-US13336 19960815
 19980924 PCT 371 date
 19980924 PCT 102(e) date
 PRAI US 1995-2347P 19950815 (60)
 DT Utility
 FS Granted
 EXNAM Primary Examiner: Lee, John R.
 LREP Webb Ziesenheim Logsdon Orkin & Hanson, P.C.
 CLMN Number of Claims: 18
 ECL Exemplary Claim: 1
 DRWN 6 Drawing Figure(s); 4 Drawing Page(s)
 LN.CNT 532
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB A detector includes a plurality of detector elements in a linear array.
 A bias source is connected to the input terminal of each detector
 element. The bias source includes a first bias connected to the input
 terminals of a first set of detector elements including alternating
 detector elements and is also connected through an associated
 measurement device to the output terminals of a second set of detector
 elements including the remaining detector elements. The bias source also
 includes a second bias, different from the first bias, and connected
 through an associated measurement device to the output terminals of the
 first set of detector elements. The second bias is also connected to the
 input terminals of the second set of detector elements.
 IT **146939-27-7P**, Ziprasidone
 (prepn. of prodrugs of ziprasidone)
 RN 146939-27-7 USPATFULL
 CN 2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-
 chloro-1,3-dihydro- (9CI) (CA INDEX NAME)



L3 ANSWER 54 OF 59 USPATFULL on STN
 AN 1999:92676 USPATFULL
 TI Pro-drugs of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one
 IN Walinsky, Stanley W., Mystic, CT, United States
 Lambert, John F., Stonington, CT, United States
 PA Pfizer Inc., New York, NY, United States (U.S. corporation)
 PI US 5935960 19990810
 AI US 1997-798395 19970207 (8)
 PRAI US 1998-11568P 19980213 (60)
 DT Utility
 FS Granted
 EXNAM Primary Examiner: Raymond, Richard L.; Assistant Examiner: Kessinger, Ann M.
 LREP Richardson, Peter C., Ginsburg, Paul H., Creagan, B. Timothy
 CLMN Number of Claims: 9
 ECL Exemplary Claim: 1
 DRWN No Drawings
 LN,CNT 677
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB The present invention relates to a pro-drug of ziprasidone or pharmaceutically acceptable salts thereof, processes for its preparation, and pharmaceutical compositions and methods of treatment comprising said pro-drug.
 IT **146939-27-7P**, Ziprasidone
 (prepn. of prodrugs of ziprasidone)
 RN 146939-27-7 USPATFULL
 CN 2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro- (9CI) (CA INDEX NAME)



L3 ANSWER 55 OF 59 USPATFULL on STN
AN 1999:73339 USPATFULL
TI Window structure of an indicator unit
IN Yahata, Noriaki, Konan, Japan
PA Zexel Corporation, Tokyo, Japan (non-U.S. corporation)
PI US 5917651 19990629
AI US 1998-81645 19980520 (9)
DT Utility
FS Granted
EXNAM Primary Examiner: Phan, James
LREP Wenderoth, Lind & Ponack, L.L.P.
CLMN Number of Claims: 12
ECL Exemplary Claim: 1
DRWN 8 Drawing Figure(s); 5 Drawing Page(s)
LN.CNT 501

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


AB A reflecting surface is formed at a rear side of a thick portion so that when viewed from the center front relative to the thick portion, light is reflected by the reflecting surface to let the color of the panel be seen as the color of the thick portion. With this, the confusing visual aspect of the window member of the indicator unit that occurs when the color of the thick portion of the window member looks different from the color of the other portion of the window member can be eliminated without having to color the rear surface side of the thick portion.

IT **146939-27-7**, Ziprasidone


(methods for treating neuropsychiatric disorders)

RN 146939-27-7 USPATFULL


CN 2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro- (9CI) (CA INDEX NAME)




L3 ANSWER 56 OF 59 USPATFULL on STN
 AN 94:93447 USPATFULL
 TI Processes and intermediates for the preparation of 5-[2-(4-(benzoisothiazol-3-yl)-piperazin-1-yl)ethyl]-6-chloro-1,3-dihydro-indol-2-one
 IN Urban, Frank J., Waterford, CT, United States
 PA Pfizer Inc., New York, NY, United States (U.S. corporation)
 PI US 5359068 19941025
 AI US 1993-83429 19930628 (8)
 DT Utility
 FS Granted
 EXNAM Primary Examiner: Tsang, Cecilia
 LREP Richardson, Peter C., Ginsburg, Paul H., Bekelnitzky, Seymour G.
 CLMN Number of Claims: 17
 ECL Exemplary Claim: 1
 DRWN No Drawings
 LN.CNT 621
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB A process for preparing the compound of the formula ##STR1## which comprises treating a compound of the formula ##STR2## wherein R.sup.2 is hydrogen, CN or CO.sub.2 R.sup.1 and R.sup.1 is hydrogen or (C.sub.1 -C.sub.6)alkyl with a reducing agent with the proviso that when R.sup.2 is CN or CO.sub.2 R.sup.1 and R.sup.1 is (C.sub.1 -C.sub.6)alkyl the product of the reduction is heated with an acid. Compounds of formula II wherein R.sup.2 is CN or CO.sub.2 R.sup.1 and R.sup.1 is (C.sub.1 -C.sub.6)alkyl or R.sup.2 is hydrogen and R.sup.1 is (C.sub.1 -C.sub.6)alkyl or hydrogen. The compound of formula VII R.sup.1 is (C.sub.1 -C.sub.6)alkyl. The compound of formula III. The compound of formula I is useful in the treatment of psychotic disorders.
 IT **146939-27-7P**
 (prepn. of 5-[2-(4-(benzoisothiazol-3-yl)piperazin-1-yl)ethyl]-6-chloro-1,3-dihydroindol-2-one via reductive cyclization of a nitrobenzeneacetate deriv.)
 RN 146939-27-7 USPATFULL
 CN 2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro- (9CI) (CA INDEX NAME)



L3 ANSWER 57 OF 59 USPATFULL on STN
 AN 94:71127 USPATFULL
 TI Process for preparing aryl piperazinyl-heterocyclic compounds with a piperazine salt
 IN Busch, Frank R., Gales Ferry, CT, United States
 Bowles, Paul, Groton, CT, United States
 John, Douglas, New London, CT, United States
 Allen, Meldrum, Uncasville, CT, United States
 DiRoma, Sabeto A., Glastonbury, CT, United States
 Godek, Dennis M., Glastonbury, CT, United States
 PA Pfizer Inc., New York, NY, United States (U.S. corporation)
 PI US 5338846 19940816
 AI US 1993-49905 19930420 (8)
 RLI Continuation-in-part of Ser. No. US 1992-936179, filed on 26 Aug 1992, now patented, Pat. No. US 5206366 And Ser. No. US 1992-939204, filed on 1 Sep 1992
 DT Utility
 FS Granted
 EXNAM Primary Examiner: Tsang, Cecilia
 LREP Richardson, Peter C., Ginsburg, Paul H., Strassburger, Philip C.
 CLMN Number of Claims: 19
 ECL Exemplary Claim: 1
 DRWN No Drawings
 LN.CNT 371
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB A process for preparing a compounds of the formula ##STR1## or a pharmaceutically acceptable acid addition salt thereof, which comprises reacting a piperazine salt of the formula ##STR2## with an alkyl halide containing compound of the formula ##STR3## in water with a reagent to neutralize the hydrohalic acid and heating the mixture under conditions which are suitable to effect the coupling of said piperazine salt with said alkyl halide containing compound.
 IT **146939-27-7P**
 (prepn. and hydrochloride salt formation of)
 RN 146939-27-7 USPATFULL
 CN 2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro- (9CI) (CA INDEX NAME)



L3 ANSWER 58 OF 59 USPATFULL on STN
 AN 94:42452 USPATFULL
 TI Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
 IN Allen, Douglas J. M., New London, CT, United States
 Busch, Frank R., Gales Ferry, CT, United States
 DiRoma, Sabeto A., Uncasville, CT, United States
 Godek, Dennis M., Glastonbury, CT, United States
 PA Pfizer Inc., New York, NY, United States (U.S. corporation)
 PI US 5312925 19940517
 AI US 1992-939204 19920901 (7)
 DT Utility
 FS Granted
 EXNAM Primary Examiner: Tsang, Cecilia
 LREP Richardson, Peter C., Ginsburg, Paul H., Holtrust, Gezina
 CLMN Number of Claims: 4
 ECL Exemplary Claim: 1
 DRWN 6 Drawing Figure(s); 6 Drawing Page(s)
 LN.CNT 193
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB The monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-2H-indole-2-one hydrochloride has advantageous stability for formulation as a neuroleptic agent.
 IT **146939-27-7P**
 (prepn. and hydrochloride salt formation of)
 RN 146939-27-7 USPATFULL
 CN 2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro- (9CI) (CA INDEX NAME)



L3 ANSWER 59 OF 59 USPATFULL on STN
AN 93:33619 USPATFULL
TI Process for preparing aryl piperazinyl-heterocyclic compounds
IN Bowles, Paul, Groton, CT, United States
PA Pfizer Inc., New York, NY, United States (U.S. corporation)
PI US 5206366 19930427
AI US 1992-936179 19920826 (7)
DT Utility
FS Granted
EXNAM Primary Examiner: Tsang, Cecilia
LREP Richardson, Peter C., Ginsburg, Paul H., Fedowich, Valerie M.
CLMN Number of Claims: 16
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 274

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A process for preparing a compounds of the formula ##STR1## or a pharmaceutically acceptable acid addition salt thereof, which comprises reacting a monosubstituted piperazine of the formula ##STR2## with an alkyl halide containing compound of the formula ##STR3## in water with a reagent to neutralize the hydrohalic acid and refluxing the mixture under conditions which are suitable to effect the coupling of said monosubstituted piperazines with said alkyl halide containing compound.

IT 146939-27-7P

(prepn. and hydrochloride salt formation of)

RN 146939-27-7 USPATFULL

CN 2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro- (9CI) (CA INDEX NAME)

